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Introduction 
It is with great pleasure that 
I present the annual report 
of the HSE Health Protection 
Surveillance Centre for 2011.
 
There have been encouraging 
trends in some areas of 
infectious disease prevention 
and control affecting those 
living in Ireland in 2011.   Ireland is now ranked a low 
incidence tuberculosis country due to a continued 
decline in the number of cases here.    This is very 
welcome but we need to remain vigilant as outbreaks 
continue to be detected, investigated and managed by 
public health departments.  We also need to be alert 
to the higher incidence of disease among vulnerable 
groups like homeless people, prisoners, substance mis-
users and immigrants from countries of high endemicity. 
This situation is reflected in other countries worldwide 
and we need to focus on strategies to prevent TB in 
these groups.
Immunisation uptake continued to improve during 2011. 
Children aged 24 months reached the target uptake of 
95% for the 6 in  1 vaccine while  coverage for the first 
dose of MMR reached 92%.   There was some slippage 
for the booster dose of Hib vaccine and the third dose 
of Men C vaccine.    Good work has been done by the 
HSE National Immunisation Office to address this and 
we need to continue to remind parents of the need to 
bring their children for the fifth visit at 13 months of 
age. 
The number of cases of meningococcal infection 
continues to decline.  This is good news and is 
partly due to the success of the Men C vaccination 
programme but is also due to a welcome reduction in 
Men B disease.  
There were no confirmed cases of Rubella in 2011 
indicating that MMR vaccination campaigns are working. 
If rubella is on the decline then the work with MMR may 
also lead to the elimination of measles in Ireland.    The 
current school based MMR campaign offers children an 
extra dose of the vaccine in case they did not receive 
the necessary two doses of MMR previously. Thankfully 
the vaccine also covers mumps as it may help reduce 
the number of cases of this disease which  is now 
common in young adults.
There has been an unwelcome increase in cases of 
Pertussis (Whooping cough), particularly in young 
infants.  This disease is on the increase in many parts of 
the world, partly due to better surveillance, but mainly 
because there has been a real increase in the disease.  
Evidence is emerging that the newer acellular pertussis 
vaccine done not provide protection for as long as 
the older whole cell vaccine.   The new vaccine was 
introduced in 1996 as it causes fewer side effects than 
the previously used vaccine.  The increase in circulating 
pertussis now requires new strategies to protect 
vulnerable young infants, such as vaccinating pregnant 
women and vaccinating  those who come into contact 
with young infants.
We had a mild influenza season in 2011 for most of 
the population. However, the season was unusual 
due to the number of influenza outbreaks in nursing 
homes and long stay units for the elderly.   Outbreaks 
in the very elderly can be difficult to diagnose 
because of atypical clinical presentations. New 
guidelines have been circulated to help manage 
these kinds of outbreaks and are available on the 
HPSC website.  Click http://www.hpsc.ie/hpsc/A-Z/
Respiratory/Influenza/SeasonalInfluenza/Guidance/
ResidentialCareFacilitiesGuidance/
 In common with most other countries, the uptake of 
influenza vaccine in health care workers is poor.  The 
uptake of influenza vaccine in these long stay units for 
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both staff and residents should be used as an indicator 
of the quality of care provided.
Ireland continues to have the highest rate in Europe 
of gastrointestinal illness caused by organisms like 
cryptosporidiosis and Verocytotoxigenic E.coli.  Both 
of these pathogens can be spread through water and 
people using private water supplies in Ireland have a 
higher risk of acquiring infections.   High rainfall can 
lead to contamination of unprotected or inadequately 
maintained private water sources and such water 
supplies need to be looked after properly.
There was an increase in the number of new cases of 
Clostridium difficile infection in 2011.  The C.difficile 
subcommittee of the Scientific Advisory Committee 
of HPSC reconvened in 2011 to update the guidance 
on C.difficile. The draft updated document is 
currently out for consultation. In June 2011 a national 
pilot study was carried out in critical care units to 
examine the prevalence of carbapemem  resistant 
Enterobacteriaceae (CRE). While CRE was not detected 
in any participating unit during this four week study, 39 
cases of CRE colonisation or infection were notified to 
HPSC during 2011.
A further study examined the prevalence of healthcare-
associated infection in long term care facilities (LTCF) 
and reported that 4% of residents had an infection 
on the day of the study. Antimicrobial guidelines for 
primary care and guidelines on the diagnosis and 
management of urinary tract infection in LTCF were 
also published in 2011. Unfortunately, antimicrobial 
consumption increased in both hospital and community 
settings during 2011. The HSE ran an education 
campaign on prudent antibiotic use in 2011 and 
have recently launched another one for 2012. This 
good work needs to continue to educate both health 
care professionals and patients about prudent and 
appropriate antimicrobial prescribing. 
The trends in relation to anti-microbial resistance in 
key pathogens causing blood stream infections, are 
mixed. 2011 saw a very welcome reduction in the 
proportion of Staphylococcus aureus that are resistent 
to methicillin, also known as MRSA. but also an increase 
in the proportion of Streptococcus pneumoniae and 
Enterococcus faecium blood stream infections that 
are resistent to multiple antmicrobial classes. Much of 
the increased resistence among E.coli blood stream 
infections was due to extended spectrum beta-
lactamase (ESBLs) producing strains. It is critical that 
comprehensive infection prevention and control and 
antimicrobial stewardship programmes continue to be 
developed, maintained and supported by resourced 
reference laboratory services.
The Scientific Advisory Committee of HPSC  worked 
on developing new guidelines during 2011. Guidelines 
for the emergency management of injuries, such as 
needlesticks, sexual exposure and human bites, are now 
available at www.emitoolkit.ie. The guidelines relate 
mainly to injuries where there is a risk of transmission 
of bloodborne viruses such as hepatitis B, hepatitis C 
and HIV. The guidance may be particularly useful in 
settings like emergency departments, occupational 
health departments, STI clinics, sexual assault units, 
dental practices, and general practice. The management 
guidelines cover first aid, risk assessment, testing, 
treatment, patient information and follow-up, records 
and documentation. The appendices include patient 
management forms, algorithms to guide management 
of specific incidents, guidelines on post-exposure 
prophylaxis (PEP) for HIV and hepatitis B, testing 
schedules, patient information leaflets and sample 
referral letters. They also contain detailed background 
information on the epidemiology and transmission risks 
of hepatitis B and C and HIV.
I would like to thank all those who worked on the HPSC 
Scientific Advisory Committee  and gave voluntarily 
of their time and expertise. I would also like to thank 
all staff at HPSC for their hard work and enthusiasm 
and also all those working throughout the HSE who 
provided surveillance data for this report.
 
Dr Darina O’Flanagan
Director
HSE Health Protection Surveillance Centre
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In 2011, 44 cases of invasive Haemophilus 
influenzae disease were notified in Ireland 
(1.0/100,000 total population). This is a sharp 
increase compared to 2010 when 28 cases were 
notified, but is very similar to that reported in 2009 
(figure 1). 
The main change in 2011, when compared to 
2010, is the marked increase in the number of non-
typeable/non-capsular strains from 20 to 34 (figure 
1). No other noteworthy change in the overall 
number of cases due to other serotypes has been 
observed since 2004 apart from the decline in the 
proportion of type b cases and the rise of non-
typeable/non-capsular strains (figure 1).
Non-typeable/non-capsular cases accounted for 
the majority of the invasive H. influenzae cases 
notified in 2011 (77.3%, n=34/44). The remaining 
cases were due to H. influenzae type b (10.7%, 
n=3), type e (2.3%; n=1), type f (2.3%; n=1), not 
type b (4.5%; n=2) and isolates that were not typed 
(6.8%; n=3). The cases ranged in age from four 
days to 93 years. The incidence rates were highest 
in infants <1 year (5.5/100,000) and those aged 55-
64 years (0.7/100,000) (table 1).
Cases occurring in children <10 years of age (n=10) 
and elderly adults over 65 years of age (n=20) 
accounted for 68.2% of all invasive H. influenzae 
notifications in 2011 (table 1). One notable trend 
since 2004 is the increase in the overall proportion 
of cases over 65 years of age from 26% to 45% 
compared to the declines in those aged less 
than five years from 26% to 18% and those aged 
between 5 and 64 years from 47% to 36%.
In 2011, male cases (n=25) exceeded female 
cases (n=19), resulting in a male to female ratio of 
1.32:1.0.
The clinical manifestations of invasive H. influenzae 
disease in the ten children <10 years of age in 
2011 were three cases of septicaemia, two cases 
1.1 Haemophilus influenzae (invasive) 
Number of cases, 2011: 44
Number of cases, 2010: 28
Number of cases, 2009: 43
Crude incidence rate, 2011: 1.0/100,000
Summary
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Figure 1. Number of invasive H. influenzae cases notified in Ireland and proportion of annual cases attributable to type b and 
non-typeable strains with 95% confidence intervals, 2004-2011
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of meningitis, one pneumonia, one meningitis and 
septicaemia combined, two ‘other’ conditions and 
one where the clinical diagnosis was not reported. 
A breakdown by clinical diagnosis for all age 
groups by year between 2004 and 2011 is 
presented in table 2. Of note is the proportion of 
cases notified each year with an unknown clinical 
diagnosis, accounting for an annual average of 
38.1% since 2004.
Death was reported in four cases: the cause 
was unknown in two cases; one death was not 
attributable to infection and another is still 
awaiting a coroner’s report at the time of writing. 
No imported cases occurred in 2011.
In 2011 three cases of H. influenzae type b (Hib) 
occurred, all of whom were > 65 years of age; two 
were unvaccinated and both were greater than 75 
years of age and another case, who was 67 years 
of age, had an unknown vaccine status. In 2010, 
three cases of Hib occurred, one in a completely 
vaccinated ten year-old child who had received 
three doses of Hib vaccine and in two other 
unvaccinated adults (age range 23-76 years).
Between Q3-2007 and Q4-2011, only one true 
Hib vaccine failure was reported, highlighting the 
positive impact the Hib booster catch up campaign 
has had in Ireland. 
Since September 2008, the, Hib booster dose has 
been administered at 13 months of age as part of 
the routine childhood immunisation schedule in 
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Figure 2. Number of invasive H. influenzae cases notified in Ireland annually by age group (years), 2004-2011
Table 1. Number and incidence rates of invasive H. influenzae cases by serotype, 2011
Age 
Group Type b Type e Type f
Not 
type b
Non-typeable/
non-capsular
Not 
Typed* Total
ASIR of 
Hib
ASIR of all 
H. influenzae
<1 0 0 0 0 3 1 4 0.00 5.52
1-4 0 0 0 1 2 1 4 0.00 1.25
5-9 0 0 0 1 1 0 2 0.00 0.66
10-14 0 0 0 0 0 0 0 0.00 0.00
15-19 0 0 0 0 1 0 1 0.00 0.34
20-24 0 0 0 0 0 0 0 0.00 0.00
25-34 0 0 0 0 4 0 4 0.00 0.58
35-44 0 0 0 0 4 0 4 0.00 0.69
45-54 0 0 0 0 1 0 1 0.00 0.22
55-64 0 0 0 0 4 0 4 0.00 0.75
65+ 3 1 1 0 14 1 20 0.07 0.44
All Ages 3 1 1 2 34 3 44 0.07 0.96
CIR 0.07 0.02 0.02 0.04 0.74 0.07 0.96 - -
CIR, crude incidence rate per 100,000 total population
ASIR, age specific incidence rate per 100,000 population
TVFs, true Hib vaccine failures
*No isolate available for typing in two of three H. influenzae not typed cases, as PCR positive (culture negative) only
Table 2. Number of invasive H. influenzae cases by clinical diagnosis, 2004- 2011
Clinical Diagnosis 2004 2005 2006 2007 2008 2009 2010 2011 Total % of Total
Septicaemia 8 14 13 6 3 9 9 11 73 26.3%
Pneumonia 5 0 3 6 3 8 5 12 42 15.1%
Meningitis 3 9 3 2 2 2 1 3 25 9.0%
Epiglottitis 1 3 3 1 1 0 2 0 11 4.0%
Cellulitis 1 1 2 1 1 0 0 1 7 2.5%
Meningitis & 
septicaemia
1 0 1 0 1 1 1 1 6 2.2%
Bacteraemia (without 
focus)
0 0 0 0 0 0 0 3 3 1.1%
Other 0 0 0 0 0 0 0 3 3 1.1%
Septic arthritis 0 1 0 0 1 0 0 0 2 0.7%
Osteomyelitis 1 0 0 0 0 0 0 0 1 0.4%
Unknown 18 6 13 15 10 23 10 10 105 37.8%
Total 38 34 38 31 22 43 28 44 278 100%
Table 3. Incidence rates per 100,000 population of invasive H. influenzae by HSE area, 2004-2011
HSE Area 2004 2005 2006 2007 2008 2009 2010 2011
E 1.1 1.0 0.9 0.8 0.5 0.7 0.6 1.1
M 1.2 1.2 0.4 1.2 0.8 1.1 0.4 1.1
MW 0.8 0.3 0.8 0.6 0.8 2.1 0.5 0.5
NE 0.3 1.3 0.3 0.0 0.0 0.2 0.5 1.6
NW 0.4 0.0 2.1 0.4 0.0 0.4 0.4 0.8
SE 1.1 0.4 0.9 1.1 0.7 1.0 1.0 0.8
S 1.1 0.3 1.3 0.3 0.6 1.2 1.1 0.3
W 0.5 1.4 0.7 1.4 0.5 1.1 0.2 1.3
Ireland 0.9 0.8 0.9 0.7 0.5 0.9 0.6 1.0
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addition to the three doses given during infancy (at 
2, 4 and 6 months of age). Furthermore, vaccination 
is routinely recommended for those at increased 
risk of Hib disease.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 29th August, 
2012. These figures may differ from those published 
previously due to ongoing updating of notification 
data on CIDR.
In 2011, there were 267 measles cases (5.8/100,000) 
notified in Ireland compared to 403 cases in 2010.  
There was a measles outbreak in the HSE-E during 
2011; the majority (87%, n=232/267) of cases notified 
in Ireland in 2011 and the highest crude incidence rate 
was in the HSE-E (table 1).  Measles cases by HSE Area 
and week and month of notification are shown in figure 
1.  Forty-nine percent (n=130/267) of cases in 2011 were 
notified from early August to mid-October (Weeks 32-
41). This increase in cases was mainly due to a measles 
cluster in school-aged children attending a residential 
summer camp in north Dublin which then spread to 
the north inner city and Ballymun areas of Dublin.  The 
HSE-E outbreak and control measures are described in 
detail in Epi-Insight.1
Of the 267 measles cases notifed in 2011, 21% (n=56) 
were classified as possible while 79% (n=211) were 
classified as confirmed, giving a crude confirmed 
incidence rate of 4.6 per 100,000 population.  Of the 
confirmed cases, it was known that 69% (n=146) were 
1.2 Measles 
Summary
Number of cases, 2011: 267
Number of confirmed cases, 2011: 211                                                                       
Crude incidence rate, 2011: 5.8/100,000
Crude confirmed incidence rate, 2011: 4.6/100,000
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Figure 1. Number of notified measles cases by week and month in 2011 and by HSE Area
HSE-E indicates measles cases notified in the HSE-E
Non HSE-E indicates measles cases notified in the HSE-M, MW, NE, NW, SE, SA and WA
laboratory confirmed and 31% (n=65) were classified as 
confirmed because they were epidemiologically linked 
to a laboratory confirmed case.  
In 2011, measles cases ranged in age from three 
months to 41 years; with a mean age of seven years 
and a median age of five years (age was unknown for 
one case).  The number of cases by age group and the 
age specific incidence rates are shown in figures 2 and 
3.  The largest number of cases was in those aged 1-2 
years (figure 2) and the highest age specific incidence 
rate was in those aged <1 year (figure 3).  Of the 267 
measles cases, 55% (n=147) were male, 45% (n=119) 
were female while gender was not reported for one 
case.
Laboratory results were provided for 69% (n=184/267) 
of cases in 2011.  Fifty-five percent (n=146/267) of 
cases were laboratory test positive for measles.  A 
further three percent (n=8/267) were specified as 
serology positive for measles; however, as these cases 
were recently vaccinated, these positive results may 
have represented serological responses to the measles 
vaccine.  The laboratory results for three percent 
(n=9/267) were recorded as inconclusive/weakly 
positive.  
Eight percent (n=21/267) of cases were laboratory 
negative for measles, however, for forty-three percent 
(n=9/21) of these the specimens were not taken at the 
optimal time following disease onset or the date of 
specimen collection in relation to disease onset was 
unknown (the optimal time following disease onset for 
collecting oral fluid specimens for measles IgM testing is 
greater than seven days to two months and the optimal 
time for collecting serum specimens for measles IgM 
testing is greater than four days to two-three months).  
Fifty-seven percent (n=12/21) of the cases that were 
laboratory negative for measles were known to have 
a specimen collected at the optimal time.  Ninety-two 
percent (n=11/12) of these were classified as possible 
cases and eight percent i.e. one case (n=1/12) was 
classified as confirmed as it was epi-linked to laboratory 
confirmed case. 
Measles vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  
In Ireland, vaccination with the first dose of MMR is 
routinely recommended at twelve months of age and 
the second dose at four to five years of age.
Vaccination data were reported for 85% (n=226/267) of 
measles cases in 2011.  Fifty-seven percent (n=152/267) 
of cases were unvaccinated; of these 20% (n=30/152) 
were less than 12 months of age.
Twenty-four percent (n=64/267) of cases were reported 
to have one dose of MMR vaccine; the majority (70%, 
n=45/64) of these were less than six years of age.  
Seventy percent (n=45/64) of those reported to have 
one dose of MMR were classified as confirmed.  Sixty-
three percent (n=40/64) with one dose of MMR had 
a vaccination date reported, 20% (n=13/64) were 
vaccinated <14 days before onset of illness and were 
probably incubating measles at the time of vaccination.
Four percent (n=10/267) of cases were reported as 
having received two doses of MMR.  Sixty-percent 
(n=6/10) of these cases were classified as confirmed and 
only a third (n=2/6) of these cases had both vaccination 
dates reported. 
Thirty cases were reported as hospitalised, representing 
11% (n=30/267) of all cases.  The median age of 
hospitalised cases was four years and the mean age was 
nine years (range six months to 33 years). The majority 
(97%, n=29/30) of hospitalised cases were classified as 
confirmed.  Length of hospitalisation was reported for 
67% (n=20/30) with a median duration of stay of four 
days (range one to 14 days).  Of the 30 hospitalised 
cases, 17% (n=5) had no MMR details reported while 
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Table 1. Number of notified measles cases and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2011
HSE Area Number CIR
HSE-E 232 14.3
HSE-M 5 1.8
HSE-MW 5 1.3
HSE-NE 8 1.8
HSE-NW 1 0.4
HSE-SE 2 0.4
HSE-S 6 0.9
HSE-W 8 1.8
Total 267 5.8
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53% (n=16) were unvaccinated.  Twenty-three percent 
(n=7/30) were reported to have one dose of MMR; 57% 
(n=4/7) of these had a vaccination date recorded, one 
(25%, n=1/4) of these was vaccinated six days prior to 
onset and may have been incubating measles at the 
time of vaccination.  The two remaining hospitalised 
cases (7%, n=2/30) was reported to have had two doses 
of MMR; however the vaccination dates and other 
vaccination details were only reported for one of these 
cases. 
Reported complications of measles included pneumonia 
(2%, n=3/160), seizures (1%, n=1/161), chest infection 
(n=1), near cot death (n=1), extremely high temperature 
(n=1), tonsillitis and chest infection (n=1) and vomiting 
and diarrhoea resulting in dehydration (n=1).
Of the 267 cases, the setting where the case most likely 
acquired measles was reported as home (31%, n=82), 
daycare or pre-school (7%, n=19), summer camp/school 
(3%, n=7), overseas (2%, n=6), secondary school (2%, 
n=6), hospital in-patient (2%, n=5), hospital out-patient 
(2%, n=5), primary school (2%, n=5), third level (1%, 
n=2), work (1%, n=2), after school club/community club 
(0.4%, n=1), other healthcare facility (0.4%, n=1) and 
was unreported for the remainder (47%, n=126).
Twenty-six localised measles outbreaks were notified 
during 2011, with 152 associated cases of illness.  The 
outbreak locations included four community outbreaks 
(with 47 ill), four crèche outbreaks (with 25 ill), four 
outbreaks occurring among extended families  (with 25 
ill), six private houses (with 19 ill), three school outbreaks 
(with 16 ill), one hospital outbreak (with four ill), one 
associated with an after school youth club (with eight 
ill), one university/college (with two ill), one workplace 
(with two ill) and for one outbreak the location was not 
specified but was reported to have cases (with four ill) 
that had links to a separate  outbreak.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 13th September 
2012.  These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR. 
Reference
1. Ward M, Ennis O, Fitzgerald M on behalf of the outbreak control 
team. Measles outbreak in Eastern Ireland, 2011. Epi-Insight. 
2011;12(11). Available online: http://ndsc.newsweaver.ie/epiinsight/
17vq05l54uf?a=1&p=18519355&t=17517774
Figure 3. The age specific incidence rate (per 100,000) of 
notified measles cases in 2011 by case classification
Figure 2. Number of notified measles cases in 2011 by age 
group and case classification
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In 2011, 94 cases (2.0/100,000) cases of invasive 
meningococcal disease (IMD) were notified in Ireland. 
This continues a downward trend observed over 
the past decade since 1999, when the rate was 
14.8/100,000 population, a decline of more than 86%.
Based on the current meningococcal disease case 
definition, 88 of the 94 cases (93.6%) notified in 2011 
were case classified as definite, one (1.1%) as presumed 
and five (5.3%) as possible. Laboratory confirmation of 
cases has improved with time. In 2011 93.6% (n=88/94) 
of cases were laboratory confirmed in comparison to 
78.7% (n=422/536) in 1999.
Typically, most cases are laboratory confirmed (93.6%; 
n=88/94) by means of blood/CSF culture testing, PCR 
testing, blood serology, detection of Gram negative 
diplococci in skin lesions/culture or in CSF specimens, 
and by screening of nasal, throat and eye swabs. 
In 2011, fifty-nine percent of all confirmed cases 
(n=52/88) were laboratory tested by PCR testing alone 
of specimens from sterile sites. Confirmation of the 
remaining 36 cases was by culture of sterile specimens 
only (10.2%; n=9/88); culture and PCR testing of sterile 
specimens (27.3%; n=24/88); by CSF microscopy, 
but not exclusively (1.1%; n=1/88); and by culture 
of specimens from non-sterile sites such as the eye, 
nose and throat, but not exclusively (4.5%; n=4/88). 
None were laboratory confirmed by detection of Gram 
negative diplococci in skin lesion microscopy or by 
serology exclusively. 
In 2011, male cases (n=57) exceeded female cases 
(n=37), resulting in a male to female ratio of 1.54:1.0. 
Cases ranged in age from one month to 83 years 
(median age of 2.1 years). The incidence of IMD was 
highest in infants and young children. Age specific 
incidence rate (ASIR) was highest among infants <1 year 
of age (41.4/100,000; n=30), followed by children in the 
1-4 year (9.5/100,000; n=27), and 5-9 year age groups 
(2.8/100,000; n=9) (table 1). 
In 2011 the overall incidence of IMD in Ireland was 
highest in the HSE-NW area (3.1/100,000) with the 
lowest in the HSE-W area (1.3/100,000) (table 2). There 
were no imported cases in 2011.
Neisseria meningitidis serogroup B was the pathogen 
most commonly associated with IMD in 2011 and 
accounted for 84 (89.4%) of the 94 notifications (figure 
1). Since 2003 serogroup B has accounted for more than 
80% of annual IMD notifications (figure 1). 
IMD due to serogroup C has remained at very low levels 
over the last nine years with no more than five cases 
occurring annually. In 2011, only two (0.04/100,000) 
serogroup C cases were notified, neither of which were 
1.3  Meningococcal Disease     
Summary
Number of cases, 2011: 94
Number of cases, 2010: 114
Number of cases, 2009: 147
Crude incidence rate, 2011: 2.0/100,000
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Table 1. Number of cases, deaths, age-group specific incidence rates per 1000,000 population and case fatality ratios of IMD in 
Ireland, 2011
Age Group No. Cases ASIR No. Deaths %CFR
<1 30 41.4 0 0.0%
1-4 27 9.5 1 3.7%
5-9 9 2.8 0 0.0%
10-14 4 1.3 0 0.0%
15-19 7 2.5 0 0.0%
20-24 4 1.3 0 0.0%
25+ 13 0.4 1 7.7%
All ages 94 2.0 2 2.1%
ASIR, age specific incidence rate per 100,000 population
% CFR, case fatality ratio
reported to be fatal (figure 1). These two cases occurred 
in patients aged between 50 and 64 years, one of whom 
was unvaccinated and had chronic meningococcaemia (a 
rare, low grade bloodstream infection), the vaccination 
status of the other was unknown. As in in 2011 there 
were no true vaccine failures in 2010, 2004 and 2003, 
but there were three failures in 2009 and one each in 
2008, 2007, 2006 and 2005.
The absence of MenC vaccine failures in the past 
two years is a measure of the positive impact with 
which the MenC conjugate vaccine continues to have 
since first introduced in October 2000. Prior to the 
introduction of this vaccine, the serogroup C incidence 
rate in 1999 was 3.7 per 100,000 total population. 
The National Immunisation Advisory Committee 
(NIAC) has recommended a booster dose of the 
MenC vaccine for close contacts of cases that have 
completed a course more than one year before, details 
of which are available at http://www.ndsc.ie/hpsc/A-Z/
VaccinePreventable/Vaccination/Guidance/
There were two IMD related notified deaths in 2011 
(case fatality ratio (%CFR) of 2.1%), the fewest number 
on record compared to an average of 6.2 deaths 
between 2005 and 2010. In 2011, the %CFR was highest 
amongst cases 25+ years of age (7.7%) as a result of 
one death among 13 cases (table 1). The next highest 
%CFR at 3.7% in children aged 1-4 years (table 1).
Both IMD deaths in 2011 were due to serogroup B 
disease (age range 18 months to 40 years). This is in 
marked contrast to the 13 deaths due to serogroup B 
out of all 25 deaths reported in 2000. In the same year, 
11 deaths were due to serogroup C disease. The decline 
in deaths associated with meningococcal disease since 
2000 has been significant, due in part to the decline in 
MenC as a result of the vaccination programme and also 
in part due to decline in meningococcal B disease (table 
3). 
Despite a marked decline in the overall incidence over 
the past decade, IMD is still an important public health 
concern due to its associated severity, high mortality 
rate and serious adverse sequelae. 
Effective vaccination is necessary for the complete 
prevention and control of IMD. Although effective 
vaccines are available against serogroups A, C, W135 
and Y forms of the disease, a suitable vaccine against 
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Figure 1. Number of invasive meningococcal disease (IMD) notifications in Ireland by serogroup and proportion of cases 
attributable to serogroup B with 95% confidence intervals, 1999-2011
Table 2. Age specific incidence rates per 100,000 population of IMD by HSE area and age group, 2011
HSE area <1 1-4 5-9 10-14 15-19 20-24 25+ Total
E 46.2 4.1 1.9 2.0 3.1 2.5 0.6 2.0
M 20.7 15.7 13.6 0.0 0.0 0.0 0.6 2.6
MW 87.7 8.8 3.8 0.0 4.1 0.0 0.4 2.7
NE 52.0 16.0 0.0 0.0 0.0 0.0 0.0 1.8
NW 51.4 25.2 5.3 0.0 0.0 0.0 0.6 3.1
SE 39.2 9.7 2.8 0.0 6.4 0.0 0.3 1.7
S 10.0 10.0 2.2 2.3 2.5 2.4 0.5 2.0
W 30.2 7.6 0.0 3.4 0.0 0.0 0.3 1.4
Ireland 41.4 9.5 2.8 1.3 2.5 1.3 0.4 2.0
serogroup B disease, the most common form of IMD 
in Ireland, is not yet available although developmental 
work is ongoing. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 29th August, 2012. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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Figure 2. Crude incidence rates per 100,000 population with 95% confidence 
intervals for IMD notifications by HSE area, 2011
Table 3. Number of cases, deaths and case fatality ratios (%CFR) by year of meningococcal serogroups B and C disease in 
Ireland, 1999-2011
Meningococcal B Meningococcal C
Year No. Cases No. Deaths %CFR No. Cases No. Deaths %CFR
1999 292 12 4.1% 135 5 3.7%
2000 258 13 5.0% 139 11 7.9%
2001 245 8 3.3% 35 3 8.6%
2002 199 8 4.0% 14 0 0.0%
2003 206 11 5.3% 5 1 20.0%
2004 163 7 4.3% 5 1 20.0%
2005 169 5 3.0% 5 0 0.0%
2006 168 5 3.0% 4 0 0.0%
2007 157 6 3.8% 2 0 0.0%
2008 149 6 4.0% 4 1 25.0%
2009 119 6 5.0% 5 0 0.0%
2010 93 4 4.3% 4 0 0.0%
2011 84 2 2.4% 2 0 0.0%
% CFR, case fatality ratio
In total, there were 165 (3.6/100,000) mumps cases 
notified in 2011.  This is a decline compared to 
2010 when 292 cases were notified and to the years 
2008/2009 and 2004/2005 when large outbreaks 
occurred (figure 1).  The number of cases notified in 
2011, however, is still higher compared to the years 
1998 to 2003 when there was an average of 43 cases 
notified each year.
In 2011, of the 165 mumps cases notified 42% (n=70) 
were classified as confirmed, two percent (n=3) were 
classified as probable and 56% (n=92) were classified as 
possible.
The largest number of cases was notified in the HSE-E 
followed by the HSE-NW, while the highest crude 
incidence rates were in the HSE-NW followed by the 
HSE-E (table 1).
In 2011, the median age of cases was 26 years (range 
one to 86 years).  The number of cases by age group 
and the age specific incidence rates are shown in figures 
2 and 3.  The highest age specific incidence rates were 
in those 0-4 years followed by those 15-19 years.  In 
contrast, during 2004-2006 and 2008-2010 the highest 
age specific incidence rates were in those 15-19 years 
and 20-24 years.  Of the 165 mumps cases, 54% (n=89) 
were male and 46% (n=76) were female.
Of the 165 mumps cases, 22% (n=36) were 
unvaccinated, 15% (n=24) had one dose of the measles-
mumps-rubella vaccine (MMR), 18% (n=29) were 
reported to have received two doses of MMR while for 
46% (n=76) of cases the number of doses of MMR was 
not reported.  The vaccination date was reported for 
71% (n=17/24) of cases reported to have received one 
dose of MMR.  Both vaccination dates were reported 
for 28% (n=8/29) of cases vaccinated with two doses of 
MMR.  Fourteen percent (n=4/29) of the cases reported 
to have received two doses of MMR were classified 
1.4 Mumps 
Summary
Number of cases, 2011: 165
Number of cases, 2010: 292
Crude incidence rate, 2011: 3.6/100,000
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Figure 1. Number of mumps notifications by year and year of introduction of the measles-mumps-rubella (MMR) 
vaccine in Ireland
MMR1- first dose of MMR
MMR2- second dose of MMR
1988-June 2000 data collated by DoHC
July 2000-2011 data collated by HPSC
as confirmed; only two of these cases had MMR 
vaccination details such as vaccination dates reported.
Thirteen cases were hospitalised, representing eight 
percent (n=13/165) of all cases and twelve percent 
(n=13/112) of cases where hospitalisation data were 
provided.  The number of days hospitalised was 
reported for ten of the hospitalised cases; the median 
number of days hospitalised was four days (range one 
to 13 days).  
Reported complications of mumps included orchitis 
(10%, n=5/50), deafness (4%, n=4/93), mastitis (3%, 
n=3/94), pancreatitis (2%, n=2/90) and encephalitis (1%, 
n=1/95).
The setting where the case most likely acquired 
mumps was reported for 22% (n=36/165) of cases. The 
identified settings for these cases were: social setting 
for 58% (n=21/36) of cases; school/university/college 
for 19% (n=7/36); day-care/preschool for eight percent 
(n=3/36); international travel for eight percent (n=3/36); 
and family/household for six percent (n=2/36) of these 
cases.
Three localised outbreaks of mumps were notified 
during 2011 with seven associated cases of illness.  The 
outbreak locations included two private houses (with 
four ill) and a community outbreak (with three ill).  
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 7th September 
2011.  These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR.  
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Figure 2.   Number of notified mumps cases in 2011 by age 
group and case classification
Figure 3. The age specific incidence rates (per 100,000) of 
notified mumps cases in 2011
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Table 1. Number of mumps cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2011
HSE Area Number CIR
HSE-E 72 4.4
HSE-M 11 3.9
HSE-MW 15 4.0
HSE-NE 11 2.5
HSE-NW 20 7.7
HSE-SE 12 2.4
HSE-S 7 1.1
HSE-W 17 3.8
Total 165 3.6
Apart from Neisseria meningitidis, which is the 
most common cause of bacterial meningitis 
in Ireland, other pathogens cause this disease 
including those caused by non-notifiable 
organisms, details of which are presented below. 
For information on invasive meningococcal disease 
(Neisseria meningitidis), see other chapter within 
this report. Information on bacterial meningitis 
caused by notifiable diseases is summarised below 
and further data are available in the organism 
specific chapter. The figures presented in this 
chapter are based on data extracted from the 
Computerised Infectious Disease Reporting (CIDR) 
system on 29th August, 2012. These figures may 
differ from those published previously due to 
ongoing updating of notification data on CIDR.
Bacterial meningitis caused by diseases not 
otherwise specified:
In total, 35 cases of meningitis under this disease 
category were notified in 2011, among which two 
patients, aged less than four months, died. The 
causative pathogens were identified in 57% (n=20) 
of cases. No causative pathogen was identified 
in the remaining 43% (n=15) cases, a decrease 
compared to that recorded during the previous 
year with 50% (n=21/42).
Among the bacterial meningitis (not otherwise 
specified) cases notified in 2011 were 15 cases 
of Beta Haemolytic Streptococcus Group B 
(Streptococcus agalactiae), 14 of which were 
infants aged 4 months or less, one of whom died 
and also in one adult aged between 50 and 54 
years. 
Staphylococcus aureus occurred in two patients 
(age range 11 months to 76 year). Other meningitis 
notifications include one caused by Escherichia coli 
in an infant eight months of age, one caused by 
Klebsiella oxytoca in an infant five months of age 
and another caused by Streptococcus species in an 
infant aged four weeks.
Bacterial meningitis caused by specified 
notifiable diseases:
Haemophilus influenzae
Four cases of meningitis due to H. influenzae were 
notified in 2011. The age range was 17 months 
to 17 years, two of which were caused by non-
typeable strains and another two caused by strains 
that were not type b. No deaths were reported. 
See the chapter on invasive H. influenzae disease 
for further details.
1.5  Other Forms of Bacterial Meningitis*    
(*excluding meningococcal disease)
Summary
Number of cases, 2011: 35
Number of cases, 2010: 42
Number of cases, 2009: 40
Crude incidence rate, 2011: 0.8/100,000
-24-HPSC Annual Report 2011 1. Vaccine Preventable Diseases
Leptospira species
In 2011, one case of leptospirosis meningitis was 
reported in a male aged more than 65 years, 
which may have been work-related. See a separate 
chapter on non-IID zoonotic diseases for further 
details.
Listeria species
Two cases of listeriosis meningitis were notified in 
2011: one in a woman aged between 80-84 years 
with an underlying medical condition, and the 
other in a neonate. See the chapter on listeriosis 
disease for further details.
Streptococcus pneumoniae
In 2011, 24 cases of pneumococcal meningitis were 
notified, compared to 25 in 2010 and 34 in 2009. 
Cases in 2011 ranged in age from three months to 
80 years. One pneumococcal meningitis related 
death in 2011 was reported in an adult aged 45-
49 years. This adult had an immunosuppressive 
condition, but was unvaccinated and developed 
a serotype 19F infection (a serotype that is 
included in both the PCV7 and PCV13 vaccines). 
See a separate chapter on invasive pneumococcal 
disease for further details.
Mycobacterium species
In 2011, three tuberculosis meningitis cases were 
notified (provisional). Cases ranged in age from 
41 to 71 years. One tuberculosis meningitis death 
was reported. See the chapter on tuberculosis for 
further details.
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Table 1. Annual notifications of bacterial meningitis other than meningococcal disease, 2009-2011
Notified under Causative organism 2009 2010 2011 2009-2011
Haemophilus influenzae disease (invasive) Haemophilus influenzae 3 2 4 9
Leptospirosis Leptospira species 1 0 1 2
Listerosis Listeria species 1 3 2 6
Salmonellosis Salmonella enteritidis 1 0 0 1
Streptococcus pneumoniae infection (invasive) Streptococcus pneumoniae 34 25 24 83
Streptococcus Group A infection (invasive) Streptococcus pyogenes (Group A strep) 0 1 0 1
Tuberculosis* Mycobacterium species 8 9 3* 20
Total Bacterial Meningitis, Specified  48 40 34 122
 Escherichia coli 3 2 1 6
 Enterobacter species 1 0 0 1
 Klebsiella oxytoca 0 0 1 1
 Mycoplasma pneumoniae 0 1 0 1
Bacterial Meningitis, Not Otherwise Specified Streptococcus agalactiae (Group B strep) 7 10 15 32
 Staphylococcus aureus 2 6 2 10
 Streptococcus bovis 1 0 0 1
 Staphylococcus capitis 0 1 0 1
 Streptococcus species 1 1 1 3
 Not reported 25 21 15 61
Total Bacterial Meningitis, Not Otherwise 
Specified
 40 42 35 117
Total Bacterial Meningitis  88 82 69 239
Notes: *Tuberculosis meningitis figure for 2011 is provisional 
Following the introduction of pertussis vaccine in the 
1950s the number of pertussis cases notified declined, 
however, following a pertussis vaccine scare in the 
mid-1970s with decline in pertussis vaccination uptake 
the notifications started to increase again (figure 1).  
This trend was reversed in the 1990s as notifications 
decreased again to a low of 40 cases in 2003 (figure 1).  
Between 2004 and 2010 there was on average 87 cases 
notified each year.  In 2011, the number of pertussis 
cases notified doubled compared to 2010 with two 
hundred and twenty nine cases (5.0/100,000) notified in 
2011 compared to 114 cases in 2010 (figure 2).  
Of the 229 cases in 2011, 113 (49%) were classified as 
confirmed, 31 (14%) were classified as probable and 85 
(37%) were classified as possible.
In 2011, the largest number of cases (n=85, 37%) and 
the highest age-specific incidence rate (117/100,000) 
were in children aged less than one year with a third 
(n=79/229, 34%) of all cases aged less than six months 
(figures 3 and 4).  One death occurred in a one month 
old.  One hundred and thirty six cases (59%) were 
female and 92 (40%) were male while gender was 
unknown for one.
1.6 Pertussis
Summary
Number of cases, 2011: 229
Number of cases, 2010: 114
Crude incidence rate, 2011: 5.0/100,000
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Figure 1. Number of notified pertussis cases in Ireland by year, 1948-2011
1948-June 2000 data collated by DoHC
July 2000-2011 data collated by HPSC
Figure 2. Number of notified pertussis cases in Ireland by year, 2000-2011
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In Ireland it is recommended that children be vaccinated 
with an acellular pertussis-containing vaccine at two, 
four and six months of age and a booster dose at four 
to five years of age.  In 2008 the National Immunisation 
Advisory Committee (NIAC) recommended a booster 
with low dose acellular pertussis vaccine for children 
aged 11-14 years.  The adolescent pertussis booster 
was introduced into the school programme (in parts 
of the country) in 2011 and is being rolled out to all 
schools in 2012.  
In 2011, the vaccination status was reported for 148 
(65%) pertussis cases.  Nearly one third of cases 
(n=74/229, 32%) were unvaccinated; these cases 
ranged in age from three weeks to 74 years, with over 
a half (n=42/74, 57%) of these cases aged less than six 
months.  Nearly one third of the unvaccinated cases 
(n=23/74, 31%) were less than two months of age and 
were therefore not eligible for pertussis vaccine in the 
Irish schedule.  Thirty-six (n=36/229, 16%) cases were 
reported as incompletely vaccinated, but these included 
21 cases (n=21/36, 58%) who were less than six months 
of age and were therefore not eligible for three doses 
of pertussis vaccine in the Irish schedule.  Thirty-eight 
(n=38/229, 17%) cases were reported as completely 
vaccinated for their age; 16 of these were reported 
to have had three doses of pertussis vaccine, 14 were 
reported as having four doses, one was known to have 
the booster dose while the number of doses was not 
specified for the remainder.  Of the 14 cases reported 
as having four doses, four (29%) were classified as 
confirmed.
Twenty-two localised pertussis outbreaks were notified 
during 2011, with 90 associated cases of illness.  
Eighteen were family outbreaks (with 69 ill), two were 
community outbreaks (with 12 ill) and two were school 
outbreaks (with nine ill).   
                                                                                                                                                      
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) system on 4th September 
2012.  These figures may differ slightly from those 
published previously due to ongoing updating of 
notification data on CIDR.
Figure 4. The age specific incidence rate (per 100,000 population) of notified 
pertussis cases in 2011 by case classification
Figure 3. Number of notified pertussis cases in 2011 by age group and case 
classification.
“Mo” in graph indicates months i.e. 0-5 months and 6-11 months, the remaining age 
groups are in years
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In 2011, four cases (0.1/100,000) of rubella were notified 
in Ireland compared to 24 cases in 2010 (table 1). 
All four cases in 2011 were classified as possible and the 
age profile of the cases ranged from one to six years 
of age, as shown in figure 1. The age specific incidence 
rates by case classification are shown in figure 2.
Of the four rubella cases, two (50%) were male and two 
(50%) were female.  
Rubella vaccine in Ireland is available as part of the 
combined measles-mumps-rubella (MMR) vaccine.  
In Ireland, vaccination with the first dose of MMR is 
routinely recommended for all children at twelve months 
of age and the second dose at four to five years of age.   
Vaccination status was reported for all four (100%) of the 
rubella cases in 2011.  Three cases (75%) were reported 
as completely vaccinated for their age, each having had 
only one dose of MMR. All three were less than five 
years of age. One case was reported as incompletely 
vaccinated.
The diagnosis of rubella based solely on clinical signs 
and symptoms is often unreliable because there are 
many other causes of fever and rash illness which 
may resemble rubella infection. Therefore, diagnostic 
samples (serum, oral fluid, urine) should always be 
obtained from patients in order to accurately diagnose 
rubella. In 2011 the laboratory diagnosis of rubella 
required the identification of rubella IgM antibodies or 
IgG seroconversion or a fourfold or greater rise in titre 
to rubella virus in the absence of recent vaccination. 
Detection of rubella virus RNA in an appropriate 
specimen or a positive culture for rubella virus (not 
routinely performed) can also be done (following 
consultation with the laboratory). Vaccination with a 
rubella-containing vaccine eight days to eight weeks 
before sample collection makes interpretation of 
laboratory results difficult as vaccination induces similar 
serologic results. Therefore laboratory results always 
need to be interpreted according to vaccination status 
and history of recent vaccination.
In 2011 one case was serology positive for rubella, but 
had been vaccinated with one MMR dose just prior to 
1.7 Rubella
Summary
Number of cases, 2011: 4
Number of confirmed cases, 2011: 0
Crude incidence rate, 2011: 0.1/100,000
Crude confirmed incidence rate, 2011: 0.0/100,000
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Table 1. Number of rubella cases notified and the crude 
incidence rate per 100,000 population (CIR) by HSE Area in 
2011
HSE Area Number CIR
HSE-E 1 0.1
HSE-M 0 0.0
HSE-MW 0 0.0
HSE-NE 1 0.2
HSE-NW 0 0.0
HSE-SE 2 0.4
HSE-S 0 0.0
HSE-W 0 0.0
Total 4 0.1
disease onset and as such could not be considered a 
confirmed case. Accurate information on vaccination 
dates in relation to disease onset is needed to 
accurately interpret serology test results. 
Accurate and detailed information on all notified rubella 
cases is needed to monitor progress towards the WHO 
European Measles and Rubella Elimination Strategy (for 
2015). HPSC is currently working with the HSE Areas to 
improve rubella surveillance data and is in the process 
of expanding the enhanced surveillance of this disease, 
recorded using the Computerised Infectious Disease 
Reporting (CIDR) system.  
The figures presented in this summary are based on 
data extracted from CIDR on 14th September 2012.  
These figures may differ slightly from those published 
previously due to ongoing updating of notification data 
on CIDR.
Guidance on tests used to diagnose rubella is available 
on the NVRL website at http://www.ucd.ie/nvrl and 
on the HPSC website www.hpsc.ie/ under the disease 
name, see Topics A-Z. 
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Figure 2. The age specific incidence rate (per 100,000 
population) of notified rubella cases in 2011 by case 
classification
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Figure 1. Number of notified rubella cases in 2011 by age 
group and case classification
Background
Invasive Streptococcus pneumoniae infection is a 
notifiable disease in Ireland; clinicians and laboratories 
are legally obliged to notify this infection.  For the 
purposes of this report the term invasive pneumococcal 
disease (IPD) will be used to describe these infections.  
IPD includes meningitis and blood stream infection (BSI) 
with and without pneumonia. 
A number of different initiatives are in place in Ireland 
for the surveillance of IPD.  Data on IPD notifications 
are collated in the Computerised Infectious Disease 
Reporting (CIDR) system.  Enhanced surveillance 
on IPD notifications is undertaken by Departments 
of Public Health particularly on children born since 
2000 and these data are also collated in CIDR. A 
separate surveillance system (EARS-Net) involving the 
microbiology laboratories and the HPSC is used to 
monitor in detail the antimicrobial resistance profiles 
of invasive S. pneumoniae isolates from blood and/
or CSF.  Since April 2007, the National Pneumococcal 
Typing Project has been offering a typing service to 
Irish laboratories for all invasive S. pneumoniae isolates 
submitted. This is a collaborative project involving the 
RCSI/Beaumont Hospital, the Children’s University 
Hospital, Temple Street and the HPSC.
In September 2008, the 7-valent pneumococcal 
conjugate vaccine (PCV7) was introduced into the Irish 
infant immunisation schedule at 2, 6 and 12 months 
of age.  A catch-up campaign was also implemented 
at that time, targeting children <2 years of age.  In 
December 2010, PCV13 replaced PCV7 in the infant 
schedule. Uptake of three doses of PCV by 24 months 
of age is currently 91%.
IPD notification data was extracted from CIDR on 16th 
October 2012. These figures may differ slightly from 
those previously published due to ongoing updating of 
notification data on CIDR.  For the 2011 notifications, 
the 2003 HPSC case definition for IPD was used.  In 
brief, isolation or detection of S. pneumoniae from 
a normally sterile site was classified as confirmed; 
detection of S. pneumoniae antigen from a normally 
sterile site was a probable case and a clinically 
1.8 Streptococcus pneumoniae (invasive)
Summary
Number of cases in 2011: 425
Number of cases in 2010: 391
Number of deaths in 2011: 11
Number of deaths in 2010: 14
Crude incidence rate, 2011: 9.3/100,000
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Figure 1.  Number of confirmed invasive pneumococcal disease 
notifications by typing status and the incidence rate (IR) of 
confirmed IPD with 95% confidence intervals, 2008-2011
Data source: CIDR
compatible case without any laboratory confirmation or 
identification of S. pneumoniae from a non-sterile site 
(including urinary antigen positive) were classified as 
possible.
Results
All IPD notifications
In 2011, 425 cases of IPD (9.3/100,000) were notified 
in Ireland.  This was an 8.7% increase in incidence 
compared with 2010 when 391 cases were notified 
(8.5/100,000).  In 2011, 82% (n=349) of notifications 
were classified as confirmed, 1.9% (n=8) as probable 
and 16% as possible (n=68).  The majority of the 
possible cases (85%, n=58/68) were notified by HSE-
SE.  These figures do not necessarily indicate a higher 
burden of IPD in this area relative to other areas, but 
rather it may reflect more consistent reporting of 
positive urinary antigen cases from that area. 
Confirmed IPD notifications
For confirmed IPD notifications, 349 cases were 
notified in 2011 (7.6/100,000; 95% CI 6.8 - 8.4/100,000) 
(figure 1).  Although this was a 16% increase in 
incidence compared with 2010 (6.6/100,000; 95% CI 
5.3 – 7.3/100,000; 301 cases), overall the incidence 
of confirmed IPD in 2011 significantly declined by 
20% compared with 2008 (9.5/100,000; 95% CI 8.6 – 
10.5/100,000; 404 cases; p<0.05) (figure 1).
In 2011, 81% of the confirmed IPD notifications had an 
isolate submitted for serotyping which was similar to 
the proportion in 2010 and a slight improvement from 
2008 and 2009 when 79% of notifications had an isolate 
typed (figure 1).  In 2011 however, 41% of notifications 
(17/41) relating to children <5 years of age did not have 
an isolate submitted for serotyping.  For 11 of the 17 
an isolate was unavailable as the cases were confirmed 
by PCR only, while the remaining six did have an isolate 
from a sterile site.
Incidence rates by HSE area ranged from 5 per 100,000 
in HSE-M and NE to 9 per 100,000 in HSE-MW, NW and 
S with the incidence highest in the HSE areas along the 
western seaboard (figure 2).  However, the incidence 
rates in each of the eight HSE areas were not statistically 
different from the national one.
A clinical diagnosis was reported for just 127 of the 
349 confirmed cases (36%), which included meningitis 
(n=23), BSI with pneumonia (n=69) and other BSI for the 
remainder.
More cases occurred in males than in females, 55% of 
cases in the former (n=193).
Cases ranged in age from 5 days to 97 years, with an 
average age of 54.6 years and a median age of 62 
years.  Those aged 65 years and older accounted for 
almost half of the cases (46%, n=160). The age specific 
incidence rate was highest in those 85 years of age 
and older (70/100,000; n=41), followed by 75-84 years 
age group (34/100,000; n=58) and then those aged 
between 65 and 74 years (20/100,000; n=61) (figure 3).  
In children < 2 years of age the age-specific incidence 
rate was 16 cases per 100,000 population (n=23).  A 
statistically significant decline (62%) in IPD incidence 
was seen in this age group when compared with 2008 
(42.8/100,000; n=52; p<0.0001), highlighting the 
positive impact the introduction of PCV7 to the infant 
schedule in September 2008 has had on reducing the 
burden of IPD in young children (figure 3).
The medical risk factor field was completed for 
132 (38%) confirmed cases; for the remainder this 
information was either unknown or not specified.  
Based on the 132 cases with information reported, 96 
(73%) had an underlying medical risk factor, with some 
patients having multiple ones. The main risk factors 
reported included immunosuppressive condition or 
therapies (n=29), chronic heart disease (n=22), chronic 
lung disease (n=18) and chronic liver disease (n=13).  
It should also be noted that being elderly, aged 65 
years and older is also a recognised IPD risk factor; 160 
cases in 2011 were in this age group.  Apart from being 
elderly, 51 cases in this age group also had a reported 
medical risk factor.
Figure 2.  Incidence rate of confirmed invasive pneumococcal 
disease notifications by HSE area, 2011
Data source: CIDR
Figure 3.  Age specific incidence rate of confirmed invasive 
pneumococcal disease notifications by age group, 2008-2011
Data source: CIDR
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IPD death notifications
Outcome was reported on just 29% (n=123) of the 
IPD notifications in 2011.  Therefore, these figures 
underestimate the burden of IPD in terms of mortality. 
Based on the data available, 19 deaths in individuals 
with IPD in 2011 were reported.  The cause of death 
was reported as directly due to IPD in five cases, not 
due to IPD in eight cases and for the remaining six 
the cause of death was not specified or was unknown.  
Therefore, based on the outcome data available, IPD 
was potentially the cause of death in 11 patients, giving 
an IPD case fatality rate of 9%.  All deaths occurred in 
adults, ranging in age from 49-94 years.  Nine of the 
eleven deaths were in confirmed cases and one death 
each in a probable and possible IPD case. 
Impact of pneumococcal conjugate vaccines (PCV)
Data from the National Pneumococcal Typing Project 
were used to assess the impact of introducing PCV on 
the distribution of S. pneumoniae serotypes associated 
with IPD and on the burden of IPD in Ireland.  In 2011, 
isolates relating to 296 cases of IPD were typed, 
99% (n=293) of these records had a corresponding 
notification in CIDR.  Twenty percent of IPD infections 
were due to serotypes covered by PCV7 (4, 6B, 9V, 14, 
18C, 19F and 23F), 36% were associated with the six 
additional serotypes included in PCV13 (1, 3, 5, 6A, 7F 
and 19A) and the remaining 44% of infections were due 
to non-vaccine types (NVTs, serotypes excluding the 13 
covered by PCV13).  
Since introducing PCV7 to the Irish childhood 
immunisation schedule towards the end of 2008, there 
has been a 20% reduction in the overall burden of 
IPD disease.  In particular reductions in the incidence 
of IPD due to PCV7 serotypes have been seen in all 
age groups (figure 4a).  Overall the incidence of IPD 
due to PCV7 serotype has significantly declined in 
2011 compared with 2008 (70% decline, p<0.001).  
The greatest impact was seen in children <2 years of 
age where the incidence of the disease due to PCV7 
serotypes has declined by 93% (p<0.01) (figure 4a).  In 
2011, the early impact of PCV13 was observed; the 
incidence of disease due to the additional six serotypes 
in PCV13 declined by over half in the <2 year olds 
compared with 2008 (figure 4b).  This decline was not 
observed in any of the other age groups and in actual 
fact the incidence of disease increased compared with 
previous years (figure 4b). An increase in incidence due 
to the NVTs was also seen in 2011, particularly in the 
elderly, those aged 65 years and greater (figure 4c).  
The predominant serotypes in circulation in 2011, were 
7F and 19A (both included in PCV13) and then followed 
by serotypes 22F and 8 (both NVTs).  In children <2 
years of age, the predominant serotype was 19A, 
accounting for a third of the isolates serotyped in this 
age group (figure 5).
For ongoing updates, see “Slides – Impact of 
PCV in Ireland” at http://www.hpsc.ie/hpsc/A-Z/
VaccinePreventable/PneumococcalDisease/
PostersPresentations/
PCV vaccine failures
Based on data obtained through the IPD enhanced 
surveillance system, no PCV vaccine failures were 
reported in 2011.  However, there were nine 
Figure 4.  Age specific incidence rate by age group of 
confirmed invasive pneumococcal disease cases due to (a) 
PCV7 serotypes, (b) the additional six serotypes covered 
by PCV13 (PCV13-7) and (c) non-vaccine types (non-PCV13 
serotypes), 2008-2011
Data source: National Pneumococcal Typing Project
Figure 4a Figure 4b
Figure 4c
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notifications where a child was reported as fully 
vaccinated but no serotype information was available 
to ascertain whether any of these cases were genuine 
vaccine failures or not.  Since 2008, four vaccine failures 
have been reported, two due to serotype 14 and two 
due to 19F.
Penicillin non-susceptible S. pneumoniae (PNSP)
In 2011, the proportion of penicillin non-susceptible 
invasive S. pneumoniae (PNSP) was 19.6%, (6.1% and 
13.5% with high and intermediate level resistance, 
respectively) while 18.9% of isolates were resistant 
to erythromycin (Data source: EARS-Net).  In the UK, 
the PNSP proportion in 2011 was 5.5% (0.8% and 
4.7%, with high and intermediate level resistance, 
respectively). 
In 2011, Ireland had one of the highest proportions of 
PNSP in Europe ranking 7th out of 27 countries overall.  
Although, 35 different serotypes were identified in 
2011, only 10 serotypes were associated with being 
penicillin non-susceptible. The predominant PNSP 
serotypes in 2011 were 19A and 6A whereas in 2008 
serotypes 9V and 14 were the leading ones.  For 
details on the antimicrobial resistance patterns of S. 
pneumoniae, please see the chapter on Antimicrobial 
Resistance within this report.  
Discussion
Although the incidence of confirmed cases of IPD 
increased in Ireland in 2011 compared with 2010, PCV7 
has had a significant impact in reducing the overall 
burden of the disease in the total population.  There 
has been a decline in IPD in all age groups due to 
serotypes covered by PCV7, indicating the indirect/herd 
immunity effect the vaccine confers on the population.  
The greatest impact has been in children <2 years of 
age where the disease incidence due to PCV7 serotypes 
has been reduced by over 90%.  Early indications that 
PCV13 introduced in December 2010, was beginning to 
have an impact was seen during 2011, when a reduction 
in the incidence of disease due to the additional six 
serotypes covered by PCV13 was observed in children 
<2 years of age.
However, despite these reductions in IPD burden, the 
incidence of disease due to non-PCV7 serotypes has 
increased in those > 2 years of age.  There has been a 
shift in the prevalent serotypes associated with invasive 
disease.  Serotypes 7F, 19A, and 22 have replaced 14, 
4 and 9V (all covered by PCV7) as the predominant 
serotypes.  The additional serotypes covered by PCV13 
(particularly 7F and 19A) will hopefully tackle some of 
the serotype replacement issues observed in 2011. 
To accurately assess the impact of PCV on immunisation 
programmes and to monitor for vaccine failures in 
Ireland, it is crucial that laboratories continue to send 
all invasive S. pneumoniae isolates for typing to the 
National Pneumococcal Typing Project.  Although 81% 
of confirmed notifications had an isolate submitted 
for serotyping in 2011, 19% (n=66) did not, including 
17 cases in children <5 years of age.  In 11 of these 
17 cases an isolate was not available for typing as 
confirmation was by PCR only.  The overall concern 
is that serotype information is unavailable for 40% of 
confirmed notifications in this age group.
Continued good quality IPD surveillance including the 
monitoring of invasive S. pneumoniae serotypes is 
crucial in identifying any epidemiological changes in the 
disease, assessing the impact of PCV13 on public health 
and in guiding further vaccination strategies as newer 
expanded valency vaccines are made available.  For 
example, due to the incomplete data we do not know 
the impact of IPD on mortality and this is a key metric 
in assessing the true impact of this disease and the 
effectiveness of interventions, including new vaccines. A 
properly resourced national reference laboratory service 
for pneumococcal typing is urgently required.
Figure 5. Serotype distribution of invasive Streptococcus pneumoniae isolates by age group 
(years) in Ireland, 2011
* Denotes serotypes included in PCV7
*^ Denotes additional six serotypes included in PCV13 (PCV13-7)
Data source: National Pneumococcal Typing Project
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HPSC has worked in collaboration with the National 
Virus Reference Laboratory (NVRL), the Irish College 
of General Practitioners (ICGP) and the Departments 
of Public Health on the influenza sentinel surveillance 
project since 2000. Sixty general practices (located in all 
HSE-Areas) were recruited to report electronically, on 
a weekly basis, the number of patients who consulted 
with influenza-like illness (ILI). Sentinel GPs were 
requested to send a combined nasal and throat swab 
on one ILI patient per week to the NVRL. The NVRL 
also tested respiratory non-sentinel specimens, referred 
mainly from hospitals. 
Other surveillance systems set up to monitor ILI/
influenza activity include: 
•  Surveillance of all calls to GP out-of-hours (OOHs) 
centres, monitored for self-reported influenza. These 
data were provided by HSE-NE.  
•  Surveillance of all confirmed influenza notifications, 
including hospitalisation status reported to the 
Computerised Infectious Disease Reporting System 
(CIDR) in Ireland. 
•  Enhanced surveillance of hospitalised influenza cases 
aged 0-14 years.   
•  Intensive Care Society of Ireland (ICSI) enhanced 
surveillance of all critical care patients with confirmed 
influenza and enhanced surveillance of all severe acute 
respiratory infections (SARI) in two pilot ICU sites.  
•  Enhanced surveillance of all confirmed influenza 
deaths. 
•  A network of sentinel hospitals reporting admissions 
data
The data presented in this summary were based on 
data reported to HPSC by the 16th November 2012. 
Due to legislation regarding the registration of deaths 
in Ireland; there can be significant delays between 
the date of death and the registration of deaths and 
subsequent reporting to HPSC.
Sentinel GP Clinical Data
Influenza activity in Ireland was low during the 
2011/2012-influenza season, with sentinel GP ILI 
consultation rates peaking at 41.3 per 100,000 
population during week 8 2012 (February) (figure 1). 
ILI rates first increased above baseline levels (25.9 per 
100,000) during week 7 2012 and remained there for 
only three weeks. ILI age specific rates in all age groups 
during the 2011/2012 season, were the lowest recorded 
for a number of seasons. The highest age specific 
ILI rates were in the 0-4 year age group (peaking at 
70.7/100,000), followed by those aged 5-14 years 
(51.4/100,000), 15-64 years (42.4/100,000) and those 
aged 65 years or older (34.7/100,000).
Virological Data
The NVRL tested 509 sentinel specimens for influenza 
virus during the 2011/2012 season. One hundred and 
eighty-six (36.5%) sentinel specimens were positive for 
influenza: 172 influenza A (169 A (H3), 1 A (H1)pdm09 
and 2 A unsubtyped) and 14 influenza B. At the peak 
of influenza activity, the proportion of influenza positive 
sentinel specimens reached 69.7% (during week 9 
2012).
The NVRL tested 4,499 non-sentinel respiratory 
specimens during the 2011/2012 season, 371 (8.2%) of 
which were positive for influenza: 355 influenza A (312 
A (H3) and 43 A (unsubtyped)) and 16 influenza B. The 
proportion of influenza positive non-sentinel specimens 
peaked at 21.3% (during week 7 2012).
Influenza A (H3) was the dominant influenza virus 
circulating during the 2011/2012 season. Influenza 
A (H3), accounted for 86.4% of all positive influenza 
specimens and 99.8% of all positive influenza A 
subtyped specimens. Influenza A accounted for 94.6% 
2.1 Influenza
Summary
2011/2012 influenza season summary: 
Peak influenza-like illness rate: 41.3 / 100,000
Total confirmed influenza cases hospitalised:  147
Total confirmed influenza cases admitted to ICU: 15
Total influenza-associated deaths: 13 (7 confirmed &  
6 probable)
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of all influenza positive specimens and influenza B for 
5.4% during the 2011/2012 season. 
Outbreaks, GP OOHs, Sentinel hospital & school data
Seventeen general ILI/influenza outbreaks were 
reported: one ILI outbreak, 15 influenza A (H3) 
outbreaks and one influenza B outbreak. Seven 
outbreaks were reported from HSE-E, two from HSE-M, 
four from HSE-NE, two from HSE-NW and two from 
HSE-W. All 17 outbreaks were associated with the 
elderly, either in community hospitals/long stay units, 
residential institutions/nursing homes or hospital units 
for the elderly. Twelve influenza-associated deaths were 
linked to these outbreaks, all of whom were in those 
aged 80 years of age or older. 
The percentage of influenza-related calls to GP out-
of-hours services in Ireland, peaked during week 52 
2011 at 3.6% (coinciding with the peak in respiratory 
syncytial virus (RSV) activity) and peaked again during 
week 8 2012 at 3.2% (coinciding with influenza activity). 
These are the lowest peak proportions recorded for 
several seasons. During the peak of activity, each service 
only received on average, 1.2 calls per hour relating to 
influenza.
  
Hospital respiratory admissions in sentinel hospitals 
peaked during week 7 2012, one week prior to the peak 
in sentinel GP ILI consultation rates. Total emergency 
admissions reported from sentinel hospitals peaked 
during week 6 2012. 
Influenza notifications
A total of 600 influenza notifications were reported 
on CIDR during the 2011/2012 influenza season. The 
peak of influenza notifications occurred during week 10 
2012, two weeks following the peak in ILI consultation 
rates and GP OOHs flu calls. Of the 600 notifications, 
333 (55.5%) were influenza A (H3), 1 (0.2%) was 
influenza A (H1)pdm2009, 222 (37.0%) were influenza A 
(unsubtyped) and 44 (7.3%) were influenza B. 
Hospitalisation 
One hundred and forty-seven cases with confirmed 
influenza were hospitalised during the 2011/2012 
influenza season. The highest age specific rate in 
hospitalised cases for the 2011/2012 season was in 
those less than one year of age (42.8 per 100,000 
population) (table 1). Of the 147 hospitalised cases, 74 
(50.3%) were influenza A (H3), 64 (43.5%) were influenza 
A (unsubtyped) and 9 (6.1%) were influenza B. 
 
Enhanced surveillance hospital data on 0-14 year age 
group
A total of 140 confirmed influenza cases aged between 
0 and 14 years were notified on CIDR for the 2011/2012 
influenza season, 66 (47.1%) of these cases were 
hospitalised. Sixty-five cases (98.5%) were positive 
for influenza A [18 A (H3) and 47 A (unsubtyped)] and 
one (1.5%) was positive for influenza B. The median 
age of cases was 1 year, ranging from 3 weeks to 14 
years. Over 75% of cases were aged between 0 and 4 
years, with almost one third of cases aged less than 6 
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Figure 1: ILI sentinel GP consultation rates per 100,000 population, baseline ILI threshold rate, and number of positive influenza 
A and B specimens tested by the NVRL, by influenza week and season. 
Source: Clinical ILI data from ICGP and virological data from the NVRL.
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months old. Enhanced surveillance data was available 
for 58 (87.9%) cases. The most frequently reported 
symptoms included: fever (96.0%), cough (87.8%), 
sore throat (44.4%), fatigue (43.2%) and gastroenteric 
manifestations (21.6%). Complications were reported 
for 61.3% of cases; of these cases more than one 
complication was reported for 29.5% of cases. The 
most frequently reported complications included 
primary influenza viral pneumonia, secondary bacterial 
pneumonia, other respiratory complications, febrile 
convulsions and liver dysfunction. The median length of 
stay in hospital was 3 days (ranging from 1 - 14 days). 
Approximately 41.9% (18/43) of cases had underlying 
medical conditions, with chronic respiratory disease 
(including asthma) and immunosuppression being the 
most frequently reported. In total, vaccination status 
was known for 45 hospitalised paediatric cases, none 
of whom were vaccinated. Fourteen of the 18 cases 
with underlying medical conditions were not vaccinated 
(vaccination status was unknown for 4/18 cases). 
Approximately, 18% of cases (8/45) commenced antiviral 
treatment and 82.2% (37/45) of cases did not. Over 
one-fifth of cases were associated with an ILI/influenza 
outbreak. Five cases were admitted to critical care (for 
further details, see disease severity below). 
Confirmed influenza cases admitted to ICU 
Of the 147 hospitalised confirmed influenza cases, 15 
(10.2%) were admitted to critical care (10 adults and 
5 paediatric cases). Age specific rates for patients 
admitted to ICU were low in all age groups, with the 
highest rates in those aged less than 1 year of age (1.4 
per 100,000 population) (table 1). The median age of 
paediatric cases was 14 months of age and the median 
age of adult cases was 66 years. Ten (100%) adults and 
three (3/4, 75.0%) paediatric cases had pre-existing 
medical conditions. The most frequently reported 
underlying medical condition for adults was chronic 
respiratory disease (7/10, 75.0%). Underlying medical 
conditions for paediatric cases were varied. Nine (9/10, 
90.0%) adults and two (2/4, 50.0%) paediatric cases 
were ventilated during their stay in ICU. The median 
length of stay in ICU for adult cases was 4.5 days 
(ranging from 1 - 65 days) and for paediatric cases was 
3.0 days (ranging from 2 - 3 days). Vaccination status 
was only known for four of the 15 cases admitted to 
ICU, two cases were vaccinated and two were not. 
Mortality data
During the 2011/2012 influenza season, 13 influenza-
associated deaths1† were reported. The case 
classification of influenza was confirmed for seven 
cases and probable for six cases. Of the seven cases 
with known virology, six were associated with influenza 
A (H3) and one with influenza B. The median age of 
cases who died during the 2011/2012 influenza season 
was 88 years, ranging from 81 – 98 years. Vaccination 
status was known for 12 of the 13 (92.3%) cases. Nine 
(75.0%) cases were vaccinated and three (25.0%) were 
not vaccinated with the 2011/2012 influenza vaccine 
(see below for further details on influenza vaccine 
effectiveness for the 2011/2012 season). 
A summary table of confirmed influenza critical care 
cases and influenza-associated deaths for all ages is 
detailed in table 2.
Overview of the 2011/2012 influenza season 
Influenza activity in Ireland during the 2011/2012 season 
started later than usual in February and was mild, 
with lower ILI consultation rates and lower influenza 
positivity rates than previous seasons. ILI rates only 
remained above baseline levels for three weeks, with 
the lowest peak rate recorded since the sentinel GP 
surveillance scheme began in 2000, with the exception 
of the 2001/2002 season (when ILI rates peaked at 29.1 
-37-HPSC Annual Report 2011 2. Respiratory and Direct Contact Diseases
Table 1: Age specific rate for confirmed influenza cases hospitalised and admitted to critical care during the 2011/2012 influenza 
season. Age specific rates are based on the 2011 CSO population census.
Hospitalised Admitted to ICU
Age (years) Number Age specific rate per 100,000 pop. Number Age specific rate per 100,000 pop.
<1 31 42.8 1 1.4
1-4 20 7.0 3 1.1
5-14 15 2.4 1 0.2
15-24 5 0.9 1 0.2
25-34 15 2.0 1 0.1
35-44 10 1.3 0 0.0
45-54 2 0.3 0 0.0
55-64 13 2.8 2 0.4
65+ 36 6.7 6 1.1
Total 147 3.2 15 0.3
† Influenza-associated deaths include all deaths where influenza is reported as the primary/main cause of death by the physician 
or if influenza is listed anywhere on the death certificate as the cause of death.
per 100,000 population). The predominant circulating 
influenza virus was influenza A (H3). There were fewer 
cases admitted to hospital or critical care units during 
the 2011/2012 season, compared to the previous 
two seasons which included the 2009 pandemic. 
The number of influenza-associated deaths reported 
was also lower than the previous two seasons. Of 
significance for the 2011/2012 season were the late 
season outbreaks associated with a number of deaths 
in residential institutions/nursing homes/units for the 
elderly. These outbreaks were reflected elsewhere in 
Europe 1, 2.
The WHO and ECDC reported that antigenic and 
genetic characterisations of circulating influenza 
viruses during the 2011/2012 season demonstrated 
an imperfect match with the A (H3N2) vaccine antigen 
used in the 2011/2012 influenza vaccine. Influenza B 
virus detections were from the Victoria and Yamagata 
lineages. These global data along with other vaccine 
effectiveness studies confirmed reduced vaccine 
effectiveness during the 2011/2012 influenza season3. 
These findings support the decision by WHO to 
recommend a change in the strains included in the 
2012/2013 influenza vaccine.4 Despite the imperfect 
match, early estimates of the efficacy of the 2011/2012 
influenza vaccine in healthy adults was 43%, which 
although low is better than no vaccine. In addition to an 
imperfect match with the vaccine, the late start of the 
2011/2012 influenza season in Europe with a resultant 
time lag between the beginning of the vaccination 
campaigns and the start of the influenza season may 
have resulted in waning immunity from the vaccine in 
the elderly population. 5
2012/2013 influenza season
For the 2012/2013 influenza season, existing 
surveillance systems have been strengthened and a 
number of additional measures have been put in place 
in Ireland to improve the surveillance of ILI/influenza. 
Influenza/ILI outbreak surveillance forms and guidance 
have been updated following the late season outbreaks 
during the 2011/2012 season. Work is in progress to 
improve reporting of influenza vaccine uptake in risk 
groups for influenza. HPSC are participating in a WHO 
pilot project to automatically calculate the intensity of 
influenza each week using sentinel GP ILI consultation 
rates. The NVRL have introduced multiplex PCR testing 
for influenza A, B, RSV, adenovirus, parainfluenza virus 
types -1 and -3 and human metapneumovirus for all 
sentinel GP swabs. Surveillance of influenza notifications 
(including hospital status), ILI/influenza outbreaks 
and enhanced surveillance of confirmed hospitalised 
influenza cases (aged 0-14 years) and of confirmed 
influenza cases in critical care units (all ages) will 
continue for the 2012/2013 influenza season. Additional 
projects not detailed in this report include an all-
cause mortality monitoring project associated with the 
European mortality monitoring group (EuroMOMO) and 
a pilot project on severe acute respiratory infections 
(SARI) cases admitted to two critical care units.  Data 
from all of these surveillance systems will assist in 
guiding the management and control of influenza and 
any future epidemics or pandemics. 
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Table 2: Summary table of confirmed influenza critical care cases and influenza-associated deaths for all ages for the pandemic 
period, 2010/2011 and 2011/2012 seasons. It should be noted that risk factor data was not available for all age groups for the 
2011/2012 season. Rates are based on the 2011 CSO population census.
Admitted to ICU Influenza-associated deaths
Pandemic period 2010/2011 2011/2012
Pandemic 
period
2010/2011 2011/2012
    Total cases 100 121 15 29 38 13
    Crude rate per 100,000 pop. 2.2 2.6 0.3 0.6 0.8 0.3
    Age range (years) 0-79 0-80 0-80 8-83 2-83 81-98
    Median age (years) 34 49 60 54 57 88
    Females 
50 64 12 15 18 5
50.0% 52.9% 80.0% 51.7% 47.4% 38.5%
    Cases with risk factor
81 90 13 27 32 7*
81.0% 74.4% 86.7% 93.1% 84.2% 87.5%
*Risk factor data for influenza-associated deaths for the 2011/2012 season were only known for 7/8 cases.
In 2011, there were seven cases of Legionnaires’ disease 
notified in Ireland, a rate of 1.5 per million population. 
No deaths associated with Legionnaires’ disease were 
reported.
Three cases were reported from HSE East, three from 
HSE South (South East), and one from HSE South (Cork 
and Kerry).
The majority of cases were male (85.7%). The median 
age was 68 years with a range from 57 to 91 years.
One of the seven cases was classified as probable. All 
six confirmed cases were diagnosed by urinary antigen 
test (UAT) and two had the organism cultured. The 
organism involved in the six cases confirmed by UAT 
was Legionella pneumophila serogroup 1. One of the 
cases where the organism was cultured was found to be 
monoclonal subtype Benidorm. 
Five cases were travel-associated. Countries of travel 
included Indonesia (2), Ireland (1) and Italy (2). All five 
cases were linked to various travel related clusters. Of 
the two remaining cases, one was healthcare-associated 
and the other was assumed to be community acquired.
The peak month for notifications was November when 
three cases were notified.
2.2 Legionellosis
Summary
Number of cases in 2011: 7
Crude incidence rate: 1.5 per million
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Table 1. Number of legionnaires’ disease cases per million population in Ireland, 2004-2011
Age group 
(years)
2004 2005 2006 2007 2008 2009 2010 2011
<30 0 0 0 1 0 0 1 0
30-39 0 2 0 3 0 0 0 0
40-49 1 3 7 4 2 0 2 0
50-59 1 1 2 2 3 2 1 1
60-69 1 1 1 3 4 3 3 4
70+ 1 1 2 2 2 2 4 2
Total 4 8 12 15 11 7 11 7
CIR 0.9 1.9 2.8 3.5 2.6 1.5 2.4 1.5
For details of denominator data used, please see Explanatory Notes section at the end of this document
Notifications
Sixty-seven cases of invasive Group A streptococcal 
(iGAS) disease were notified in 2011.  This corresponds 
to 1.46 iGAS cases per 100,000 population [95% 
confidence interval (CI), 1.13 to 1.85 per 100,000], which 
is similar to 2010 when the iGAS rate was 1.48 per 
100,000 population (95% CI, 1.15 to 1.88 per 100,000).  
Sixty-five cases were confirmed, defined as patients 
with Group A streptococcus (GAS), or Streptococcus 
pyogenes, isolated from a sterile site. Two cases were 
probable, defined as patients with streptococcal toxic 
shock syndrome (STSS) and GAS isolated from a non-
sterile site (e.g. throat, sputum, vagina).
Patient demographics
Of the 67 cases, 28 (42%) were males and 39 (58%) were 
females, with ages ranging from 3 months to 97 years 
(mean, 46 years; median, 39 years). iGAS was more 
common in young children and older adults (Figure 1). 
Geographic spread and seasonal variation
Table 1 outlines the numbers and crude incidence 
rates (CIRs) of iGAS disease by HSE area from 2005 to 
2011. Of note, the highest number of cases in 2011 
occurred in the HSE-East (n=29; CIR, 1.79 per 100,000 
population) while the highest CIR occurred in the HSE-
South (n=12; CIR, 2.41 per 100,000 population). 
In 2011, the peak periods were February/March (17 
cases) and May-July (20 cases), which is broadly similar 
to previous years with the peak occurring during the 
first half of the year. Note, the number of monthly cases 
(based on the date the case was positive for GAS and 
not the date the case was reported) is small, ranging 
from one to eleven.
Enhanced surveillance data 
Enhanced data fields were entered for 61 (90%) of 
the iGAS cases, which is similar to 2010 (88%, 60 of 
68 cases). The source laboratory could be ascertained 
for all cases. As in previous years, a wide variation in 
completed fields was observed. 
2.3  Invasive Group A Streptococcal 
 Disease
Summary
Number of cases, 2011:  67
Crude incidence rate, 2011: 1.46 per 100,000 
population
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Figure 1. Age and sex specific rates of iGAS disease in 2011
Isolate details
GAS was isolated from a sterile site in 58 of 65 
confirmed cases (no data on the source were available 
for seven cases), primarily from blood cultures (n=53 
isolates, 91%), but also deep tissue (n=2), an abscess 
(n=1), a joint (n=1) and cerebrospinal fluid (CSF) (n=1). 
For the two probable cases, GAS source was provided 
for one: as a vaginal swab.
Serological typing data, based on the detection of M 
and T-proteins, were available on 16 isolates submitted 
from five laboratories: emm/M12 (n=6), M1 (n=5) and 
M3, M4, M5.3, M63 and M89 (one isolate of each). Of 
these, enhanced data were available on 13 patients with 
iGAS, none of whom presented with STSS or necrotising 
fasciitis. 
Clinical details
As in 2010 and previous years, bacteraemia (n=53 cases, 
including cases where bacteraemia was not specifically 
stated but GAS was isolated from blood) and cellulitis 
(n=24) were the most common clinical presentations, 
followed by pneumonia (n=8), STSS (n=5; one of which 
was implied based on the information provided on 
the clinical presentation), necrotising fasciitis (n=3), 
peritonitis (n=3), septic arthritis (n=2), puerperal sepsis 
(n=2) and meningitis (n=1). Note that cases could have 
more than one clinical manifestation of infection.  
Risk factors
Risk factors associated with iGAS disease included 
age ≥65 years (n=22), presence of skin and wound 
lesions (n=20), diabetes mellitus (n=8), intravenous 
drug use (IVDU) (n=7), malignancy (n=6), non-steroidal 
anti-inflammatory drug (NSAID) use (n=1), childbirth 
(n=5), injecting drug use (n=1), varicella infection (n=3), 
alcoholism (n=1) and steroid use (n=1). Note that cases 
could have one or more associated risk factors: 27 
cases had one risk factor, 16 had two risk factors, two 
had three risk factors and one had four risk factors. No 
risk factors were identified for eight cases. Among the 
five cases with STSS, skin/wound lesions and age 65 
years and over was identified as a risk factor in two, and 
childbirth in one. No risk factors were identified for the 
other two STSS cases. 
Clinical management
Surgical intervention was required for eight patients 
ranging in age from 26 to 86 years (compared to 12 in 
2010).
Eleven patients ranging in age from 26 to 87 years were 
admitted to an intensive care unit (ICU) (compared to 
13 in 2010). This included two patients with STSS, one 
patient with necrotising fasciitis and two patients with 
both STSS and necrotising fasciitis.
Risk factors for patients admitted to an ICU included 
skin and wound lesions (n=4), age over 65 years (n=2), 
diabetes mellitus (n=1), childbirth (n=2), alcoholism 
(n=1), injecting drug use (n=1) and malignancy (n=1). 
Four patients had one and four had two risk factors. No 
risk factors were identified in two patients. No risk factor 
data were available for one patient.
Length of ICU stay was provided for eight cases ranging 
from one to seven days (mean, 3.3 days; median, 3 
days). 
Other epidemiological information
Two cases (both bacteraemia, one with necrotising 
fasciitis and puerperal sepsis and the other with 
peritonitis) were reported as hospital-acquired, 
compared to three in 2010. 
As in 2010, no outbreaks of iGAS were notified in 2011.
Outcome
Outcome at seven-days following GAS isolation was 
reported for 43 cases: 
• 37 were still alive 
•  Six patients died: GAS was the main or contributory 
cause of death for five patients 
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Table 1. Numbers (n) and Crude Incidence Rates (CIRs) per 100,000 population of iGAS disease by HSE Area, 2005-2011
HSE Area 2005 2006 2007 2008 2009 2010 2011
 n CIR n  CIR   n   CIR    n   CIR    n   CIR    n   CIR    n   CIR    
HSE-E 19 1.27 37 2.47 28 1.87 31 2.07 32 1.98 22 1.36 29 1.79
HSE-M 1 0.40 2 0.79 0 0.00 0 0.00 2 0.71 2 0.71 5 1.77
HSE-MW 3 0.83 2 0.55 2 0.55 3 0.83 5 1.32 6 1.58 6 1.58
HSE-NE 3 0.76 5 1.27 3 0.76 10 2.54 3 0.68 7 1.59 1 0.23
HSE-NW 3 1.27 1 0.42 3 1.27 3 1.27 1 0.39 8 3.10 2 0.77
HSE-SE 1 0.22 4 0.87 10 2.17 8 1.74 8 1.20 5 0.75 7 1.05
HSE-S 1 0.16 3 0.48 4 0.64 5 0.80 5 1.00 12 2.41 12 2.41
HSE-W 18 4.34 7 1.69 7 1.69 10 2.41 4 0.90 6 1.35 5 1.12
IRELAND 49 1.16 61 1.44 57 1.34 70 1.65 60 1.31 68 1.48 67 1.46
CIRs for 2005-2008 calculated using the 2006 census; CIRs for 2010-2011 calculated using the 2011 census [note: CIRs for 2009 and 2010 
updated from last year’s (2010) report]
The seven-day case fatality rate (CFR) for iGAS disease 
was 12% in 2010, which is similar to that in 2009 (10%).
In addition to the above, the overall outcome was 
stated for a further 12 cases:
•  Three patients were reported to have died but it was 
not stated if these were directly attributable to iGAS  
•  Six patients were recovering or recovered
•  One patient was still ill 
Of the five STSS cases, one patient died due to GAS 
resulting in a CFR of 20%.  One other patient with STSS 
died but GAS was not identified as the cause of death.
Antimicrobial susceptibility
Antimicrobial susceptibility data were reported on 42 
iGAS isolates (39 from blood, two from wounds and 
one from a joint) by 14 laboratories in 2011 (note: 
these were reported via the EARS-Net Antimicrobial 
Resistance Surveillance Network, of which 38 (90%) 
were also notified to public health via CIDR). All isolates 
tested were susceptible to penicillin (n=41), clindamycin 
(n=13) and vancomycin (n=31).  Resistance to 
erythromycin was reported in four (10%) of 41 isolates 
and to tetracycline in one (6%) of 16 isolates.
Conclusion
In 2011, iGAS infection remains an uncommon but 
potentially severe disease in Ireland.  Ongoing 
surveillance is essential, specifically completion of 
the enhanced data questionnaire, to gain a greater 
understanding of iGAS, to enable early detection of 
clusters/outbreaks, to ensure prompt implementation 
of infection prevention and control precautions and 
appropriate management of contacts. Between 2006 
and 2011, the number of cases of iGAS has fluctuated 
from 57 to 70, while the incidence has fluctuated from 
1.3 to 1.65 per 100,000 population. Over the last 
two years (2010 and 2011), the number of cases and 
incidence of iGAS have stabilised at 67 cases and 1.5 
per 100,000 population, respectively. Antimicrobial 
susceptibility data confirm that iGAS remains 
susceptible to penicillin and that penicillin should 
continue to be the first line treatment where iGAS is 
suspected.  
HPSC would like to thank participating microbiology 
laboratories for their contribution to iGAS enhanced 
surveillance scheme. 
All microbiology laboratories are encouraged:
•  to return enhanced iGAS surveillance forms for all 
patients with iGAS 
•  to submit all iGAS isolates to the Epidemiology and 
Molecular Biology Unit (EMBU) at the Children’s 
University Hospital, Temple Street for emm-typing 
•  to submit antimicrobial susceptibility data on all iGAS 
cases along with their EARS-Net quarterly returns
The enhanced surveillance form can be downloaded 
from the HPSC web site at: http://www.hpsc.ie/
hpsc/A-Z/Other/GroupAStreptococcalDiseaseGAS/
SurveillanceForms/
Further information on iGAS disease in Ireland, 
including factsheets for patients and contacts and 
national guidelines, is available at: http://www.ndsc.ie/
hpsc/A-Z/Other/GroupAStreptococcalDiseaseGAS/
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Diseases Reporting (CIDR) System on 5th October 2012. 
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In 2010, 420 cases of tuberculosis (TB) were notified 
in Ireland, corresponding to a crude notification rate 
of 9.2 per 100,000 population, which is a decrease 
compared to 2009 (10.4/100,000 population) and 
2008 (11.0/100,000 population). A summary of the 
epidemiology of TB in Ireland during 2010 is shown in 
table 1 while the number of cases and crude incidence 
rates from 1991 to 2011* with three-year moving 
averages are shown in figure 1. 
The highest crude incidence rates were reported 
by HSE-S (13.5/100,000 population) and HSE-E 
(11.1/100,000 population) while the lowest rates were 
reported by HSE-W (4.7/100,000 population) and HSE-
SE (5.4/100,000 population). 
The highest age-specific rate in 2010 occurred among 
those aged 65 years and over (14.8/100,000 population) 
followed by those aged 25-34 years (13.9/100,000 
population). The rate among males (11.5/100,000 
population) was higher than that among females 
(6.9/100,000 population). Rates among males were 
higher than females for all age groups except in the 
15-24 year age group where the rate in males was 
lower (13.1/100,000 population in females compared 
to 11.0/100,000 population in males). The highest rate 
among males (21.0/100,000 population) was in the 
group aged 65 years and older while the highest rate 
in females (13.1/100,000 population) was in the 15-
24 year age group. The male to female ratio (1.6:0.6) 
reported in 2010 was consistent with the ratio reported 
in previous years. 
Geographic origin
During 2010, 40.7% (171 cases) of TB cases were born 
outside Ireland. This is similar to the proportion of 
foreign-born cases reported annually since 2007 (range: 
40%-43%). The crude rate in the indigenous population 
was 6.5 per 100,000 population, a slight decrease 
compared to 2009 (7.2/100,000 population). Similarly, 
the crude rate in the foreign-born population decreased 
to 22.3 per 100,000 population compared to 26.9 per 
2.4 Tuberculosis, 2010
Summary
Number of cases in 2010: 420
Number of culture confirmed cases: 281
Crude incidence rate in 2010: 9.2/100,000
Number of TB deaths in 2010: 8
Number of cases in 2011*: 424
Crude incidence rate in 2011*: 9.2/100,000
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Table 1: Summary of the epidemiology of TB in Ireland, 2010
Parameter Number % of Total 
cases
Total number of cases 420
Crude notification rate per 100,000 9.2
Cases in indigenous population† 246 58.6
Cases in foreign-born persons† 171 40.7
Culture positive cases 281 66.9
Pulmonary cases 270 64.3
Smear positive pulmonary cases 111 26.4
Multi-drug resistant cases 2 0.5
Mono-resistant to isoniazid 10 2.4
Deaths attributable to TB 8 1.9
Outcomes reported in cases 370 88.1
TB meningitis cases 9 2.1
*Data for 2011 are provisional data which may change significantly following validation
†Country of birth was unknown for 3 cases 
100,000 population reported in 2009. There was a 
notable difference in age between those born in Ireland 
and those born outside Ireland, with a median age of 
49 years and 30 years respectively. In 2010, among 
countries in the EU and Western Europe who reported 
data to the European Centre for Disease Prevention and 
Control (ECDC), 25.1% of notifications were in foreign-
born cases. In Belgium, Slovakia and Slovenia, where 
crude incidence rates are similar to those reported in 
Ireland, the percentage of cases of foreign origin in 
2010 ranged from 1.8%-54.6%.†
Site of infection 
Pulmonary TB was reported in 270 (64.3%) cases and 
150 (35.7%) had exclusively extrapulmonary disease. Of 
the extrapulmonary cases reported in 2010, there were 
nine cases of TB meningitis corresponding to a rate of 
0.2/100,000 population (1.96/million population).
Microbiology
Of the 420 cases reported in 2010, 66.9% (281 cases) 
were culture confirmed. Of the 281 culture confirmed 
cases, species identification showed M. tuberculosis 
in 94.3% (265 cases), M. bovis in 4.3% (12 cases) and 
M. africanum in 1.1% (3 cases) while organism was not 
reported for the remaining culture confirmed case. 
The number of M. bovis isolates detected in 2010 was 
higher than the number detected during 2009 (n=8) 
and also higher than the mean annual number reported 
between 2002 and 2009 (n=6). Of the 270 cases with a 
pulmonary component, 206 (76.3%) were reported as 
culture confirmed, and 111 (41.1%) were reported as  
smear positive.  
Drug sensitivity 
Information on antibiotic sensitivity testing was available 
for 257 (91.5%) of the 281 culture confirmed cases. Of 
these, resistance was documented in 26 (9.3%) cases, 
two (0.5% of total cases) of which were MDR-TB cases. 
Mono-resistance to isoniazid was recorded in 10 cases, 
to streptomycin in five, to rifampicin in two cases, to 
pyrazinamide in one case and to ethambutol in one. 
Further details on the resistance profiles of TB cases 
reported in 2010 will be available in the HPSC Report on 
the Epidemiology of TB in Ireland, 2010 (www.hpsc.ie).
Outcome
In 2010, information on treatment outcome was 
provided for 88.1% (370) of cases, an increase 
compared to 82.3% in 2009. Treatment outcome was 
reported as completed for 304 (72.4%) cases, 30 (7.1%) 
were lost to follow up, 27 (6.4%) cases died, seven 
(1.7%) had treatment interrupted and two were still on 
treatment (0.5%). Eight (29.6%) of the 27 deaths were 
attributable to TB. During 2010, the reported treatment 
success rate was 72.6% for new culture confirmed 
pulmonary TB cases and 70.6% for new smear-positive 
pulmonary TB cases. 
Outbreaks 
The introduction of the amendment to the Infectious 
Disease Regulations 1981 on January 1st 2004, made 
outbreaks, unusual clusters or changing patterns of 
illness statutorily notifiable by medical practitioners and 
clinical directors of laboratories to the medical officer of 
health. Standard reporting procedures for surveillance 
of TB outbreaks were formally agreed in 2007. 
During 2010, seven outbreaks of TB were reported to 
HSPC, with 41 cases of active TB, 60 with latent TB 
infection (LTBI) and 20 hospitalisations. Two outbreaks 
were reported by HSE-M and five by HSE-S. There 
were five general outbreaks, three of which occurred 
in schools and one each in a community setting and a 
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Figure 1: Notified cases of TB in Ireland with crude rates per 100,000 population, 1991 to 2011* and 
3-year moving averages, 1992-2010
workplace. There were also two family outbreaks, both 
of which occurred across extended families. The number 
of outbreaks reported during 2010 remained stable in 
comparison to 2009, however the number of active TB 
cases and cases of LTBI associated with the outbreaks 
increased. Figure 2 shows a summary of TB outbreaks 
from 2004 to 2011 by year of outbreak, number of 
active TB cases and number of persons with LTBI. Please 
note that numbers of LTBI for outbreaks reported during 
2011 are provisional and may increase as outbreak 
investigations continue.
Summary:
In comparison to recent years, the crude notification 
rate of TB for 2010 (9.2/100,000 population) has 
decreased. Rates were higher in males for almost all age 
groups with the highest age specific rates reported in 
males aged 65 years and over. Over 40% of all TB cases 
notified were foreign born which is comparable to other 
European countries with similar crude incidence rates to 
Ireland. The rate in the indigenous population showed 
a slight decline at 6.5 per 100,000 population. Irish 
born cases were older than foreign born which is also 
reflected in other European countries.1 
Of the 270 cases with a pulmonary component 76.3% 
were culture confirmed, a slight decrease from 77.4% 
in 2009. The proportion of new culture confirmed cases 
with a pulmonary component, also decreased to 77.4%, 
a decrease compared to 2009 (80.1%), and also falls 
below the EU monitoring framework target of ≥ 80% 
culture confirmation among new pulmonary TB cases.2 
Two MDR-TB cases were reported for 2010 which 
remains stable compared to recent years with one 
reported in 2009 and two in 2008. The proportion of 
new culture confirmed pulmonary cases with reported 
DST results increased from 94.7% in 2009 to 98.8% in 
2010, almost achieving the EU monitoring framework 
action plan target of 100% of new culture confirmed 
pulmonary cases with DST results.2 Continuous vigilance 
is needed in relation to drug resistance especially with 
the global emergence of XDR-TB. 
There was an increase in the level of outcome 
data reported during 2010 compared to 2009. 
The proportion of total cases where outcome was 
reported as completed (72.4%) also increased during 
2010 compared to 2009 (64.6%). The proportion of 
new culture-confirmed pulmonary TB cases where 
outcome was reported as completed was 72.6%, 
falling short of EU monitoring framework action plan 
targets of successfully treating 85% or more of all new 
culture-confirmed pulmonary TB cases.2  It is of critical 
importance to TB control in Ireland that surveillance of 
TB and reporting of outcome data be maintained at a 
high level especially with the global threat of resistant 
strains.
Guidelines on the Prevention and Control of 
Tuberculosis in Ireland were published in April 2010.3 
The recommendations in these guidelines are based 
on a review of international literature, expert opinion 
and an extensive consultation process. They provide 
advice on the diagnosis and treatment of active TB 
and latent TB Infection (LTBI), outbreak management 
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Figure 2: TB outbreak summary by year
and contact tracing procedures and screening for 
TB in special situations e.g. healthcare settings, new 
entrants to Ireland, prison and homeless settings. The 
guidelines aim to improve the prevention and control 
of the disease and to help Ireland meet World Health 
Organization (WHO) targets for the elimination of 
TB. Stop TB partnership aims to reduce the global 
incidence of TB to less than one case per million 
population by 2050, which will eliminate the disease 
as a global health problem.4 The importance of good 
surveillance data cannot be underestimated in this 
context as they will help guide where resources should 
be directed e.g. risk groups in order to implement 
effective TB prevention and control strategies in Ireland 
and in order to reach the elimination target by 2050.
Provisional 2011 data
There were 424 cases of TB provisionally notified in 
2011, corresponding to a crude rate of 9.2 per 100,000 
population. It is important to note that these data are 
provisional and may change significantly following 
validation. 
Of the 424 cases provisionally notified in 2011, 
•  Pulmonary TB was diagnosed in 262 cases (61.8%), 
extrapulmonary TB in 121 cases (28.5%) and 
pulmonary and extrapulmonary TB in 30 cases (7.1%). 
Diagnostic type was not reported for 11 cases (2.6%).
•  Of the 292 cases with a pulmonary disease 
component, 220 (75.3%) were culture positive and 
122 (41.8%) were smear positive.
•  There were three cases of TB meningitis provisionally 
notified corresponding to a rate of 0.07 per 100,000 
population (0.65/million population).
•  There were 188 (44.3%) cases born in Ireland and 179 
(42.2%) were foreign-born. Country of birth was not 
reported for 57 (13.4%) cases.
•  There were 181 cases (42.7%) notified in females and 
243 cases (57.3%) in males. 
•  The mean age of cases was 42.7 years (range: 1 to 91 
years).
•  Resistance was reported in 26 cases, nine of which 
were mono-resistant to isoniazid. Three cases of MDR-
TB were reported during 2011. Seventeen (65.4%) of 
the 26 resistant cases (including two MDR cases) were 
born outside Ireland.
•  There were five TB outbreaks reported to HPSC 
during 2011, with 38 active TB cases, 15 cases of 
latent TB infection and 6 hospitalisations. No deaths 
were reported from these outbreaks. Please note 
that numbers of LTBI for outbreaks reported during 
2011 are provisional and may increase as outbreak 
investigations continue.
Further details on the epidemiology of TB cases 
reported in 2010 will be available in the HPSC Report 
on the Epidemiology of TB in Ireland, 2010 (www.hpsc.
ie).
References:
1. European Centre for Disease Prevention and Control/WHO 
Regional Office for Europe: Tuberculosis surveillance and 
monitoring in Europe. Stockholm, European Centre for Disease 
Prevention and Control, 2012. Available at: http://ecdc.europa.eu/
en/publications/Publications/Forms/ECDC_DispForm.aspx?ID=841  
2. European Centre for Disease Prevention and Control. Progressing 
Towards TB Elimination. A follow up to the Framework Action Plan 
to Fight Tuberculosis in the European Union. ECDC Stockholm, 
November 2010. Available at: http://ecdc.europa.eu/en/
publications/Publications/101111_SPR_Progressing_towards_TB_
elimination.pdf 
3. Health Protection Surveillance Centre. Guidelines on the Prevention 
and Control of Tuberculosis in Ireland 2010. National TB Advisory 
Committee. April 2010. Available at: http://www.hpsc.ie/hpsc/A-Z/
VaccinePreventable/TuberculosisTB/Publications/File,4349,en.pdf 
4. Stop TB Partnership. The Global Plan to Stop TB 2011-2015. World 
Health Organisation. Geneva, 2011. Available at: http://www.
stoptb.org/global/plan
-46-HPSC Annual Report 2011 2. Respiratory and Direct Contact Diseases
Health Protection Surveillance Centre   Annual Report 2011
Infectious Intestinal Diseases
03
Campylobacteriosis became a notifiable disease 
in Ireland in 2004 under the Infectious Diseases 
regulations. Prior to this, data on laboratory-confirmed 
cases of Campylobacter infection in humans were 
collected nationally as part of the EU Zoonoses 
Regulations (while some cases were included in the 
former category of “Food Poisoning (bacterial other 
than salmonella)”). It is an acute zoonotic bacterial 
disease characterised by diarrhoea, abdominal pain, 
malaise, fever, nausea and vomiting. Symptoms 
generally last for only a few days. Campylobacteriosis 
is the commonest bacterial cause of gastroenteritis in 
Ireland and Europe. In the EU it is estimated that 9.2 
million cases occur annually, resulting in a public health 
impact of 0.35 million disability adjusted life years 
(DALYs) per year and an annual cost of approximately 
€2.4 billion.1
During 2008, a European Union-wide baseline survey of 
Campylobacter in broiler batches and broiler carcasses 
was carried out by The European Food Safety Authority 
(EFSA). This survey found that 75.8% of broiler carcasses 
sampled were contaminated with Campylobacter while 
98% of Irish broiler carcasses sampled were positive 
for Campylobacter.2 EFSA currently estimates that 
handling, preparation and consumption of broiler meat 
may account for 20-30% of human campylobacteriosis 
while 50-80% of cases may be attributed to the broiler 
reservoir as a whole.3 The importance of poultry meat 
as a source of human Campylobacter infection was 
supported by the food-borne outbreak data reported 
to EFSA during 2010, where 63.0% of food-borne 
outbreaks of campylobacteriosis (with strong evidence 
and a specified food item) were poultry related.4  In 
response to such evidence, the food Safety Authority 
of Ireland (FSAI) published “Recommendations for a 
Practical Control Programme for Campylobacter in the 
Poultry Production and Slaughter Chain” during 2011.5
Findings of a national case control study conducted 
in Ireland that investigated risk factors for sporadic 
Campylobacter infections, showed that consuming 
chicken, lettuce and eating in takeaways were 
important risk factors for contracting the disease in 
Ireland. Contact with sheep, peptic ulcer, hiatus hernia 
and lower bowel problems were also independently 
associated with infection. However mains water supply 
showed protective effect from contracting the illness.6
3.1 Campylobacter 
Summary
Number of cases:   2,427
Crude incidence rate:   52.9/100,000
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Figure 1: Campylobacteriosis crude incidence rates per 100,000 population by HSE area, 2004- 2011
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During 2011, 2,427 campylobacteriosis notifications 
were reported to HPSC, corresponding to a crude 
incidence rate of 52.9/100,000 population. This rate 
represents an increase of 46.2% compared to 2010, and 
is comparable with the 2010 European crude incidence 
rate of 48.6 per 100,000 population.7 Previously in 
Ireland, the annual percentage increase/decrease 
observed in campylobacteriosis notifications has ranged 
between -8.2% to +6.1%.
Historically, variation in campylobacteriosis crude 
incidence rates (CIRs) has been reported between HSE 
areas. Between 2004 and 2010, the highest CIRs have 
usually occurred in HSE-M and HSE-W. A comparison of 
the mean annual incidence rate of notifications in each 
HSE area between 2004 and 2010 and the incidence 
rate of notifications in 2011 showed an increase of >50% 
in HSE-MW, HSE-NE and HSE-SE. No HSE area showed 
a decrease in the number of notifications reported 
during 2011. Figure 1 compares the campylobacteriosis 
CIRs between 2004 and 2011 by HSE area with the 
mean campylobacteriosis incidence rates for 2004 to 
2010. This figure also shows the associated percentage 
increase in campylobacteriosis CIRs during 2011 
compared to the mean for 2004 to 2010. 
Campylobacteriosis occurs in all age groups with the 
highest burden of illness experienced in the 0-4 year 
age group. This preponderance in younger children 
is a well described characteristic of the disease and is 
also observed at European level. The highest European 
notification rate during 2009 was reported in males in 
the 0-4 year age group (144.3/100,000 population) and 
in females of the same age (114.7/100,000 population).7
In Ireland between 2004 and 2010, the highest mean 
ASIR occurred in the 0-4 year age group (103.3/100,000 
population) followed by the 25-34 year age group 
(23.8/100,000 population). However, a comparison of 
the mean age-specific incidence rate between 2004-
2010 and the number of notifications in 2011 showed 
an increase of >40% in the 5-14 year (41.0%), 15-24 
year (47.6%) and the 55-64 year (40.4%) age groups. 
Figure 2 compares the campylobacteriosis age specific 
rates (ASIR) between 2004 and 2011 with the mean 
campylobacteriosis ASIR for 2004 to 2010. This figure 
also shows the associated percentage increase in 
campylobacteriosis ASIR during 2011 compared to the 
mean for 2004 to 2010.
In females, increases of >50% were seen in the 5-14 year 
(57.5%), 45-54 year (63.3%) and the 65+ years (53.3%) 
age groups. In males, increases of >50% were also seen 
in the 5-14 year (56.0%) and the 55-64 year (67.4%) age 
groups. Overall, the age groups with highest increases 
within the sexes were broadly similar to the age groups 
with the highest increases for all notifications.
During 2011, 46.1% of all cases were female, 53.6% of 
cases were female and sex was not reported for 0.2% 
of cases. Further analysis of the age-sex distribution of 
campylobacteriosis cases shows that the highest ASIRs 
for both males and females were observed in the 0-4 
year and 20-24 years age groups. 
Campylobacteriosis has a well documented seasonal 
distribution with a peak in summer. In Ireland, 
campylobacteriosis notifications typically peak during 
June and July. While campylobacteriosis notifications 
did peak as usual during June 2011, large increases 
were also seen outside this period. A comparison of the 
mean monthly number of notifications between 2004 
and 2010 and the monthly number of notifications in 
2011 showed an increase of >50% in February (54.9%), 
March (72.8%), June (75.6%), August (50.5%) and 
November (52.1%). 
Figure 3 compares the monthly number of 
campylobacteriosis notifications between 2004 
and 2011 to the mean monthly number of 
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Figure 2: Campylobacteriosis age specific incidence rate per 100,000 population by age group (years), 
2004-2011 (CIDR)
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campylobacteriosis notifications between 2004 and 
2010. This graph also shows the percentage increase 
in campylobacteriosis notifications by month observed 
during 2011 compared to the monthly mean 2004-2010.
Of the cases notified in Ireland during 2011, 99.9% were 
laboratory confirmed. However, as there is currently 
no national reference facility for routine typing of 
Campylobacter isolates, information on Campylobacter 
species is strikingly incomplete. In 2011, 34.0% (n=830) 
of isolates were speciated. Of the 830 speciated 
isolates, 93.1% of isolates were C. jejuni, 6.4% were 
C. coli, 0.2% were C. fetus, 0.1% were C. lari and 
0.1% were C. laridis. The remaining 66.0% (n=1,610) 
of Campylobacter isolates identified were not further 
speciated. This compares with 51% of Campylobacter 
isolates in Europe reported to ECDC during 2009 
remaining unspeciated.7 
During 2011, there were seven outbreaks of 
campylobacteriosis reported to HPSC with 16 associated 
cases of illness, one of whom was hospitalised. This 
is the same as the average number of outbreaks per 
annum between 2004 and 2010. All seven outbreaks 
were family outbreaks occurring in private houses. 
Three reported mode of transmission as person to 
person spread while mode of transmission was unknown 
for the remaining four outbreaks. During 2010, 19 
European countries reported 470 food-borne outbreaks 
of campylobacteriosis which accounted for 9% of the 
total food-borne outbreaks reported to EFSA. These 
outbreaks comprised 1,789 associated cases of illness 
and 132 hospitalisations.4
References:
1. European Food Safety Authority (EFSA), Scientific opinion on 
Campylobacter in broiler meat production: control options and 
performance objectives and/or targets at different stages of the 
food chain The EFSA Journal (2011); 9 (4): 2105.  Available at: http://
www.efsa.europa.eu/en/efsajournal/pub/2105.htm 
2. European Food Safety Authority (EFSA), Analysis of the baseline 
survey on the prevalence of Campylobacter in broiler batches and of 
Campylobacter and Salmonella on broiler carcasses ni the EU, 2008. 
The EFSA Journal (2010); 8 (03): 1503.  Available at: http://www.
efsa.europa.eu/en/efsajournal/pub/1503.htm 
3. European Food Safety Authority (EFSA), Scientific Opinion of the 
Panel on Biological Hazards (BIOHAZ) related to Campylobacter 
in animals and Foodstuffs. The EFSA Journal (2010); 8 (1): 1437.  
Available at: http://www.efsa.europa.eu/en/efsajournal/pub/173.htm 
4. European Food Safety Authority (EFSA), European Centre for 
Disease Prevention and Control (ECDC). The Community summary 
report on trends and sources of zoonoses, zoonotic agents and 
food-borne outbreaks in the European Union in 2010. The EFSA 
Journal (2012); 10 (3):2597. Available at: http://www.efsa.europa.eu/
en/efsajournal/pub/2597.htm 
5. Food Safety Authority of Ireland (FSAI), Recommendations for a 
Practical Control Programme for Campylobacter in the Poultry 
Production and Slaughter Chain. 2011 Available at: www.fsai.ie 
6. Danis K et al., Risk factors for sporadic Campylobacter infection: an 
all-Ireland case-control study. Euro-Surveillance. 2009 Feb 19;14(7). 
pii: 19123
7. European Centre for Disease Prevention and Control. Annual 
epidemiological report Reporting on 2009 surveillance data and 
2010 epidemic intelligence data. Stockholm, European Centre for 
Disease Prevention and Control. Available at: http://www.ecdc.
europa.eu/en/publications/Publications/Forms/ECDC_DispForm.
aspx?ID=767 
Table 1: Campylobacteriosis outbreaks summary, 2011 (CIDR)
Mode of 
transmission
Outbreak location Number outbreaks Number ill Number 
hospitalised
Number dead
Person-to-person Private house 3 8 0 0
Unknown Private house 4 8 1 0
Total 7 16 1 0
Figure 3: Number of campylobacteriosis notifications by month, 2004-2011
Cryptosporidium is a protozoal parasite that causes a 
diarrhoeal illness in humans known as cryptosporidiosis. 
It is transmitted by the faecal-oral route, with both 
animals and humans serving as potential reservoirs. 
Human cryptosporidiosis became a notifiable disease 
in Ireland in 2004, and the case definition in use is 
published in the HPSC case definition booklet. 
In 2011, 428 cases of cryptosporidiosis were notified in 
Ireland, a crude incidence rate (CIR) of 9.3 per 100,000 
population (95% CI 8.4-10.2), with 40% of notified cases 
reported as hospitalised for their illness. There were no 
reported deaths.
This was a 46% increase on the number of cases notified 
in 2010 (Figure 1), being closer to the rate reported in 
2009. In 2009 (the most recent year for which data are 
available), the ECDC reported an incidence rate overall 
of 2.74 per 100,000 population in the European Union, 
with Ireland reporting the highest rate among those 
countries reporting on this disease at the time (ECDC 
Annual Epidemiological Report). The second highest 
incidence rate among EU Member States in 2009 was 
reported by the United Kingdom at 9.1 per 100,000.
Consistent with previous years, the highest reported 
incidence was in children under 5 years, with around 70 
cases per 100,000 population in this age group (Figure 
2). While there is likely to be a bias towards testing of 
diarrhoeal stool specimens from children (as opposed 
to adults) for Cryptosporidium, it is also likely that this 
distribution reflects to some extent a true difference in 
risk between adults and children.
The crude incidence (CIR) rates by HSE area for 2011 
are reported in Figure 3. As in previous years, there 
was a strong urban-rural divide, with the HSE-E having 
a much lower reported incidence rate (0.7 per 100,000) 
than all other HSE areas. The HSE- W reported the 
highest crude incidence rate (23.1 per 100,000) –over 
twice the national rate. Compared to 2010, six areas 
reported increased rates, aligning more closely with the 
regional distribution of cases reported in 2009.
As in previous years, the highest number of cases was 
recorded in spring (Figure 4). 
Risk factors
The first complete calendar year for which enhanced 
surveillance data were available at a national level for 
cases of Cryptosporidium was 2011. Exposure to farm 
animals or their faeces either by virtue of residence on a 
farm or by visiting a farm during the potential incubation 
period were common among cases; 42.7% and 36.1% 
reported these exposures respectively (Table 1). This is 
3.2 Cryptosporidiosis
Summary
Number of cases, 2011: 428
Number of cases, 2010: 294
Crude incidence rate, 2011: 9.3/100,000
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Figure 1: Annual number and crude incidence rate 
cryptosporidiosis, Ireland 2004-2011
Figure 2: Age-specific incidence rate cryptosporidiosis, Ireland 
2011
consistent with the low incidence of cryptosporidiosis 
among residents in the largely urban HSE-E population 
and the higher incidence recorded in more rural parts 
of the country. Unlike salmonellosis, foreign travel plays 
only a minor role in cryptosporidiosis in Ireland, with the 
majority of infections acquired indigenously (93.1%). 
Table 2 shows the distribution of notified cases by home 
water supply type. It appears that persons who are not 
served by public water supplies have an increased risk 
of cryptosporidiosis as they are over-represented among 
the cases relative to the distribution of households 
by water supply type nationally, although it should be 
borne in mind that persons whose household drinking 
water is not from a public supply are more likely to be 
rural dwellers who may also have a higher likelihood of 
exposure to farm animals and rural environments which 
is also likely to increase their risk.
Outbreaks
There was a large increase in the number of 
cryptosporidiosis outbreaks reported in 2011; in total 
there were three general and 27 family outbreaks 
(Figure 5). The increase in outbreaks is most likely due 
to increased recognition of outbreaks (in particular small 
family outbreaks) following the introduction of enhanced 
surveillance for cryptosporidiosis cases late in 2010. 
The most common mode of transmission reported was 
person-to-person spread (11 outbreaks due solely to 
person-to-person transmission resulted in 35 illnesses), 
with animal contact being the second most common 
transmission route reported (contact with animals 
contributed to transmission in nine outbreaks resulting 
in 36 cases) (Table 3 and Figure 6). 
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Figure 3: Regional crude incidence rates cryptosporidiosis, 
Ireland 2009-2011. 
Figure 4. Seasonal distribution of cryptosporidiosis cases 
2008-2011 
 
 
Table 1: Number of cases (and percentage of cases where information available) where selected risk factors were reported for 
cryptosporidiosis cases, Ireland 2011
Risk factor Yes (% of known) No Unknown Not Specified Total
Travel 27(6.9%) 367 1 33 428
Lives/cared for on farm 135 (42.7%) 181 3 109 428
Visited farm 122 (36.1%) 216 4 86 428
Lives/works on or visited farma 231 (70.6%) 96 3 98 428
Swimming pool visit 68 (19.9%) 274 4 82 428
Pets 221 (68.0%) 104 8 95 428
Other water based activities 16 (6.2%) 244 4 164 428
aComposite of 2 previous variables
Table 2: Number of cases (and percentage of cases where information available) for cryptosporidiosis cases compared to the 
number and percentage of households in Ireland by home water supply type, Ireland 2011
Home water supply of 
notified cases
Number of 
cases
% of known
No. households served by these 
water supply types in the general 
population 2011 (Census 2011)
% of known X2 and P value
Group water scheme (private) 24 6.8% 45,774 2.9%
X2=347.1, 
P<.001
Group water scheme (public) 51 14.4% 144,428 9.0%
Other 9 2.5% 2,080 0.1%
Private well 101 28.5% 161,532 10.1%
Public water supply 170 47.9% 1,247,185 77.9%
Unknown 5
Not specified 68 48,409
Total 428 100% 1,649,408 100%
Comparing the proportion of cases and households served by public water supplies versus all other supply types: X2=185.7, P<.001
Moreover, two of the three general outbreaks were 
reported to be due to animal contact. In the first, fifteen 
third-level students out of a group of 43 developed 
gastrointestinal symptoms following exposure to farm 
animals as part of their training. Two were confirmed 
positive for Cryptosporidium and one was hospitalised. 
In a second general outbreak, two schoolchildren 
developed cryptosporidiosis. 
The third general outbreak was reported in a child 
care facility (CCF); six children were ill in total and two 
were laboratory confirmed. Cryptosporidium was not 
detected in the water serving the premises, although 
the small public water supply to which the CCF was 
connected had a history of being sub-optimal. It was 
concluded that while the most likely transmission route 
was person to person (which is a common method of 
spread among young children), waterborne transmission 
could not be definitively outruled as the initial source 
of the infection. The water supply serving the CCF has 
since been upgraded.
Summary
The overall incidence of cryptosporidiosis in Ireland has 
remained similar in the eight years since surveillance 
began in 2004, with no reliable trend up- or downwards. 
The seasonal and regional incidence reported in 2011 
was typical of previous years; consistently there has 
been a higher incidence in springtime and in non HSE-E 
areas. 
Person-to-person spread appears to be an important 
mode of transmission within families, while both 
enhanced surveillance data and outbreak surveillance 
data are consistent with animal contact being an 
important risk factor for cryptosporidiosis in Ireland. 
Unlike in the United Kingdom, travel-associated 
disease is reported infrequently, and is likely to be a 
minor contributor to transmission, as is transmission 
associated with food or swimming pools. 
While there are fewer general waterborne outbreaks 
reported relative to earlier years, water from non-public 
supplies may present a risk of cryptosporidiosis; from 
the enhanced dataset, persons who are not served by 
public water supplies were over-represented among the 
cases relative to the distribution of households by water 
supply type nationally. The EPA drinking water reports 
provide information on improvements in the public 
water supply sector in relation to Cryptosporidium.1  
1. EPA. 2011. The Provision and Quality of Drinking Water in Ireland 
A Report for the Year 2010. http://www.epa.ie/downloads/pubs/
water/drinking/name,31739,en.html 
Figure 5: Number of cryptosporidiosis outbreaks notified by 
type, Ireland 2004-2011
Figure 6: Number of cryptosporidiosis outbreaks notified by 
reported transmission route, Ireland 2004-2011
Table 3: Number of outbreaks, number ill and number 
laboratory-confirmed cases by transmission route, Ireland 2011
Transmission mode
Number of 
outbreaks
Total 
number ill
Number lab 
confirmed
Animal contact 6 26 8
Person-to-person 11 35 22
P-P and Animal 3 10 8
P-P and Waterborne 3 11 6
Waterborne 1 2 2
Unknown 3 6 6
Not Specified 3 4 4
Total 30 94 56
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Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as 
foodborne, any outbreak where water contributed was reported as 
waterborne, any outbreak where animal contact contributed was 
reported as Animal contact. Person-to-person outbreaks include only 
those outbreaks reported as being due only to person-to-person 
transmission.
Introduction
One of the most serious outbreaks of foodborne 
disease ever reported in the European Union was 
a verotoxigenic E. coli O104 outbreak identified in 
Germany in May 2011. Cases related to this outbreak 
were detected in several European countries, including 
a cluster of cases which were exposed in the Bordeaux 
region of France. As of 27/07/2011, a total of 782 HUS 
cases, including 29 deaths, and 3,128 non-HUS cases, 
including 17 deaths, were reported to the European 
Centre for Disease Prevention and Control (ECDC).1 
A Task Force of the European Food Safety Authority 
(EFSA) reported on 5/7/2011 that fenugreek seeds 
imported from Egypt were the most likely source of the 
outbreaks in Germany and France.2 This outbreak is a 
reminder of the potential severity of disease associated 
with VTEC infections, and the magnitude of outbreaks 
that can result from contamination of food produced 
and distributed on a large scale.
Fortunately, there were no cases related to this 
outbreak identified in Ireland, however, the reported 
verotoxigenic E. coli (VTEC) incidence rate in Ireland is 
generally high relative to other European countries. In 
2010 (the latest year for which data are published), the 
overall VTEC incidence rate in the European Union was 
0.83 per 100,000. For several years, Ireland has reported 
the highest VTEC incidence rate of any Member State 
in the EU, although Denmark and Sweden also reported 
relatively high incidence rates of >3.0 per 100,000 in 
2010.3 
The dominant transmission routes reported for VTEC 
infection in Ireland have been person-to-person spread, 
especially in childcare facilities and among families with 
young children, and waterborne transmission associated 
with exposure to water from untreated or poorly treated 
private water sources. 4-7 Other important transmission 
routes identified internationally include food (often 
minced beef products or fresh produce such as lettuce 
and spinach), and contact with infected animals or 
contaminated environments.3, 8-10
Materials and Methods
Infection due to Enterohaemorrhagic E. coli (EHEC) 
is a notifiable disease (S.I. 707 of 2003) since 2004 by 
clinicians and laboratory directors. This report focuses 
3.3 Verotoxigenic E. coli 
Summary
Number of VTEC cases, 2011: 283
Crude incidence rate, 2011: 6.2/100,000
Number of VTEC-associated HUS 2011: 19
Number of VTEC cases, 2010: 199
-54-HPSC Annual Report 2011 3. Infectious Intestinal Diseases
Table 1. Number and crude incidence rates confirmed and 
probable VTEC, Ireland 2004-2011
Year Confirmed 
cases 
Probable 
cases 
Total VTEC CIR VTECa 
(95% CI) 
2004 61 0 61 1.4 (1.1-1.8)
2005 125 0 125 3.0 (2.4-3.5)
2006 153 5 158 3.7 (3.2-4.3)
2007 115 52 167 3.9 (3.3-4.5)
2008 213 13 226 5.3 (4.6-6.0)
2009 238 3 241 5.7 (5.0-6.4)
2010 197 2 199 4.7 (4.0-5.4)
2011b 272 11 283 6.2 (5.5-6.9)
a Data from the 2011 census were used to calculate rates in 2011, and 
2006 to calculate incidence rates for 2004-2010
b Confirmed cases include 194 VTEC O157 cases, 48 VTEC O26 cases, 
25 VTEC strains of other serogroups, and five mixed infections. Nine 
probable cases were reported on the basis of being epidemiologically 
linked to laboratory confirmed cases of VTEC O157, and one VTEC 
O26 and one VTEC O145 probable case were reported on the basis of 
detection of vt genes only.  
on cases that conform to the case definition used 
for VTEC enhanced surveillance (http://www.ndsc.ie/
hpsc/A-Z/Gastroenteric/VTEC/SurveillanceForms/). 
Enhanced epidemiological information was supplied 
as in previous years by HSE personnel, and VTEC 
confirmation and typing data were provided by the HSE 
Dublin Mid Leinster Public Health Laboratory at Cherry 
Orchard Hospital (DML-PHL). Data from all sources are 
maintained in the Computerised Infectious Disease 
Reporting (CIDR) system. Outbreaks of VTEC are 
notifiable since 2004 and data are provided to CIDR by 
regional public health departments. 
Data from the CSO 2011 census were used to provide 
denominators for the calculation of national, regional 
and age-specific incidence rates in 2011.
Results
Incidence
In 2011, there were 283 confirmed and probable cases 
of VTEC notified, equating to a crude incidence rate 
(CIR) of 6.17 per 100,000 (Table 1). If only confirmed 
VTEC cases are considered, the 272 cases (CIR=5.93 
[5.22-6.63]) notified this year represent a 38% increase 
overall on the number of confirmed cases notified in 
2010, and a 14% increase on the number reported in 
2009, the year with the highest number of confirmed 
cases prior to this (Table 1 and Figure 1). One additional 
suspected case of VTEC was reported. An elderly 
female in HSE-E developed HUS, but was not confirmed 
as VTEC. 
For comparison, in England and Wales there was a 49% 
increase in E. coli O157 numbers in 2011 compared to 
2010, however, the reported incidence rate for 2010 
was lower than usual, and the increase in E. coli case 
numbers in 2011 was only 14% on 2009 case numbers11. 
E. coli O157 case numbers were reported to be 19% 
higher in Scotland in 2011 relative to 2010, but it was 
stated that 2011 incidence was closer to the historical 
average than to 2010, again because case number in 
2010 were relatively low12. 
Of 268 cases where information was available on 
symptoms, 192 (72%) were symptomatic, 78 (41%) of 
which developed bloody diarrhoea. Nineteen individuals 
(6.7%) developed HUS, the same number as last year. 
One elderly HUS case with VTEC O157 VT2 infection 
died but death was not due to VTEC infection. The 
elderly patient reported as a suspected VTEC case also 
died; the cause of death in this case was reported as 
unknown. Where reported (n=250), 76 (30%) of notified 
cases required hospitalisation (38% of symptomatic 
cases). 
Seasonal distribution
Typically, VTEC cases are most commonly associated 
with late summer, however in 2011, the highest 
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Figure 1. Annual number of confirmed and probable VTEC 
cases by serogroup, Ireland 1999-2011
Note: For simplicity in this figure, cases with mixed VTEC O157/other 
serogroup infections are included in the data for O157.
Figure 2. Seasonal distribution of VTEC cases, Ireland 2008-
2011
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Table 2. Number and crude incidence rate confirmed and probable VTEC by serogroup and HSE area, and number and crude 
incidence rate VTEC-associated HUS by HSE area, Ireland 2011
HSE-area Number [CIR (95% CI)] 
VTEC O157
Number [CIR (95% CI)] 
non-O157 VTEC
Number [CIR (95% CI)] all 
VTEC
Number [CIR (95% CI)] 
VTEC-associated HUS
East 18 [1.1 (0.6-1.6)] 11 [0.7 (0.3-1.1)] 29 [1.8 (1.1-2.4)] 4 [0.3 (0.0-0.5]
Midlands 57 [20.2 (14.9-25.4)] 7 [2.5 (0.6-4.3)] 64 [22.7 (17.1-28.2)] 4 [1.4 (0.0-2.8)]
Mid-West 17 [4.5 (2.4-6.6)] 39 [10.3 (7.1-13.5)] 56 [14.8 (10.9-18.6)] 1 [0.3 (-0.3-0.8)]
North-East 21 [4.8 (2.7-6.8)] 2 [0.5 (-0.2-1.1)] 23 [5.2 (3.1-7.4)] 2 [0.5 (-0.2-1.1)]
North-West 17 [6.6 (3.5-9.7)] 7 [2.7 (0.7-4.7)] 24 [9.3 (5.6-13.0)] 0 [0.0 (0.0-0.0)]
South-East 22 [4.4 (2.6-6.3)] 1 [0.2 (-.0.2-0.6)] 23 [4.6 (2.7-6.5)] 5 [1.0 (0.1-1.9)]
South 37 [5.6 (3.8-7.4)] 4 [0.6 (0.0-1.2)] 41 [6.2 (4.3-8.1)] 2 [0.3 (-0.1-0.7)]
West 19 [4.3 (2.4-6.2)] 4 [0.9 (0.0-1.8)] 23 [5.2 (3.0-7.3)] 1 [0.2 (-0.2-0.7)]
Ireland 208 [4.5 (3.9-5.2)] 75 [1.6(1.3-2.0)] 283 [6.2 (5.5-6.9)] 19 {0.4 (0.2-0.6)]
*Rates per 100,000 calculated using CSO census 2011 for denominator data
proportion of cases was in quarter 4; overall this year, 
42% of cases were reported in quarter 4 with 34% 
of cases in quarter 3. Figure 2 shows the seasonal 
distribution in 2011 relative to previous years. 
Regional distribution
The highest VTEC incidence rates were reported in 
the HSE-M followed by the HSE-MW, where the rates 
were over three times and twice the national crude rate 
respectively (Table 2). The HSE-M rate was significant 
higher than the rates for all other areas except the HSE-
MW, while the HSE-MW rate was significantly higher 
than five other HSE-areas. As in previous years, the 
HSE-E reported the lowest overall crude incidence rate 
(Table 2), around 30% of the national rate this year. 
The particularly high rate for VTEC incidence in the 
HSE-M was largely due to one community waterborne 
VTEC O157 outbreak described in detail later in this 
chapter (Table 2 and Figure 3). The elevated overall 
incidence rate in the HSE-MW was strongly influenced 
by a high reported incidence rate for non-O157 
infections (Figure 3). Historically, the HSE-MW have 
reported relatively high numbers of non-O157 
VTEC infections; it is likely that much of the regional 
variation in non-O157 VTEC incidence reflects regional 
differences in laboratory diagnostic practice for 
non-O157 infections.
Reviewing the VTEC-associated HUS incidence rates by 
region, the HSE-M reported the highest rate, however, 
the numbers of HUS cases in all regions were too low 
to establish if there was any statistically significant 
difference in rates (Table 2).
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Figure 3: Crude incidence rate VTEC O157 and non-O157, 
Ireland 2011
Table 3. Serotype and verotoxin (VT) profiles for VTEC isolates as determined at the PHL HSE Dublin Mid Leinster, Cherry 
Orchard Hospital in 2011 
Serogroup VT1 VT1+VT2 VT2 Total
O157a 0 60 138 198
O26 29 19 1 49
O5 5 2 0 7
Ungroupable 1 1 4 6
O128 0 3 0 3
O146 0 3 0 3
O145 0 0 2 2
O111 0 1 0 1
O150 0 1 0 1
O185 0 0 1 1
O44 0 0 1 1
O76 1 0 0 1
Total 36 90 147 273b
aFor one confirmed E. coli O157 case diagnosed in another jurisdiction, no vt typing data were available.
b Nine notifications were reported on the basis of being epidemiologically linked to laboratory confirmed cases, and thus no isolates were 
available for inclusion in this table. 
Table 4. Number of cases (and percentage where known) for selected risk factors, Ireland 2011
Risk factor
Number ‘Yes’ and % where 
reported
Number ‘No’ and % where 
reported
Number where risk fac-
tor was unknown or not 
reported
Food suspected 23 (17.8%) 106 (82.2%) 155
Exposure to farm animals or their faeces 74 (43.3%) 97 (56.7%) 113
Exposure to private well watera 69 (36.9%) 118 (63.1%) 96
Travel-associatedb 4 (1.8%) 215 (98.2%) 64
Attendance at a CCF 51 (32.3%) 107 (67.7%) 125
Attendance at a CCF (among <5 yrs) 49 (67.1%) 24 (32.9%) 57
aComposite variable recoded from two different water supply exposure enhanced variables in CIDR
bBased on CIDR core variable Country of Infection
c Childcare Facility
Laboratory typing
In 2011, the serogroup and verotoxin profiles of VTEC 
isolates referred to the HSE PHL Dublin Mid Leinster, 
Cherry Orchard Hospital are displayed in Table 3. As 
usual among VTEC O157 in Ireland, isolates containing 
the genes for verotoxin 2 (vt2) were more common 
(70%) than strains containing both vt1 and vt2. VTEC 
O26 strains containing only vt1 made up 59% of all 
VTEC O26 reported, with 39% of VTEC O26 containing 
the genes for both vt1 and vt2. 
Risk factors
Under enhanced surveillance for VTEC, risk factor 
information is routinely collected on VTEC notifications 
(Table 4).
Exposure to farm animals or their faeces and exposure 
to private well water were relatively common among 
cases; 43.3% and 36.9% reported these exposures 
respectively. This is consistent with the low incidence 
of VTEC infection among residents in the largely urban 
HSE-E population and the higher incidence recorded 
in more rural parts of the country. According to CSO 
data, in the general population, around 10.1% of 
households are served by private wells, indicating that, 
on a national basis, exposure to private wells is likely to 
be more common among VTEC cases than among the 
general population.
Unlike salmonellosis, foreign travel plays only a minor 
role in VTEC infection in Ireland, with the majority of 
infections acquired indigenously. The countries where 
the four travel-associated Irish VTEC cases had travelled 
to during their incubation periods were Portugal (n=2), 
Spain (n=1) and Hungary (n=1). 
Where the information was available, around a third of 
VTEC cases in 2011 were reported to attend a Childcare 
Facility (CCF). When these analyses were restricted to 
notified VTEC under five years of age, around two-
thirds reported attendance at a childcare facility. In 
the absence of knowing the proportion of the general 
population less than 5 years of age who attend a CCF, 
it is not possible to estimate if attendance at a CCF 
increases a child’s risk of VTEC infection.
Outbreak and environmental investigations
The outbreak surveillance system plays a key role in 
our understanding of VTEC transmission in Ireland. 
Fifty-one VTEC outbreaks were notified in 2011, which 
included 198 of the 283 VTEC notifications. Thirty-eight 
outbreaks were due to VTEC O157, seven to VTEC 
O26, two were mixed VTEC strain outbreaks, and four 
were caused by other VTEC strains. The suspected 
modes of transmission are listed in Table 5. 
Person-to-person spread is an important mode of VTEC 
transmission particularly between young children, and 
was suspected to have played a role in 24 (47%) VTEC 
outbreaks in 2011 in which 85 persons were reported 
ill (Table 5 and Figure 4). Seventeen of these outbreaks 
were reported as being solely due to person-to-person 
transmission. The second most common transmission 
route reported was waterborne transmission, which 
was reported to have contributed to six outbreaks 
(12%) with 31 persons ill. Microbiological evidence 
was obtained implicating private water sources in 
three of these outbreaks (further details below on a 
general waterborne outbreak). Two family outbreaks 
were reported as being suspected to be foodborne, 
but no suspected foods were reported and animal/
environmental contact was reported as the suspected 
mode of transmission in three family outbreaks. For 
43% (n=22) of VTEC outbreaks in 2011, the transmission 
route was reported as unknown or not specified (Table 5 
and Figure 4).
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Figure 4. Number of VTEC outbreaks by suspected transmission 
route and year, Ireland 2004-2011
Note: In this figure, reported transmission routes were grouped for 
simplicity. Any outbreak where food contributed was reported as 
foodborne, any outbreak where water contributed was reported as 
waterborne, any outbreak where animal contact contributed was reported 
as Animal contact. Person-to-person outbreaks include only those 
outbreaks reported as being due only to person-to-person transmission.
Table 5. VTEC outbreaks by suspected mode of transmission, 
Ireland 2011
Suspected mode of 
transmission
Number of 
outbreaks
Number 
ill
Number 
confirmed 
cases
Animal contact 1 4 3
Environmental / Fomite 1 2 2
Person-to-person 17 65 59
Person-to-person and 
possibly Waterborne 1 3 3
P-P and Animal contact 1 1 4
P-P and Foodborne 2 9 3
P-P and Waterborne 2 5 3
Unknown/P-P 1 2 3
Waterborne 3 23 37
Not Specified 1 1 2
Unknown 21 63 61
Total 51 178 180
The majority of outbreaks (76%) were family outbreaks, 
with twelve general outbreaks notified. The 39 family 
outbreaks resulted in 82 persons becoming ill, an 
average of 2.1 persons per outbreak, while the twelve 
general outbreaks resulted in 96 persons becoming ill, 
an average of 8 persons per outbreak. 
Nine general outbreaks were associated with childcare 
facilities/arrangements (CCFs), two were reported as 
community outbreaks and one small general outbreak 
was linked to a hotel. This is the highest number of 
general VTEC outbreaks reported in a single year since 
surveillance for VTEC infection commenced in 1999.
Four of the outbreaks associated with CCFs were 
reported as being due to person-to-person spread. 
The mode of transmission for a fifth outbreak was 
waterborne transmission within a private house followed 
by person-to-person transmission to a CCF contact, 
while the transmission routes for the remaining four 
CCF outbreaks were unknown. The number of persons 
ill within these outbreaks ranged from 1 to 29 (median 
5). 
Among the community VTEC outbreaks, a large 
waterborne outbreak was reported in the HSE-M 
associated with two VTEC O157 strains (one VT2 and 
one VT1+2). There were 38 cases in total, 23 of whom 
were symptomatic. Seven cases required hospitalisation 
and one developed HUS.  Epidemiological and 
microbiological evidence pointed towards drinking 
water from a private group water scheme serving 
around 300 homes as being the most likely source of 
illness. Both outbreak strains were detected in a water 
sample from the group water scheme, and 89% of cases 
had a definite epidemiological link to this supply13. Two 
days in advance of the first outbreak cases coming to 
the attention of health authorities, a boil water notice 
had been already been put on the supply following 
detection of E. coli and coliforms in a water sample. 
In the second community outbreak, two geographically 
and temporally linked adult HUS cases were notified, 
however, no definite epidemiological link was 
established between the cases. In the hotel related 
outbreak, two visitors to a hotel developed illness; the 
mode of transmission was not established. 
Summary
There was an increase in the reported incidence 
of VTEC infection in Ireland in 2011 reversing the 
downward trend observed in 2010. Notably the 
incidence rates in the United Kingdom reported by 
the Health Protection Agency and Health Protection 
Scotland were also higher in 2011 following reporting of 
low VTEC incidence rates in 2010. It is possible that the 
low rates reported in 2010 reflected a reduction in some 
common risk factor between the three jurisdictions that 
year.
In 2010, HPSC had noted a decrease in the number of 
waterborne VTEC outbreaks reported, and this would 
be consistent with the reported low rainfall in Ireland 
in 201014. A common effect such as a change in climate 
could explain an international change in the trend such 
as was observed in 2010. 
In 2011, person-to person spread and drinking water 
were significant transmission routes for VTEC outbreaks 
in Ireland. Person-to person spread was important 
both in CCFs and private households, and exclusion 
of children with infectious gastrointestinal disease 
symptoms from CCFs remains an important control 
measure in the prevention of outbreaks in these 
settings15. 
The large waterborne outbreak in the HSE-M associated 
with a private group scheme was particularly significant. 
Private wells serve around 10% of households in Ireland, 
with private group water schemes serving a further 3% 
of homes 16. According to the latest EPA drinking water 
report17, there were improving levels of compliance with 
the drinking water quality standards in the group water 
scheme sector during 2010 but it was also reported 
that the microbiological water quality in a significant 
proportion of group water schemes continued to be 
inferior to that in public water supplies, in particular in 
privately-sourced group water schemes. Exposure to 
untreated or poorly treated private supplies have long 
been recognised as a risk factor for VTEC infection in 
Ireland, however, outbreaks to date have generally been 
smaller and mostly confined to household settings. This 
outbreak highlights the vulnerability of some larger 
private water supplies in Ireland, and the potential for a 
high impact on human health when a vulnerable supply 
serves a large population.
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Hepatitis A virus causes an acute, usually self-limiting 
disease of the liver. It is primarily transmitted from per-
son to person via the faecal-oral route and is associated 
with poor hygiene and sanitation. Common source out-
breaks due to contaminated food or water also occur.
The incidence of hepatitis A in Ireland has been low in 
recent years and remained low in 2011, with 19 cases 
notified. This corresponds to a crude notification rate of 
0.4/100,000 population.  This represents a considerable 
decrease in cases compared to 2010 when 46 cases were 
notified (figure 1). Case classification was reported for 
all cases. Eighteen cases were laboratory confirmed and 
one case was classified as possible.
Fifty three percent of cases were male (n=10) and 47% 
were female (n=9). Only two cases (11%) of hepatitis A 
were detected in children, while the remaining 17 cases 
(89%) were in adults (figure 2). 
3.4 Hepatitis A
Summary
Number of cases, 2011: 19
Crude notification rate, 2011: 0.4/100,000 population
Number of cases, 2010: 46
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Figure 1. Number of hepatitis A notifications, 1995-2011
Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis A, 2011
Five cases were linked to travel outside of Ireland and 
six cases were infected in Ireland.  Country of infection 
was not known for the remaining eight cases.
There were no hepatitis A outbreaks recorded in Ireland 
for 2011.
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 27th July 2012. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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Rotavirus is the commonest cause of paediatric 
gastrointestinal infection and causes sporadic, seasonal 
and occasionally severe gastroenteritis of infants and 
young children, characterised by vomiting, fever and 
watery diarrhoea. Transmission is usually person-to-
person, mainly via the faecal-oral route. Children 
less than two years of age are most susceptible to 
infection, although cases are often seen in elderly and 
immunocompromised adults, particularly in institutional 
settings. By the age of six years old, virtually all 
children will have had at least one episode of rotavirus 
infection. Symptoms usually last for only a few days but 
in severe cases hospitalisation may be required due to 
dehydration. In developed countries, mortality due to 
rotavirus is low; however, the morbidity and economic 
costs associated with infection are significant. Three 
primary serogroups of rotaviruses infect humans; A, B 
and C; A being the commonest infecting serogroup. 
Given the universal distribution of rotavirus, the 
numbers of notifications will always represent an 
underestimate of the true incidence and are likely to 
be more reflective of habits of presentation to medical 
practitioners and of styles of investigation, notification 
and testing.
Since 2004, rotavirus, although not specifically listed, 
has been a notifiable disease in Ireland under the Acute 
Infectious Gastroenteritis (AIG) disease category. Prior 
to 2004, rotavirus cases were notified in the former 
notification category of “Gastroenteritis in children 
under two years”. In April 2008 the case definition 
of AIG was amended specifying definitions for both 
rotavirus and the newly notifiable Clostridium difficile 
associated disease. On 4th May 2008 these amended 
definitions formally replaced the previous AIG case 
classification. 
3.5 Rotavirus
Summary
Number of cases:  2,450
Crude incidence rate:   53.4/100,000 population
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Figure 1: Rotavirus crude incidence rate by HSE area and year, 2004-2011 (CIDR).
Rotavirus case definition:
A case of rotavirus infection is a patient with acute onset 
of vomiting followed by watery diarrhea with fever, 
which typically lasts between three and eight days, AND 
one of the following laboratory criteria for diagnosis:
• Detection of rotavirus by antigen assay
• Detection of rotavirus-specific RNA
• Detection of rotavirus by electron microscopy 
• Isolation of rotavirus
During 2011, there were 2,450 cases of rotavirus 
notified in Ireland, corresponding to a national crude 
incidence rate (CIR) of 53.4 per 100,000 population and 
representing a decrease of 2.1% compared to 2010. 
Significant geographical variation was observed in 
regional rotavirus CIR. The highest regional CIR was 
observed in HSE-M at 106.2 per 100,000 population and 
in HSE-W at 80.4 per 100,000 population. The lowest 
regional CIR was observed in HSE-E at 28.1 per 100,000 
and HSE-MW at 45.3 per 100,000 population. Figure 1 
illustrates the rotavirus CIR by HSE area and year. 
Rotavirus infection has a well documented seasonal 
pattern in Ireland with the number of cases peaking 
each year in early spring. During 2011, this pattern 
was evident with rotavirus notifications peaking during 
March (n=705) and April (n=478). Figure 2* illustrates 
the seasonal variation in rotavirus cases by month of 
notification from 2004 to 2011. 
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Figure 2: Number of rotavirus notifications by month, 2004-2011 (CIDR).
Figure 3: Number of cases of rotavirus in children less than two years of age by year, 2001 to 2011
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* There is a ‘false’ second peak seen in 2005 during week 33, 2005 caused by bulk uploading of notifications for the HSE-W
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Rotavirus is the most common cause of acute 
gastroenteritis in children worldwide with children 
generally affected in the first 2-3 years of life. In 2011, 
74.1% (n=1,816) of cases were aged two years or under. 
Data from 2004 to 2011 show that the peak incidence 
of clinical disease occurred in the 6-18 month age 
group, with 68.4% of notifications in this age group. 
Figure 3 presents the number of cases of rotavirus in 
children less than two years of age by year, 2001 to 
2011.
During 2011, 1,188 cases (48.5%) were female and 
1,246 (50.9%) were male. Sex was not reported for 16 
(0.6%) cases. This represented a ratio of females: males 
of 0.95:1.05, which was similar to the ratio observed in 
previous years.
There were five outbreaks of rotavirus notified during 
2011 with 25 cases of associated illness and seven cases 
were hospitalised. Of the five outbreaks, three were 
family outbreaks occurring in private homes while two 
general outbreaks occurred in a crèche and a private 
house. Mode of transmission was reported as person to 
person spread for all five outbreaks. Table 1 summarises 
the number of rotavirus outbreaks by location and 
month during 2011.
Table 1: Summary of rotavirus outbreaks by location and month, 2011 
Month Location Number of outbreaks Number ill Number hospitalised Number dead
January Private house 2 4 4 0
February Crèche 1 17 0 0
April Private house 1 2 2 0
June Other 1 2 1 0
Total 5 25 7 0
Salmonella, 2011
Salmonellosis typically presents clinically as an acute 
enterocolitis, with sudden onset of, abdominal pain, 
diarrhoea, nausea, headache and occasionally vomiting. 
Fever is almost always present. Dehydration, especially 
amongst vulnerable populations such as infants, the 
immunocompromised and the elderly, may be severe. 
Invasive infection occurs in a proportion of cases. 
S. Typhi and S. Paratyphi can cause enteric fever, a 
severe systemic life threatening condition, but this is 
not common in Ireland and is almost invariably travel-
associated.
Notification data (CIDR)
There were 311 cases of salmonellosis in reported 
in 2011, all of which were laboratory confirmed. The 
national crude incidence rate (CIR) for salmonellosis in 
2011 was 6.8 per 100,000 population which was a slight 
decrease compared to 2010 (7.8/100,000) as shown 
in figure 1. Figure 2 illustrates the regional variation in 
CIR during 2011. The highest CIR occurred in HSE-MW 
(10.5/100,000), representing an increase of 3.2 per 
100,000 population compared to 2010. This was the 
only region to experience an increase in the regional 
CIR during 2011. The lowest CIR occurred in HSE-S 
(4.1/100,000), which is a decrease compared to 6.0 per 
100,000 population during 2010. The largest decrease 
in regional CIR during 2011 was observed in HSE-M, 
with a decrease of 8.1 per 100,000 population. 
The female:male ratio for 2011 was 0.93:1.08. In 
terms of age distribution, 27.7% of cases occurred in 
children under five. This is likely to be, at least in part, 
a reflection of clinicians more readily seeking clinical 
samples in that age group. This is also reflected in the 
age specific incidence rate (ASIR) with the 0-4 age 
group having the highest ASIR nationally (28.1/100,000 
in females and 19.8/100,000 in males) in both sexes 
(figure 3). 
The seasonality of salmonellosis notifications in Ireland 
during 2011 is shown in figure 4, with the highest 
number of notifications occurring between June and 
3.6 Salmonella 
Summary
Number of confirmed cases: 311
Number of probable cases: 0
Crude incidence rate: 6.8/100,000
Figure 1: Salmonellosis notifications and crude incidence rate per 100,000 population by year of 
notification (CIDR)
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October. During 2011, the peaks observed during 
July and August were largely due to travel associated 
salmonellosis notifications, which are anticipated 
seasonal increases that correlate with peak holiday 
periods and resultant increase of people travelling 
abroad. However, a peak in indigenous notifications 
was also observed during August due to a mixed 
strain outbreak of S. Newport and monophasic S. 
Typhimurium.
Of the 311 cases notified on CIDR during 2011, travel 
history was provided for 241 cases (77.5%). Of the 241 
cases where travel history was reported, 124 (51.5%) of 
salmonellosis cases were indigenous to Ireland and 117 
cases (48.5%) reported a recent history of travel. Where 
travel history was documented, the three countries with 
highest occurrence of recent travel and subsequent 
development of salmonellosis were; Spain (n=13), 
Turkey (n=13) and Thailand (n=12). When serotyping 
data were analysed by travel history, 31.6% of all travel 
associated cases were S. Enteritidis whereas 40.3% of 
cases indigenous to Ireland are S. Typhimurium (table 
1). 
There is a considerable degree of underreporting of 
salmonellosis. A study undertaken in Sweden in which 
reviewers ascertained the degree of underreporting of 
salmonellosis cases amongst Swedish holidaymakers 
returning to Sweden from a range of European 
countries indicated that when compared with national 
statistics, salmonellosis cases were underreported by a 
factor of four. Given the high degree of sensitivity and 
specificity of the Swedish national surveillance system, 
this is probably an reasonable accurate estimation 
signifying that for every sporadic case of salmonellosis 
that is notified nationally in Ireland, there are a further 
four cases that go un recognised in the community.2 
Figure 2: Salmonellosis notifications and crude incidence rate per 100,000 population 
by HSE area, 2011 (CIDR)
Figure 3: Salmonellosis notifications and age specific incidence rate per 100,000 population by 
age group (years) and sex, 2011 (CIDR)
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NSSLRL data:
The National Salmonella, Shigella and Listeria 
Reference Laboratory (NSSLRL) based in Galway has 
been providing reference services nationally since 2000. 
In 2011, the NSSLRL analysed 321 human Salmonella 
isolates referred for further typing, identifying 54 
serotypes. Table 2 presents the most dominant 
serotypes detected during 2011.  S. Typhimurium* 
(n=116) was the most common serotype, followed by S. 
Enteritidis (n=58). 
The NSSLRL conducted phage typing analysis on 
all 116 S. Typhimurium and all 58 S. Enteritidis 
isolates. Phage types DT104 (23.3%) and DT193 
(19.8%) were the commonest phage types observed 
among S. Typhimurium isolates while phage types 
PT1 (17.2%), RDNC (17.2%) and PT21(10.3%) were 
the dominant types observed among S. Enteritidis 
isolates.1Of the 321 human isolates analysed by the 
NSSLRL, 168 (52.3%) were fully susceptible to all 
antimicrobials tested. The remaining 153 isolates 
exhibited some degree of antimicrobial resistance. 
The three commonest resistance patterns§ seen were 
resistance to ampicillin, chloramphenicol, streptomycin, 
sulphadiazine and tetracycline (ACSSuT, n=30, 9.3% 
of total and 19.6% of resistant isolates), resistance to 
nalidixic acid (Na, n=29, 9.0% of total and 19.0% of 
resistant isolates), followed by resistance to ampicillin, 
streptomycin, sulphadiazine and tetracycline (ASSuT, 
n=24, 7.5% of total and 15.7% of resistant isolates). 
Over 98% of human isolates with a resistance profile 
of ACSSuT or ASSuT were S. Typhimurium (including 
19 monophasic isolates) while 51.7% of human isolates 
with a resistance profile of Na were S. Enteritidis. 
Four isolates of S. Concord and one S. Stanley were 
resistant to nine antibiotics tested; two S. Concord and 
one S. Typhimurium isolates were resistant to eight 
antibiotics tested while one isolate each of S. Kentucky 
and S. Worthington were resistant to seven antibiotics 
tested. Please refer to the NSSLRL’s Annual Report 
2011 for more detailed analysis of results1. The pattern 
of antimicrobial resistance observed is broadly similar to 
previous years. To date carbapenemase production in 
salmonella has not been detected in Ireland.
Outbreaks:
There were 13 outbreaks of Salmonella during 2011 
which is similar to the number of salmonellosis 
outbreaks reported in 2010. These outbreaks resulted 
in 49 cases of illness and an associated hospitalisation 
rate of 20.4% (n=10 cases). Table 3 outlines the number 
of salmonellosis outbreaks and number ill by outbreak 
location and outbreak transmission mode during 2011.
There were eight family outbreaks during 2011, 
six of which were in private houses and two were 
Figure 4: Salmonellosis notifications by month of notification and travel history, 2011 (CIDR)
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* This includes 28 S. Typhimurium isolates with serotype 4,5,12:1
§  Where A= Ampicillin, C= Chloramphenicol, Na = Naladixic acid, S= Streptomycin, Su= Sulphonamide and T= Tetracycline
Table 1: Percentage of Salmonellosis notifications by serotype and travel history, 2011 (CIDR)
Salmonella serotype Travel associated Indigenous Travel history unknown Total
S. Enteritidis (%) 31.6 9.7 12.9 18.6
S. Typhimurium (%) 11.1 40.3 27.1 26.4
Other serotypes (%) 47.9 32.3 47.1 41.5
Serotype not specified (%) 9.4 17.7 12.9 13.5
All serotypes (n) 117 124 70 311
All serotypes (%) 37.6 39.9 22.5 100.0
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travel associated. Of the two travel associated 
family outbreaks, one reported exposure in Turkey 
and the other reported exposure in the UK. Three 
family outbreaks were reported as person to person 
transmission while two were reported as food-borne 
transmission. Transmission was unknown for the 
remaining three outbreaks. Of the two food-borne 
outbreaks, suspected food items reported included a 
buffet meal. 
There were five general outbreaks during 2011, two 
were national travel related outbreaks, one was a 
national outbreak in a community setting and the 
remaining two were local outbreaks occurring in a hotel 
and a community setting. 
One national general outbreak involving 25 cases 
associated with a flight from Tanzania was reported in 
2011. Cases were identified from Ireland, Netherlands, 
Norway, US and Canada. All cases had travelled to 
Tanzania at the beginning of July 2011. A descriptive 
study strongly suggested that the flight was the location 
of this outbreak with 98% of total cases and 100% of 
confirmed cases are explained by the flight. In two 
analytical studies two food items served on board the 
flight were significantly associated with illness.
One national general outbreak of S. Napoli, consisting 
of two associated cases in a community setting , was 
detected by NSSLRL during 2011. No history of recent 
travel was reported by the cases and the route of 
transmission remains unknown for this outbreak.
One national general outbreak was caused by S. 
Enteritidis RDNC was detected by NSSLRL during 2011. 
This outbreak resulted in six cases of illness, three of 
whom were hospitalised. All cases reported a history of 
recent travel to Turkey. Route of transmission remains 
unknown for this outbreak.
One local general outbreak in HSE-MW was caused by 
S. Umbilo with three confirmed cases, one of whom 
was hospitalised. Mode of transmission was reported as 
unknown for this outbreak. 
One local general outbreak in HSE-E was caused 
by S. Newport and monophasic S. Typhimurium. 
This outbreak resulted in 13 cases of illness and was 
reported as food-borne transmission associated with a 
meal eaten in a hotel.
†This includes 28 (8.7%) S. Typhimurium isolates with serotype 4,5,12:1
‡  Unnamed is not a serotype.  The term refers to a very diverse group of isolates where the complete antigenic formula cannot be determined 
and which therefore can not be formally designated as belonging to any specific serovar
**Includes 1 outbreak reported as person to person and foodborne
† †Includes 1 outbreak reported as person to person and animal contact
Table 2: Number and percentage of human Salmonella isolates by 
serotype, NSSLRL 2011 
Salmonella serotype Number of isolates % Isolates
Typhimurium† 116 36.1
Enteritidis 58 18.1
Typhi 13 4.0
Unnamed‡ 12 3.7
Newport 10 3.1
Heidelberg 9 2.8
Stanley 9 2.8
Braenderup 7 2.2
Concord 7 2.2
Infantis 6 1.9
Agona 5 1.6
Other 69 21.5
Total 321 100.0
Table 3: Number of salmonellosis outbreaks and number ill by outbreak location and outbreak transmission mode, 2011 (CIDR)
Location Food-borne** Person-to-person† † Unknown Total
No. 
outbreaks
No. ill
No. 
outbreaks
No. ill
No. 
outbreaks
No. ill
No. 
outbreaks
No. ill
Community outbreak 0 0 0 0 2 5 2 5
Hotel 1 13 0 0 0 0 1 13
Private house 1 1 3 10 2 4 6 15
Travel related 2 6 0 0 2 10 4 16
Total 4 20 3 10 6 19 13 49
Typhoid/Paratyphoid:
The number of S. Typhi and S. Paratyphi cases 
diagnosed in Ireland remains elevated when compared 
to previous years. In 2011 there were 14 cases of S. 
Typhi reported and two cases of S. Paratyphi. 
Ten of the S. Typhi reported a recent history of travel, 
with three travelling to Bangladesh, two to Pakistan, 
two to India and one each to Philippines, Ghana and 
Cameroon. Two cases reported country of infection 
as Ireland, following secondary transmission from a 
recently returned traveller to an endemic area. The 
remaining two cases did not report country of infection, 
however one was born in an endemic area and 
identified on contact tracing. In the S. Paratyphi cases 
one had known recent travel history to Bangladesh and 
one to Pakistan.
References: 
1. National Salmonella Reference Laboratory of Ireland, Annual 
Report for 2011. Available at: http://www.nuigalway.ie/research/
salmonella_lab/reports.html 
2. De Jong B and Ekdahl K. The comparative burden of salmonellosis 
in the European Union member states, associated and candidate 
countries. BMC Public Health 2006, 6:4. Available at: http://www.
ncbi.nlm.nih.gov/pmc/articles/PMC1352352/pdf/1471-2458-6-4.
pdf 
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Listeriosis 
Seven cases of human listeriosis were notified in 2011, 
lower that the ten cases reported in 2010. This equates 
to a crude incidence rate of 0.15 (95% CI 0.04-0.27) per 
100,000, below the EU average of 0.35 per 100,000 in 
2010.  
Among these, there were two pregnancy-related and 
two neonatal cases. This is equivalent to the number of 
pregnancy-associated cases reported in 2010 (Figure 1). 
There were also three adult cases, one female and two 
males, with ages ranging from 62 to 80 years. All three 
cases were reported as suffering from an underlying 
illness that predisposed them to listeriosis. 
There was one miscarriage and one adult death 
reported in 2011, although it was not known if the adult 
death was due to listeriosis. 
One case was reported as being acquired abroad.
Since 2007, the National Salmonella, Shigella and 
Listeria Reference Laboratory in Galway has offered a 
national service for typing of Listeria strains. In 2011, 
isolates from six of the seven notified cases were 
referred. The serotypes for these six cases are listed in 
table 1 below. 
Listeriosis in Ireland remains a hazard for the elderly, 
persons with underlying illness, and other vulnerable 
groups such as pregnant women and neonates.
3.7  Less common gastroenteric 
 infections
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Table 1. Listeriosis notifications by case type and serotype, Ireland 2011 -typing data provided courtesy of Prof Martin Cormican 
and staff at the NSSLRL
Type Serotype 1/2 Serotype 4b Not referred for serotyping Total
Adult or juvenile 2 1 0 3
Pregnancy-related 0 1 1 2
Neonatal 1 1 0 2
Total 3 3 1 7
Figure 1: Number listeriosis notifications by case type, Ireland 2006-2011
Giardiasis
In 2011, there were 57 cases of giardiasis notified; the 
same number as was notified in 2010. This equates to 
a crude incidence rate of 1.24 (95% CI 0.92-1.56) per 
100,000. 
Cases ranged in age from 0-84 years (median age=32 
years) with only 12 cases reported in children under 15 
years of age.  According to CDC, Giardia infects nearly 
2% of adults and 6% to 8% of children in developed 
countries worldwide so it is likely that there is a high 
degree of underreporting of the illness in Ireland 1. 
Lower numbers of males (n=21) were affected than 
females (n=35) –sex was unknown for one case. 
Hospitalization rates were low with five cases admitted 
out of 46 (11%) for which this information was available. 
The number of cases for which travel status was 
reported has increased markedly over the last five years 
from 11% of cases in 2006 to 54% of cases this year 
(Figure 2). Twenty-four cases (42%) were reported as 
being associated with foreign travel: the countries of 
infection reported were India (n=14), Ethiopia (n=3), 
Nepal (n=2), and there was one case each reported 
associated with travel to Spain, Turkey, Morocco, 
Mauritius and Chile. Seven cases were reported as being 
acquired in Ireland, and for the remaining 26 cases, 
country of infection was unknown or not specified. 
In 2011, there were three small family outbreaks with 
eight persons ill; exposure abroad was reported for 
some or all of the cases in all three outbreaks.  
Giardiasis in Ireland is mainly identified among adults, 
unlike countries such as the US, Australia and the UK 
where children are mainly affected. And if the travel 
histories of those with known Country of infection 
are representative of all reported giardiasis cases in 
Ireland, then as many as three-quarters may be related 
to foreign travel. Among these cases, Asia figures most 
prominently as a travel destination. 
1 http://www.cdc.gov/parasites/giardia/epi.html 
Yersiniosis 
In 2011, there were six cases of yersiniosis, double the 
number in 2010 and 2009. Three were male and three 
were female, and four were less than 15 years of age. 
All were reported as Y. enterocolitica. The reported 
incidence of yersiniosis in Ireland is low relative to the 
EU as a whole, and to Northern Europe in particular. 
Yersiniosis is commonly associated with consumption of 
pork products however, in Spring 2011, an outbreak was 
reported in Norway associated with salad leaves.1
1 E MacDonald et al. 2011. Yersinia enterocolitica O:9 infections 
associated with bagged salad mix in Norway, February to April 2011. 
Eurosurveillance, Volume 16, Issue 19, 12 May 2011
Foodborne intoxications 
Notifications of foodborne intoxications in Ireland are 
uncommon. In 2011, there were no cases or outbreaks 
of Clostridium perfringens (type A) food-borne disease, 
staphylococcal food poisoning or Bacillus cereus food-
borne infection/intoxication notified. 
There was one case of infant botulism notified in Ireland 
in 2011; exposure to turtles or to turtle feed was 
identified as being the most likely source in this case of 
infant botulism. http://www.hpsc.ie/hpsc/A-Z/Zoonotic/
ReptilesandRisksofInfectiousDiseases/ 
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Figure 2: Number Giardiasis Notifications by Travel Status, Ireland 2006-2011
Note: Travel status is inferred from Country of Infection variable on CIDR
Summary
Number of cases, 2011: 42
Crude Incidence rate, 2011: 0.92 per 100,000
Number of cases, 2010: 60
In the last twenty years, the number of cases of 
shigellosis in Ireland has been low in comparison to 
the number of cases notified in the early 1990s (Figure 
1). Shigellosis, however, remains a common cause of 
gastrointestinal illness in developing countries, and 
many cases notified in Ireland are now identified as 
being travel-associated.  
While person-to-person spread is an important 
transmission route between children, risks also remain 
from food, with at least four general outbreaks having 
been reported in Scandinavia in 2009 associated with 
imported fresh produce.1-5  Transmission between men 
who had sex with men (MSM) has been reported.6, 7
Forty-two cases of shigellosis were notified in Ireland 
in 2011 (CIR 0.92 per 100,000, 95% CI 0.64-1.19), all 
of which were laboratory confirmed. This compares to 
60 cases in 2010 and 70 cases in 2009 (Figure 1). Of 
35 cases where hospitalisation status was recorded, 5 
(14%) were reported as hospital in-patients.
Cases ranged in age from 11 months to 65 years 
(median age=26 years). Like 2009 and 2010, more 
males (n=25) than females (n=17) were notified (Figure 
2). This differs to the three years previous to that when 
there were more females than males reported each 
year. 
3.8 Shigellosis
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Figure 1: Annual number of notifications shigellosis, Ireland 1991-2011
Table 1: Number of notifications shigellosis by species and country of infection, Ireland 2011
Organism S. America Africa Asia Europe Ireland Not specified Total
Shigella boydii 0 2 0 0 0 0 2
Shigella flexneri 1 3 1 2 1 2 10
Shigella sonnei 1 8 5 1 9 5 29
Shigella species 0 0 1 0 0 0 1
Total 2 13 7 3 10 7 42
(Data source: CIDR)
Information on travel history is very valuable when 
reviewing surveillance data for possible indigenous 
clusters, and data on country of infection in the national 
dataset continues to improve, being available for 83% 
of shigellosis notifications this year. Twenty-five cases 
were reported associated with foreign travel (Table 
1). The countries of infection reported were India 
(n=4), Morocco (n=3), with two cases each associated 
with Spain, Gambia, Egypt and Ghana, and one case 
associated each with travel to Argentina, Timor-Leste, 
Panama, Thailand, Sudan, Nigeria, Belgium, Ethiopia, 
Kenya and Lebanon.  Ten infections were reported as 
being acquired in Ireland, while no country of infection 
information was available for seven cases. 
Shigella sonnei was the most common species reported 
(n=29), followed by S. flexneri (n=10). There were also 
two S. boydii and one confirmed case for which the 
species was not reported. The species distribution of 
cases by country of infection is reported in Table 1. 
More detailed typing of Shigella isolates can provide 
useful information on the relatedness of strains 
which can be used by public health personnel to 
outrule/provide evidence for links between cases 
during investigations of case clusters. The National 
Salmonella, Shigella and Listeria Reference Laboratory 
(NSSLRL) in University College Hospital, Galway can 
provide laboratory services for speciation, serotyping, 
antimicrobial resistance profiling, and where 
appropriate, Pulsed Field Gel Electrophoresis (PFGE) of 
Shigella isolates.
In 2010, 30 human Shigella isolates were referred to the 
NSRL, three-quarters of the isolates from all confirmed 
cases. The species/serotype distribution of these cases 
is reported in Table 2. 
There were two shigellosis outbreaks notified in 2011, 
details of which are provided in Table 3. Both were 
caused by Shigella sonnei. 
Figure 2: Age-sex distribution shigellosis notifications, Ireland 2011 relative to 2006-2011
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Table 2: Species/serotypes of Shigella isolates referred to NSRL in 
2011 (Data courtesy of Martin Cormican, Niall de Lappe and Jean 
O Connor at NSSLRL)
Strain Number of isolates
Shigella flexneri 1a 1
Shigella flexneri 2a 5
Shigella flexneri 3a 1
Shigella flexneri 3b 1
Shigella flexneri 6 2
Shigella sonnei 20
Total 30
[Data source: NSSLRL]
Male cases Female cases
Although foreign travel is a major risk factor for 
shigellosis among Irish residents, indigenous risks are 
likely to be through person-to-person spread (in some 
instances from persons who have contracted shigellosis 
abroad), and from food as demonstrated by the 
Scandinavian outbreaks associated with imported foods 
in recent years. 
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Table 3: Shigellosis outbreaks, Ireland 2011
Month HSE-area Transmission Route Location Type Number ill
Sep MW Person to person Creche General 3
Oct E Person to person Extended family Family 3
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In 2011, the number of malaria cases in Ireland declined 
by 25% to 61 cases, the lowest level since 2005 (Figure 
1). The incidence rate now stands at 1.3 per 100,000 
population. Among EU Member States reporting 
malaria data to the European Centre for Disease 
Control, Ireland had the second highest incidence 
rate for imported malaria in 2009 (the latest year for 
which comparative data are available) -only the United 
Kingdom had a higher reported incidence rate. Despite 
the decreased incidence in 2011, it is likely that Ireland 
will continue to have one of the highest reported 
incidence rates in the EU for 2011. 1
Among the 61 cases, males predominated (n=41), 
with the highest numbers of cases among males aged 
between 35 and 55. The eight paediatric cases reported 
this year represent a 70% decrease on 2006 (n=26), the 
year in which notifications of paediatric malaria cases 
peaked (Figure 1). Six of these reported ‘visiting family 
in country of origin’ as their reason for travel, and one 
was a ‘new entrant’; there was no information on reason 
for travel for the remaining paediatric case.
The group most affected in Ireland continued to be 
African immigrants and their families who were exposed 
while returning to ‘visit family in country of origin’ (Table 
4.1 Malaria 
Summary
Number of cases 2011: 61
Crude incidence rate 2011: 1.3 per 100,000 population
Number of cases 2010: 82
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Figure 1. Annual number of notifications malaria by age, Ireland 2001-2011
Table 1. Number of cases malaria by reason for travel and country of birth, Ireland 2011
Reason for travel
Country of birth
Nigeria Other Africa Asia Ireland Other Not specified Total
Visit family country origin 15 7 6 3  1 32
Business/Professional Travel 1 3 4
Holiday travel  1 1
Irish citizen living abroad  1 1 2
New entrant to Ireland  2 2
Other  2 2 4
Not reported 1 1 14 16
Total 17 10 6 10 2 16 61
Other includes: aid/volunteer workers (n=2), and child visiting parents (n=2)
1). This almost certainly reflects the greater frequency 
with which this group travels to malarious areas; and 
also reflects Ireland’s importance as a destination for 
those emigrating from English speaking West Africa. 
Seventy-one per cent of cases with a known reason for 
travel in 2011 cited ‘visiting family in country of origin’, 
with at least 69% of these being of African origin (Table 
1). 
The second most common reason for travel this year 
was ’Business/professional travel’ (4 cases -9% of cases 
with known reason for travel). This compares with a total 
of 13 cases listing this as their reason for travel over 
the previous ten years. All four travelled to Africa for 
periods varying from 2 weeks to 12 months. 
A welcome finding was that there was only one case 
associated with holiday travel in 2011, down from a high 
of thirteen holiday-related cases in 2006. 
Nigeria remained the country most frequently visited 
-33% of all cases, or 43% of those with country of 
infection reported (Table 2). The second most common 
destination reported was Pakistan with eight reported 
cases (five were reported in one family group). This 
compares with a total of nine cases related to travel to 
Pakistan in the previous 10 years. 
The majority of cases who reported travel to Nigeria 
and Pakistan were ‘visiting family in country of origin’ 
(25/28), whereas visitors to other parts of Africa 
reported a variety of reasons for travel.
P. falciparum cases numbers declined, making up 70% of 
cases in 2011, while P. vivax case numbers increased (10 
cases versus 1-7 cases annually in the previous 10 years). 
This increase was strongly correlated with the increased 
number of cases reporting exposure in Pakistan. As 
expected, the median interval between arrival from a 
malarious country and onset of symptoms was lower for 
P. falciparum cases -9 days (n=20) -and P. vivax cases-8 
days (n=8) - relative to the interval reported for the one 
P. ovale case with this information -251 days. 
Several factors could have contributed to this decline 
in cases in 2011. It could reflect improved awareness of 
the risk of malaria, and better uptake of travel advice, 
but it is probably at least in part due to fewer journeys 
by Irish residents to Africa in recent years, following 
Ireland’s economic contraction –data from the CSO 
quarterly household survey shows that travel to Africa 
by Irish residents peaked in 2007-2008, and declined in 
2009, the latest complete year for which these data are 
available.2 
It may also be due to global efforts to reduce the 
incidence of malaria across affected regions. The WHO 
report that ‘in Africa, malaria deaths have been cut 
by one third within the last decade, and that outside 
of Africa, 35 out of the 53 countries, affected by 
malaria, have reduced cases by 50% in the same time 
period’.3 The measures taken to reduce incidence 
among residents of these countries are also likely to be 
effective for travellers, in particular those travelling to 
‘visit family in country of origin’. 
While this report has highlighted the high incidence 
among immigrants travelling to ‘visit family in their 
country of origin’, malaria prevention messages should 
also be targeted at tourists and other travellers with 
little previous exposure to malaria. A recent study in 
the United Kingdom has shown that while the highest 
numbers of cases may be among those of African 
heritage visiting family and friends, that the highest risk 
of dying among those who acquired malaria was among 
the elderly, among tourists and among those presenting 
to health professionals in areas where malaria is 
uncommon, making these important groups to target in 
pre-travel advice.4  Children can be particularly at risk; 
it is important that those born in Western and Central  
Africa who take up residence in Ireland and who return 
to their country of origin with their Irish-born children 
are made aware of the fact that their children have no 
innate immunity to malaria (and their own immunity will 
likely have waned considerably) and must complete 
their full course of advised chemoprophylaxis while 
taking steps to ensure they avoid mosquito bites. 
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Table 2. Number of cases malaria by infecting species and country of infection, Ireland 2011
Organism
Country of Infection
Total
Nigeria Pakistan Other Africaa Not specified
P.falciparum 20 11 12 43
P.ovale 2 1 3
P.vivax 8 1 1 10
Not Specified 4 1 5
Total 20 8 18 15 61
aIncludes cases associated with Congo (n=5), Ghana (n=3), Uganda(n=3), Sudan (n=2), and one each with Benin, DRC, Kenya, Somalia, and 
Western sahara
Sixteen cases of leptospirosis were notified in Ireland 
in 2011, similar to the 17 cases notified in 2010 (Figure 
1). This equates to a crude incidence rate of 0.35 per 
100,000 (95% CI 0.18-0.52). The latest year for which 
data is available across the European Union is 2009. 
Among the 25 countries that reported leptospirosis 
incidence in 2009, Ireland reported the third highest 
incidence rate. The incidence in the EU as a whole was 
0.14 per 100,000. 
The leptospirosis notification dataset is typically 
dominated by adult males, and this year is no exception 
(Table 1). Fourteen cases (87.5%) were male and the age 
range was 20-68 (mean age =42 years, median age=42 
years). This is consistent with the exposures most 
commonly associated with leptospirosis in temperate 
regions, e.g. occupational contact with farm animals, 
and watersports.
Among the 15 cases for which hospital admission status 
was reported, 12 (80%) required hospitalization. No 
deaths were reported. 
Seven cases (44%) were believed to have acquired 
their illness occupationally –all were either farmers 
or reported contact with farm environments. Four 
(25%) cases were reported as being associated with 
recreational activities: two with travel to a tropical 
destination, and one each with kayaking, and freshwater 
swimming. Two cases (13%) may have been exposed 
while gardening, while for one case (6%), no obvious 
risk factors were identified. No risk factor information 
was available for the remaining two (13%) cases.  
While a number of regional hospital laboratories offer 
a diagnostic service for leptospirosis, around two thirds 
of cases are diagnosed by the National Virus Reference 
Laboratory each year. Positive specimens are generally 
referred to the United Kingdom’s Leptospirosis 
Reference Unit (LRU) for confirmation and for typing 
where possible. 
A recent study reviewed the available information on 
Leptospira serovar data on CIDR compared to the 
typing data available at LRU on Irish cases.  This study 
established that there had been under-reporting of 
serovar information to CIDR (Garvey et al –submitted 
for publication).  In consequence, Departments of 
Public Health were encouraged to make a special effort 
to improve the reporting of Leptospira serovar data 
to CIDR. In 2011, species information was available on 
CIDR for seven cases (44%) in 2011–three Leptospira 
icterohaemorrhagiae, two L. hardjo, and one each L. 
saxkoebing and L. grippotyphosa. This is a substantial 
improvement on serovar reporting relative to the 
previous two years when linked serovar data was 
reported for only two cases in each year. For many of 
the remaining cases, it was reported that serovar was 
not determined. Failure to provide follow-up samples is 
one contributory factor in this. 
Activities that continue to be associated with 
leptospirosis risk in Ireland include recreational activities 
such as water sports, and farming. In recent years, travel 
to Asia and other tropical destinations has emerged as a 
risk factor for leptospirosis. 
4.2 Leptospirosis           
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Figure 1: Annual number of leptospirosis notifications, Ireland 
1991-2011
(data source: CIDR)
Summary
Number of cases, 2011: 16
Crude incidence rate, 2011: .035/100,000
Number of cases, 2010: 17
Table 1: Leptopirosis notifications by age and sex, Ireland 2011
Age group Male Female Total
<5 yr 0 0 0
5-14 yrs 0 0 0
15-24 yrs 1 1 2
25-44 yrs 7 1 8
45-64 yrs 4 0 4
65+ yrs 2 0 2
Total 14 2 16
Toxoplasmosis
During 2011, 32 cases of toxoplasmosis were notified 
compared to 36 in 2010 and 37 in 2009.  
One congenital case was reported. The remaining 31 
cases ranged in age from 1 year to 77 years (median, 33 
years).  As in previous years, female cases dominated 
(75%). The high number of cases reported among 
women of child-bearing age may reflect enhanced 
testing during pregnancy (Table 1). 
Q Fever
One probable and four confirmed cases of Q fever 
were notified during 2011, two of which were reported 
to have been hospitalized (40%). This is a decrease 
compared to 9 notifications in 2010 and 17 notifications 
in 2009. 
Three cases occurred in males and two in females (Table 
2). The cases ranged in age from 39 to 81 years (median 
age, 58 years). 
Cases were reported from five different HSE-areas: M, 
NE, SE, S and W. This distribution may reflect a regional 
difference in risk or variation in diagnostic policy/
practice in different parts of the country. 
The disease is commonly acquired through occupational 
exposure to infected sheep and other small ruminants, 
e.g. by farmers, veterinarians, and abattoir workers. 
Over the last number of years, the south of the 
Netherlands has been experiencing large community 
outbreaks of Q fever during the summer months. Some 
clusters have been linked with Q fever outbreaks on 
goat farms.1
1. Schwimmer et al, B. 2009. Sustained intensive transmission of 
Q fever in the South of the Netherlands, 2009. http://www.
eurosurveillance.org/images/dynamic/EE/V14N19/art19210.pdf
4.3 Other Non-IID Zoonotic Diseases
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Table 1: Toxoplasmosis notifications by age and sex, Ireland 2011
Age group Male Female Total
<1 yr 0 1 1
1-4 yrs 0 1 1
5-14 yrs 1 0 1
15-24 yrs 1 3 4
25-44 yrs 5 15 20
45-64 yrs 0 4 4
65+ yrs 1 0 1
Total 8 24 32
Table 2: Q fever notifications by age and sex, Ireland 2011
Age group Male Female Total
<5 yr 0 0 0
5-14 yrs 0 0 0
15-24 yrs 0 0 0
25-44 yrs 0 1 1
45-64 yrs 1 1 2
65+ yrs 2 0 2
Total 3 2 5
Brucellosis
During 2011, only one case of brucellosis was notified in 
an adult male. This compares to two notifications in total 
for brucellosis in 2010 and zero in 2009. The species 
reported for the 2011 case was Brucella melitensis, and 
infection was associated with travel to the Middle East. 
The age and sex distribution for brucellosis in recent 
years in Ireland suggests that occupational exposure is 
likely to be the main transmission route for this disease. 
The case definition permits inclusion of acute and 
chronic cases. In previous years, many cases were 
reported as chronic cases with only small numbers of 
acute cases reported.  
Echinococcosis
In 2011, there were no notifications of echinococcosis. 
Prior to this there have only been four cases of  
echinococcosis notified in Ireland since the disease 
became notifiable in 2004; in 2008, two adult cases 
were notified, and one adult case was notified each in 
2009 and 2010. 
Because of the long incubation period for this disease, 
it is possible that these infections occurred many years 
ago. 
Trichinosis
No cases of trichinosis were notified in Ireland in 2011.
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Blood-borne and 
Sexually Transmitted Infections
Hepatitis B is a vaccine preventable disease caused 
by the hepatitis B virus. It is transmitted through 
percutaneous or mucocutaneous contact with the blood 
or body fluids of an infected person. Over 90% of 
people infected in late childhood and adulthood clear 
the virus within a year of infection, but there is a high 
probability of developing chronic infection if hepatitis 
B is acquired in infancy (approx. 90%) or when aged 
under five years (approx. 30%).1 Between 15 and 40% 
of people with chronic infection ultimately develop 
cirrhosis, liver failure or hepatocellular carcinoma (liver 
cancer).2
The prevalence of hepatitis B in the general population 
in Ireland is low (less than 1%) and most cases fall 
into defined risk groups such as people with multiple 
sexual partners, household or sexual contacts of known 
cases, injecting drug users and people who were born 
in countries with intermediate (2-7%) or high (>8%) 
hepatitis B endemicity.
The number of hepatitis B cases reported in 
Ireland decreased by 19% in 2011, with 525 cases 
(12.4/100,000 population) notified compared to 
645 in 2010 (figure 1). Sixty two percent (n=327) of 
notifications were from the HSE-E, corresponding to a 
notification rate of 19.2/100,000 population.
All cases were laboratory confirmed and 96% contained 
information on acute/chronic status. Where status was 
known, 9% of cases were acute (n=45) and 91% were 
chronic (n=460).
Acute cases (recent infections)
Of the 45 acute cases notified in 2011, 84% (n=38) 
were male and 16% (n=7) were female. The highest 
notification rates were in young to middle aged adults, 
and 62% (n=28) of acute cases were aged between 
20 and 44 years when notified (figure 2). Female cases 
were younger than males overall, with a median age of 
26 years compared to 31 years for males.
5.1 Hepatitis B
Summary
Number of cases, 2011: 525
Crude notification rate, 2011: 12.4/100,000 population
Number of cases, 2010: 645
HPSC Annual Report 2008  
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Chronic Acute Total
Figure 1. Number of hepatitis B notifications by acute/chronic status, 1997-2011
Information on risk factor was available for 89% (n=40) 
of acute cases. Of these, 78% (n=31) were likely to have 
been sexually acquired. Ten were men who have sex 
with men, ten were heterosexual and sexual orientation 
was not known for eleven cases.  Four (10%) acute cases 
were acquired through surgical and/or tattoo body 
piercing procedures and two cases (5%) were born in 
hepatitis B endemic countries.  No risk factors were 
identified for three cases (8%) despite follow up being 
carried out.
Country of birth was known for 89% (n=40) of acute 
cases.  Of these, sixty eight percent (n=27) were born 
in Ireland, 15% (n=6) were born in Eastern or Central 
European countries, 5% (n=2) were born in Asia, 5% 
(n=2) were born in southern America and a further 5% 
(n=2) were born in western Europe.  Where country of 
infection was known, 73% (n=22) of acute cases were 
infected in Ireland. Information on reason for testing 
was available for 42 acute cases (93%). Most were 
identified because they were symptomatic (81%, n=34) 
or through STI screening (12%, n=5).
The number of acute cases of hepatitis B notified in 
Ireland is generally relatively low and decreased by 8% 
in 2010 (n=45) compared to 2010 (n=49). The decrease 
is mostly attributable to decreases in sexually acquired 
cases of acute hepatitis B in both men who have sex 
with men and heterosexuals. 
Chronic cases (long-term infections)  
Of the 460 chronic cases notified in 2011, 50% (n=228) 
were female, 49% (n=224) were male and sex was not 
known for 1% (n=8). Eighty five percent (n=389) of 
chronic cases were aged between 20 and 44 years when 
notified (figure 2). The median age at notification for 
female cases was 30 years and the median age for males 
was 33 years. 
Some data on risk factor, country of birth or asylum 
seeker status were available for 40% (n=185) of the 
chronic cases notified in 2011. Of these, 71% (n=132) 
were born in hepatitis B endemic countries or were 
identified as asylum seekers. 
Other risk factors included sexual acquisition (11%, 
n=21), recipient of blood or blood products (3%, n=5), 
vertical transmission (2%, n=3), tattoo/body piercing 
(2%, n=3) and household contact with a known case 
(1%, n=2). Despite follow up been carried out, no risk 
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Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis B by acute/chronic status, 2011
factor could be identified for 7% of these cases (n=13).
Data on country of birth was available for 38% (n=173). 
The most common regions of birth were Eastern or 
Central Europe (44%, n=76), Asia (28%, n=48) and Sub-
Saharan Africa (27%, n=46). 
Reason for testing was known for 60% (n=275) of 
chronic cases. Thirty two percent (n=89) were identified 
through antenatal screening programmes,19% (n=52) 
were tested in STI settings, 17% (n=48) were diagnosed 
as a result of routine health screens and 11% (n=31) 
were identified through asylum seeker screening 
centres.  Five per cent (n=15) represented cases that 
were previously diagnosed but not notified, 2% (n=6) 
were asymptomatic but had contact with a known 
case, 1% (n=4) were health care workers, 1% (n=3) 
were blood/organ donors, 1% (n=3) were vertically 
transmitted and 1% (n=3) were tested due to life 
assurance/mortgage policies.
Chronic hepatitis B notifications continue to decline in 
2011 compared to other years, with 460 chronic cases 
in 2011 compared to 554 cases in 2010 and 683 cases 
in 2009.  The large numbers of hepatitis B notifications 
between 1997 and 2008 (figure 1) were mostly 
attributed to increased numbers of people immigrating 
to Ireland from hepatitis B endemic countries.  The 
current economic climate has most likely contributed 
to reduced immigration to Ireland between 2009 
and 2011, which correlates with a steady decrease in 
hepatitis B notifications over the same time period. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 18th July 2012. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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Hepatitis C is a major cause of liver disease worldwide. 
The hepatitis C virus is primarily transmitted through 
sharing contaminated equipment when injecting 
drugs or through receipt of unscreened blood or 
blood products. Sexual, occupational and perinatal 
transmission can also occur but are less common. 
Infection is initially asymptomatic in most cases, but 
approximately 75% of those infected fail to clear 
the virus and develop chronic infection. Between 5 
and 20% of chronically infected individuals develop 
cirrhosis of the liver after 20 years of infection. Of 
those with cirrhosis, 1.5 to 2.5% will go on to develop 
hepatocellular carcinoma (liver cancer) each year.1 
Effective treatment, which eradicates the virus in over 
50% of cases, is available for hepatitis C.2 
The overall prevalence of chronic hepatitis C in Ireland 
is comparable to other Northern European countries, 
and is estimated to be between 0.5 and 1.2%. The 
prevalence in the general population is low and most 
cases fall into defined risk groups such as injecting drug 
users, people who received unscreened blood or blood 
products in the past and people who were born in 
hepatitis C endemic countries.3
The number of cases of hepatitis C reported in 2011 
was very similar to 2010, with 1,257 notifications 
(29.6/100,000 population) compared to 1,239 in 2010 
(figure 1). There was a strong predominance of males:  
65% (n=824) of cases were male, 34% (n=428) were 
female and sex was not known for 5 cases (figure 1). The 
highest notification rates were in young to middle aged 
adults. Seventy three percent (n=917) of cases were 
aged between 25 and 44 years (figure 2). The median 
age for females was slightly younger (34 years) than that 
for males (36 years). 
The geographic distribution of cases was skewed, 
with the HSE-E reporting 76% of all cases notified in 
2011. The highest notification rates were in the HSE-E 
5.2 Hepatitis C
Summary
Number of cases, 2011: 1,257
Crude notification rate, 2011: 29.6/100,000 population
Number of cases in 2010: 1,239
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Figure 1. Number of hepatitis C notifications, 2004-2011
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(68/100,000 population, n=957) and the HSE-M 
(18.7/100,000 population, n=47) (figure 3).
Data on most likely risk factor were available for 
59% of cases (n=741). The most common risk factors 
reported were injecting drug use (83%, n=616), being 
an asylum seeker/born in an endemic country (6%, 
n=43), sexual exposure (3%, n=24), receipt of blood or 
blood products (3%, n=19), vertical transmission (1%, 
n=11), tattoo/body piercing procedures (1%, n=6) and 
accidental needlestick exposure (0.5%, n=4).  Although 
information on risk factor was not available for 41% of 
cases, the age and sex profile of these cases did not 
differ significantly from those for whom information was 
available.
Where sexual orientation was known, men who have 
sex with men (MSM) represented 42% (n=10) of sexual 
exposure cases.  Of the nineteen cases acquired 
through blood or blood products, six were infected in 
Ireland, six were infected outside Ireland and country of 
infection was not known for seven. All cases acquired in 
Ireland were infected many years in the past, but were 
notified for the first time in 2011. 
Data on country of birth and country of infection were 
too incomplete to allow for reporting. 
The figures presented in this summary are based on 
data extracted from the Computerised Infectious 
Disease Reporting (CIDR) System on 18th July 2012. 
These figures may differ from those published previously 
due to ongoing updating of notification data on CIDR.
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Figure 3. Notification rates/100,000 population for hepatitis C by HSE area, 2008-2011
Figure 2. Age and sex-specific notification rates/100,000 population for hepatitis C, 2011
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A total of 320 new HIV diagnoses (235 men and 85 
women) were reported to HSPC during 2011. This 
compares with 330 in 2010 and represents a 3% 
decrease. The rate of newly diagnosed HIV infection in 
Ireland in 2011 was 7.0 per 100,000 population (10.3 
per 100,000 in men and 3.7 per 100,000 in women).
Since the early 1980’s, 6,287 people have been 
diagnosed with HIV in Ireland but this number does not 
represent the number of people living with HIV (PLHIV) 
in Ireland, as it does not take into account factors such 
as death and migration. A recent study identified that 
3,254 patients accessed HIV outpatient care in six 
centres in Ireland over a 12 month period in 2009/20101. 
The number of people living with HIV in Ireland is not 
known. 
There were 46 new AIDS diagnoses reported in 2011. 
Of these, 33 were simultaneously diagnosed with an 
AIDS defining illness at the time of their HIV diagnosis. 
There were seven deaths among AIDS cases reported in 
2011.
HIV testing data from 14 laboratories (14/16 laboratories 
who test for HIV responded to a survey on HIV testing) 
showed that 184,521 HIV tests were performed in 2011 
giving a testing rate of 40.2 per 1000 population.  
Figure 1 shows the number of HIV cases diagnosed 
annually in Ireland from 2000 to 2011, in males and 
females.
Probable route of transmission
The predominant route of transmission of HIV in Ireland 
in 2011 was sex between men. Heterosexuals accounted 
for 34% and Injecting Drug Users (IDUs) for 5%. There 
were three cases where the route of transmission was 
identified as Mother to Child transmission (MTCT). 
The probable route of transmission was unknown or 
unreported for 56 cases (17.5%). 
5.3 HIV and AIDS
Summary – 2011 cases
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Figure 1: New HIV diagnoses by year of diagnosis (2000 to 2011) 
Number of HIV cases: 320 Probable route of transmission
Rate per 100,000: 7.0 MSM: 136 (42.5%)
Male to female ratio: 235:85 Hetero: 108 (33.8%)
Median Age: 34 yrs IDU: 16 (5.0%)
% with AIDS defining illness at diagnosis: 10.6%
Figure 2 shows probable route of transmission among 
the three major risk groups; MSM, heterosexual contact 
and IDUs between 2000 and 2011. 
Men who have sex with men (MSM)
Of the 136 new diagnoses among MSM in 2011
•  Median age was 33 years (range: 18-77 years). The 
largest number of new diagnoses among MSM 
occurred in those aged 30-39 years, followed by those 
aged 40-49 years. 12% of new diagnoses in MSM were 
aged over 50. 
•  54% were born in Ireland, 14% were born in South 
America, 8% in Western Europe and 8% in Central and 
Eastern Europe. 
•  The probable country of infection was Ireland for 58% 
of cases and South America for 10% of cases. 
•  72% were white (54% white Irish, 18% white other). 
•  Where CD4 count was reported (in 115 of 136 cases; 
84.5%), 40% of MSM were diagnosed late (CD4 count 
<350 cells/mm3) including 23% who were severely 
immune-compromised (CD4 count <200 cells/mm3). 
•  13 MSM (10%) were diagnosed with an AIDS defining 
illness at the time of their HIV diagnosis.  
Heterosexual transmission
Of the 108 cases diagnosed in 2011, 
•  59 were female and 49 were male.
•  Median age was 33 years (range: 16 to 63), 34 years 
in men (range: 22 to 63 years) and 32 years in women 
(range: 16 to 61 years). 
•  The probable source of the infection was unknown 
for 40% of the heterosexually acquired cases. Of 
the remaining 60%, 43% were among individuals 
originating from countries with generalised epidemics, 
11% had a high-risk partner or a partner known to be 
HIV positive and 7% had a partner originating from a 
country with a generalised epidemic.
•  45% cases were born in sub-Saharan Africa and 31% 
were born in Ireland. Of the 33 Irish born cases, 22 
were male and 11 were female. The probable source 
of infection was unknown or undetermined for 73% 
(24) of the Irish born cases. 
•  45% were white and 45% were black African. 
•  The probable country of infection was Ireland for 38% 
of cases and Sub-Saharan Africa for a further 38%. 
•  Where CD4 count was available (84 of 108 cases; 
77.8%), 62% of heterosexual cases were diagnosed 
late including 40% who were severely immune-
compromised. The proportion diagnosed late was 
higher in male heterosexuals (70%) than female 
heterosexuals (53%). 
•  14 cases (13%) were diagnosed with an AIDS defining 
illness at the time of their HIV diagnosis. 
Injecting Drug Users (IDUs)
Of the 16 IDU cases, 
•  13 were men and 3 were women.
•  Median age was 37 years (range: 22 to 48 years).
•  50% were born in Ireland, 19% were born in Central 
and Eastern Europe and 13% were born in sub-
Saharan Africa. 
•  63% were White (50% were white Irish and 13% were 
white other).  
•  Where CD4 count was reported (13 of 16 cases; 
81.3%), 85% of IDUs in 2011 were diagnosed 
late including 62% who were severely immune-
compromised.  
•  Three IDUs (19%) were diagnosed with an AIDS 
defining illness at the time of their HIV diagnosis. 
Discussion
HIV infection is of major public health importance with 
evidence of continuing transmission in Ireland and 
Europe. In 2011, a total of 320 individuals were newly 
diagnosed, corresponding to a crude rate of 7.0 per 
100,000 population. This compares with a rate of 6.6 in 
the WHO European West region in 20102.
MSM are the most affected by HIV in Ireland and new 
diagnoses in this group increased sharply between 2005 
and 2009 (from 60 to 138; 130%) and has remained high 
in 2010 and 2011. Among heterosexuals, the number of 
new diagnoses has decreased from a peak of 232 cases 
in 2002. This decline in the number of heterosexual 
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Figure 2: New HIV diagnoses in Ireland by probable route of transmission 
(2000 to 2011)
cases is largely due to a decrease among people 
born in countries with a generalised HIV epidemic. 
The number of new diagnoses among IDUs has been 
steadily decreasing from 74 in 2004 to 16 in 2011 (a 
decline of 78%).
Late HIV diagnosis, where a person is unaware of their 
HIV status for many years, carries an increased risk of 
HIV-related illness and death3,4. In addition, prompt HIV 
diagnosis prevents further HIV transmission by ensuring 
that the patient’s viral load is low. During 2011, 52% of 
cases (where CD4 count was available) presented at a 
late stage of infection including 33% who were severely 
immune-compromised at diagnosis. The proportion 
diagnosed late was highest among IDUs (85%) and 
heterosexual males (70%) compared with heterosexual 
females (53%) and MSM (40.0%). By ethnicity, late 
diagnosis was highest among black Africans (72%). 
More detailed reports can be found at www.hpsc.ie. 
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Background
A HIV infected mother can transmit the virus to her 
baby during pregnancy, delivery, or breastfeeding.  It 
has been clearly shown that the risk of mother-to-child 
transmission (MTCT) of the virus can be dramatically 
reduced by treatment of the mother, management 
of the delivery and avoidance of breastfeeding.  The 
combined effect of these interventions is reported in 
some studies to reduce the transmission risk from 15-
30% to 2% or less.1, 2, 3 However, measures to prevent 
transmission of HIV from mother to child can only be 
offered if HIV infection is diagnosed prior to delivery.  
In April 1999, the Department of Health and Children 
(DoHC), on the advice of the National AIDS Strategy 
Committee (NASC), introduced a policy of voluntary 
antenatal HIV testing in Ireland.  As part of this 
programme, it is recommended that antenatal screening 
for HIV is offered routinely to all pregnant women. 
Antenatal HIV testing commenced in all health boards 
during 1999, with the exception of the North Western 
Health Board where it commenced in 2000. On a 
recommendation from NASC, as outlined in the AIDS 
Strategy 2000 report,4 a system for monitoring and 
evaluating the routine antenatal testing programme was 
established by the Health Protection Surveillance Centre 
(HPSC) in July 2001. The voluntary testing replaced an 
anonymous unlinked testing scheme. 
Methods
HPSC collect aggregate data on a quarterly basis from 
20 maternity hospitals. Forms are completed on paper 
or electronically, usually by a clinic midwife, and are 
then posted, faxed or emailed to HPSC. In the HSE-
Northwest and HSE-Southeast, data are collated at 
regional level prior to sending on to HPSC. 
Results
All 20 maternity hospitals/units provided antenatal HIV 
screening data for 2011. Table 1 describes the data 
collected from maternity hospitals between 2002 and 
2011. 
5.4  Voluntary antenatal HIV testing in 
Ireland: 2011
Key Points
	 National reported uptake rate: 98.6% 
	 Number HIV positive cases: 109
	 Prevalence rate: 0.16%
	 Number new HIV positive cases: 17
Table 1: Results of the antenatal screening programme, 2002 to 2011
Parameter 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
Number of hospitals participating 20/22 21/22 20/22 21/22 19/21 19/20 18/20 19/20 19/20 20/20
Number of live births per year (from 
CSO)
60,503 61,529 61,972 61,372 65,425 71,389 75,065 74,728 na na
Number of women booked 51,777 45,259 40,171 44,874 52,434 60,111 66,558 68,378 70,024 68,111
Number offered test 51,777 45,259 40,171 44,874 52,434 60,052 66,558 68,026 69,615 67,849
Number tested 48,922 43,815 39,049 44,292 51,649 59,522 66,210 67,694 69,292 67,135
Uptake of HIV antenatal test (%) 94.5 96.8 97.2 98.7 98.5 99.0 99.5 99.0 99.0 98.6
Number HIV positive 157 144 103 118 113 117 123 140 118 109
% HIV positive 0.32 0.33 0.26 0.27 0.22 0.20 0.19 0.21 0.17 0.16
Number newly diagnosed HIV 
positive 
112 93 39 43 34 38 34 32 21 17
% Newly diagnosed HIV positive 0.23 0.21 0.10 0.10 0.07 0.06 0.05 0.05 0.03 0.03
•  All 20 maternity hospitals/units provided data on HIV 
antenatal screening for 2011. However only 52.6% of 
hospitals reported information on private patients. 
•  The national reported uptake of HIV antenatal 
screening was 98.6% in 2011. The uptake rate ranged 
from 75% to 100% among participating hospitals. 
•  In 2011, 109 pregnant women tested HIV positive at 
their antenatal screen, giving a prevalence of 0.16%. 
This is the lowest prevalence rate since screening 
began in 2002. 
•  In 2011, the prevalence of HIV infection among 
pregnant women varied among HSE areas, ranging 
from 0.04% in HSE West to 0.27% in Dublin 
Northeast. 
•  In 2011, 17 pregnant women were newly diagnosed 
with HIV at antenatal screening. This is the lowest 
number since screening began and has decreased on 
an annual basis. The prevalence of newly diagnosed 
HIV infection among pregnant women was 0.03% in 
2011. 
•  Between 2002 and 2011, 1,242 antenatal HIV 
screening tests were positive. Of these 463 (37.3%) 
were not previously known to be HIV positive and 
were first diagnosed at antenatal screening. 
Key limitations of the antenatal screening data 
In order to investigate some of the limitations of the 
antenatal screening data, hospitals were asked four key 
questions: 
1.  Does the data refer to (i) public patients or (ii) public 
and private patients?  
  Nine hospitals stated that the 2011 data related to 
public patients only and nine stated that the data 
related to all patients. One hospital was a private 
hospital and one did not respond.
2.  Do you record the reason for refusal? 
  Twelve hospitals record the reason for refusal and six 
do not. Two hospitals did not respond.   
3.  Where do you derive the booking data? 
  Seven hospitals used maternity IT systems, four used 
laboratory systems, four used patient administrations 
systems and four extracted the data manually. One 
hospital did not respond
4.  Do you have a computerised system for recording 
the antenatal data? Fifteen hospitals do not have a 
computerised system and four do. One hospital did 
not respond  
Discussion
HIV antenatal screening is vital to identify women 
who are HIV positive and to ensure they can avail of 
appropriate treatment and care, to decrease the risk 
of mother to child transmission and to help prevent 
transmission of HIV to sexual partners of pregnant 
women. 
The number of women newly diagnosed with HIV 
infection at antenatal screening has decreased over 
time. The prevalence rate in 2011 (0.16%), is the lowest 
prevalence rate since the screening program began. 
In 2011, prevalence of HIV infection among pregnant 
women varied among different HSE areas ranging 
from 0.04% to 0.27%.  Throughout Europe, pockets of 
higher prevalence among pregnant women have been 
reported in major urban areas.6 The prevalence of newly 
diagnosed HIV infection has decreased steadily from 
0.23% in 2002 to 0.03% in 2011. 
Data from the national HIV case based reporting system 
shows that there were reports of 23 new diagnoses in 
pregnant women in 2011.5 This difference between the 
number of women reported through the HIV case based 
reporting system, and the antenatal surveillance system 
demonstrate that coverage of the antenatal programme 
is incomplete. It is not possible to link these two stand 
alone systems. 
As highlighted in this report, there are some limitations 
to the antenatal screening data. In particular, 
information on the uptake of screening should be 
interpreted with care as some hospitals could only 
provide estimates or proxy measures for the numbers 
offered testing and some hospitals could not provide 
data relating to their private patients. 
More detailed reports can be found at www.hpsc.ie 
Technical notes:
1.  Uptake was calculated as the number of women 
tested divided by the number of women booked. 
2.  Prevalence of HIV infection was calculated as the 
number of women testing positive divided by the 
number of women tested. 
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There were 13,259 notifications of STIs in 2011, an 
increase of 12.2% when compared with 2010 (n=11,815) 
and continuing an upward trend since 1995 (figure 1). 
The crude incidence rate (CIR) for total STI notifications 
in 2011 was 289.0 per 100,000 population compared 
with 257.5/100,000 in 2010. The impact of poor sexual 
health is occurring in young adults, with more than half 
of notifications  among those aged 20 to 29 years in 
both 2010 (61.3%) and 2011 (59.3%). 
In line with previous years, Chlamydia trachomatis was 
the most frequently notified STI in 2010 and 2011, 
accounting for 45.7% and 48.3% of notifications, 
respectively.
Chlamydia, 2010-2011
Following decreases in the CIR for Chlamydia in 2009 
(126.0/100,000) and 2010 (117.7/100,000), the CIR 
increased in 2011 to 139.6 per 100,000 population; this 
rate is still lower than the peak CIR of 148.4/100,000 
recorded in 2008 (figure 2). 
Chlamydia was more frequently reported among women 
in 2010 and 2011, continuing the trend seen in previous 
years (figure 2).  Chlamydia was most frequently 
reported in those aged 20-29 years (2010: 65.5%; 2011: 
65.1%); there has been a slight increase in notifications 
in those aged 30 years and older since 2009. 
5.5  Sexually Transmitted Infections  
 (STIs), 2010-2011
Summary
Total number of STI notifications in 2010: 11,815
Total number of STI notifications in 2011: 13,259
Crude incidence rate, 2010: 257.5/100,000
Crude incidence rate, 2011: 289.0/100,000
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Table 1. Number of notifications and percentage change, 
2010-2011
Sexually transmitted infection 2010 2011 % change
Ano-genital warts 2556 2459 -3.8
Chancroid 0 0 -
Chlamydia trachomatis infection 5399 6407 +18.7
Gonorrhoea 625 834 +33.4
Granuloma inguinale 0 0 -
Herpes simplex (genital) 877 1226 +39.8
Lymphogranuloma venereum 3 2 -33.3
Non-specific urethritis 1657 1603 -3.3
Syphilis 614 653 +6.4
Trichomoniasis 84 75 -10.7
Total 11815 13259 +12.2
Figure 1.Number of notifications by age group and crude 
incidence rate* per 100,000 of all sexually transmitted 
infections by year, 1995-2011
Gonorrhoea, 2010-2011
The number of gonorrhoea notifications continued to 
increase (+33.4%) in 2011 (table 1). The CIR now stands 
at 18.2 per 100,000 population, the highest rate ever 
recorded for gonorrhoea (figure 4). 
The majority of gonorrhoea notifications continue to 
be reported in men in 2011 (n=650; 77.9%).  Between 
2006 and 2010, there was an increase in notifications in 
women. This increase was reversed somewhat in 2011 
with the male-to-female ratio increasing to 4:1 from 3:1 
in 2010.
In line with previous years, the majority of gonorrhoea 
notifications in 2010 and 2011 were reported in those 
aged 20-29 years (52.6% and 55.6%, respectively). 
Notifications among the 0-19 year age group decreased 
in both 2010 (12.5%) and 2011 (11.5%). This follows a 
peak in 2009 when 16.1% of gonorrhoea notifications 
were among those aged 19 years or younger.
Ano-genital warts, 2010-2011
After Chlamydia, ano-genital warts was the second 
most frequently reported STI in 2010 and 2011, 
accounting for 21.6% and 18.5%, respectively, of all 
STI notifications. The number of notifications in 2011 
(n=2,459) was largely unchanged from 2010 when 
there were 2,556 notifications (table 1). Full annual 
data returns from one large STI clinic are outstanding 
and quarter 4 data are missing from another so the 
true incidence of ano-genital warts in the population is 
likely to be higher. As seen in previous years, there were 
slightly more notifications among men (58.1%in 2010; 
55.4% in 2011) and almost two-thirds of cases in 2010 
and 2011 were aged 20-29 years (62.2% in 2010; 63.4% 
in 2011).
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Figure 2. Percentage of Chlamydia trachomatis notifications by gender and crude incidence 
rate per 100,000, 1995-2011
Figure 3. Crude incidence rate* of sexually transmitted infections (>1,000 notifications per 
year) by year, 1995-2011
Herpes simplex (genital), 2010-2011
Notifications of herpes simplex (genital) increased by 
39.8% between 2010 and 2011 (table 1). The CIR was 
26.7 per 100,000 in 2011, the highest rate recorded for 
herpes simplex (genital) since it was added to the list 
of notifiable diseases in 1985 (figure 2). The increase 
in notifications may be due to improved detection as 
a result of the introduction of molecular testing which 
is more sensitive than viral culture. Almost two-thirds 
of herpes simplex (genital) notifications were reported 
in women (61.1% in 2010; 64.8% in 2011). The most 
frequently reported age group was 20-29 years old 
(48.6% in 2010; 47.4% in 2011).
Non-specific urethritis, 2010-2011
There was little change in the number of notifications 
of non-specific urethritis (NSU) in 2011 (n=1,603) 
compared with 2010 (n=1,657) (table 1). Full annual 
data returns from one large STI clinic are outstanding 
and quarter 4 data are missing from another so the true 
incidence of NSU in the population is likely to be higher. 
While the case definition for NSU notifications in 2011 
specifies “any male meeting the clinical criteria” NSU 
continues to be reported among women (9.4% in 2010, 
6.2% in 2011).
Trichomoniasis, 2010-2011
Notifications of trichomoniasis decreased from 84 
in 2010 to 75 in 2011. Notifications were almost 
exclusively among women (96.0% in both 2010 and 
2011). Trichomoniasis continues to be reported more 
commonly among older age groups, with just 31.0% and 
28.0% of cases in 2010 and 2011 reported in those aged 
20-29 years.
Data on syphilis, HIV and Hepatitis B are presented 
elsewhere in this report.  More detailed reports on STIs 
in 2010 and 2011 are available on the HPSC website 
(www.hpsc.ie). 
* Crude incidence rate has been calculated using data 
from Census 1996 (1995-1999), Census 2002 (2000-
2003), Census 2006 (2004-2008) and Census 2011 
(2009-2011)
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Figure 4. Crude incidence rate* of sexually transmitted infections (<1,000 
notifications per year) by year, 1995-2011
Case-based syphilis records have been collated 
nationally since 2000. Case-based syphilis data provided 
by some clinicians is a subset of aggregate syphilis 
notification data. Forms are completed by Departments 
of Public Health in conjunction with the clinician and 
are then forwarded to HPSC. The data presented in this 
chapter relate to case-based reports received on syphilis 
which are held on a national database at HPSC. The 
syphilis figures presented are not comparable with the 
aggregate counts of syphilis notifications provided by 
HSE areas as part of the routine quarterly reporting of 
sexually transmitted infections (see Sexually Transmitted 
Infections, 2010-2011, for more details). 
Syphilis case reports, 2010
In 2010, case-based reports were received on 260 
syphilis notifications, a decrease of 8.1% compared 
with 2009 (n=283). One-hundred-and-thirty-nine 
(3.0/100,000 population) cases (53.5%) were diagnosed 
with early, infectious syphilis (i.e. primary, secondary and 
early latent stages) and 97 (37.3%) cases were latent, 
late latent or tertiary, syphilis. The stage of infection 
was not recorded for 24 (9.2%) cases.
The crude incidence rate (CIR) for all stages of syphilis 
was 5.7 per 100,000 population a slight decrease 
compared with 2009 (6.1/100,000). The CIR for early 
syphilis also decreased in 2010 to 3.0 per 100,000. 
For all cases the age range was 18 years to 70 years, 
and the median was 32 years. The age range among 
early cases was also 18 years to 70 years but the median 
age was 33 years. More than eighty per cent (81.5%) 
of cases were in men and fifty per cent of cases were 
among 25-39 year olds.
5.6 Syphilis, 2010
Summary
Number of case-based syphilis reports, 2010: 260
Number of early syphilis cases, 2010: 139
Crude incidence rate of early syphilis, 2010: 3.0 per 
100,000 population
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Figure 1 Crude incidence rate (CIR)* per 100,000 population and number of early syphilis 
cases by sexual orientation, 2000-2010, based on completed case-based surveillance forms 
*CIR calculated using data from Census 2002 (2000-2003), Census 2006 (2004-2008) and Census 2011 
(2009-2010) 
Syphilis cases were reported from just five HSE areas: 
East (n=204), Midlands (n=1), South East (n=19), 
South (n=14) and West (n=22). This is a reflection of 
the areas in which STI services are located as well as 
reporting practices. Analysis of the 2010 cases by area 
of residence shows that these cases are from all eight 
HSE areas.
Early syphilis was diagnosed more frequently amongst 
MSM while heterosexual men and women were more 
likely to be diagnosed with late syphilis (table 1).
Just over thirteen per cent (n=35) of all cases were 
re-infections, with the majority being diagnosed as 
early syphilis (n=28). Almost all cases recorded as re-
infections were among MSM (n=32).
Early syphilis case reports, 2010
Just over half of all reported cases were classified as 
early syphilis (n=139, 53.5%). Cases of early syphilis 
continues to be predominantly among MSM (n=111, 
79.1%) in particular those aged 30-34 years (n=25/111, 
22.5%).  Among heterosexuals, cases of early syphilis 
were reported most frequently in those aged 20-24 
years (n=9/27).
As in previous years, the majority of early cases 
continue to be resident in the East, though the 
proportion has decreased to 68.3% in 2010, from 80.6% 
in 2009. Most cases of early syphilis were among those 
born in Ireland (69.1%); the second most frequently 
reported country of birth was Brazil (5.0%).Eighty per 
cent of early cases were acquired in Ireland. Spain and 
the United Kingdom were the most frequently reported 
countries of infection outside of Ireland (5.8%).
HIV status was provided for 130 cases of early syphilis; 
24.5% of early syphilis cases were HIV positive (n=34). 
The proportion of early cases reported as re-infections 
increased slightly in 2010 to 20.1%. Ninety per 
cent of re-infections were in MSM and 10% among 
heterosexuals.
There were 4 cases of early syphilis in pregnancy, 
accounting for a third of the cases in women. Two 
of these cases were primary syphilis and two were 
secondary.
A more detailed report Epidemiology of Syphilis in 
Ireland, 2010, is available on the HPSC website 
www.hpsc.ie.
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Table 1 Number of syphilis cases by stage of infection and sexual 
orientation, 2010
Stage of infection Sexual Orientation Total
 MSM Non-MSM Unknown
Early syphilis 111 27 1 139
Late syphilis 42 54 1 97
Unknown 16 8 0 24
Total 169 89 2 260
% All cases 65.0 34.2 0.8 100.0
Since 1st May, 2011, the Computerised Infectious 
Disease Reporting (CIDR) system has been used to 
record notifications of syphilis, thereby allowing the 
replacement of the case-based and aggregate syphilis 
databases previously in use in Departments of Public 
Health and at HPSC. Collating syphilis notifications from 
all sources in a standard database has enabled timely 
weekly reporting of syphilis, as well as providing a more 
accurate assessment of the burden of syphilis nationally, 
based on area of residence. 
A total of 653 cases of syphilis were notified in 2011. Of 
these 653 cases, case-based data were available for 466 
cases (71.4%), including some cases notified before 1st 
May, 2011. Stage of infection was reported for less than 
40% of all cases notified in 2011. There were 171 cases 
of early syphilis, 22 cases of late syphilis and 59 cases 
were classified as latent of undetermined duration. One 
case of probable congenital syphilis was also reported.
The crude incidence rate (CIR) for all stages of syphilis 
reported in 2011 was 14.2 per 100,000 population, 
continuing the upward trend which began in 2006 
(figure 1). The CIR for early syphilis was 3.7/100,000 
in 2011, a slight increase from 2010 (3.0/100,000) but 
similar to the rate for 2009 (3.6/100,000; figure 1). 
Three-quarters of all cases were reported in men 
(n=491) and the largest number were reported in the 
30-39 years age group (n=249).
Early syphilis
A total of 171 cases of early syphilis were reported in 
2011; 89 (52.0%) were classified as primary syphilis, 54 
(31.6%) as secondary syphilis and 28 (16.4%) as early 
latent syphilis (table 1). 
5.7 Syphilis, 2011
Summary
Number of case-based syphilis reports, 2011: 653
Number of early syphilis cases, 2011: 171 
Crude incidence rate of early syphilis, 2011: 3.7 per 
100,000 population
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Figure 1. Crude incidence rate* per 100,000 of early syphilis and total syphilis by year, 
2000-2011 
*Crude incidence rate has been calculated using data from Census 1996 (1995-1999), Census 2002 
(2000-2003), Census 2006 (2004-2008) and Census 2011 (2009-2011)
There is considerable geographic variation in the 
distribution of early syphilis, with CIR in the HSE 
East area (8.0/100,000) higher than elsewhere in the 
country, confirming that this region remains a centre of 
transmission within Ireland. The majority of early syphilis 
(69.0%) was acquired in Ireland.
There were 154 cases among men and 17 cases among 
women, giving a male-to-female ratio of 9:1. The 
majority of cases (79.5%) were among men who have 
sex with men (MSM). The most frequently reported age 
groups were 25-29 years (n=42; 24.6%). The age range 
was 17 years to 68 years (median 31 years).
The proportion of re-infections was 13.5% overall 
with the proportion amongst MSM (15.4%) more than 
double the proportion among heterosexuals (7.1%) in 
2011.
HIV status was reported for 91.8% of early cases 
(n=157); 32 cases of early syphilis were reported as HIV 
positive. Of these 32 cases, 12 (37.5%) were diagnosed 
with HIV in 2011. HIV status was reported as positive for 
22.1% of early cases among MSM, compared to 7.1% of 
cases among heterosexuals.
A more detailed analysis of syphilis in Ireland in 2011 is 
available in the report Sexually Transmitted Infections 
in Ireland, 2011, which is available on the HPSC website 
www.hpsc.ie.
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Table 1. Summary of early syphilis cases, 2011
Early syphilis cases n %
Total number of early cases 171 -
Primary syphilis 89 52.0
Secondary syphilis 54 31.6
Early latent syphilis 28 16.4
Re-infections 23 13.5
Number of early cases who are MSM 136 79.5
Number who are HIV positive 32 18.7
Number who are pregnant 9 5.3
Number acquired in Ireland 118 69.0
Number born in Ireland 97 56.7
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Other infections
Encephalitis due to viruses not otherwise specified 
(NOS) in the Irish Infectious Disease (Amendment) (No. 
3) Regulations 2003 (SI No. 707 of 203) are notifiable 
under the disease viral encephalitis. (Details of viral 
encephalitis cases caused by other notifiable diseases 
are presented in other chapters in this report). Clinicians 
and laboratories (the latter since 2004) are legally 
obliged to notify all cases of viral encephalitis.
In 2011, 23 cases of viral encephalitis (NOS) were 
notified in Ireland (0.5/100.000 population). This was 
just one case more than that reported in the previous 
year (2010) which was substantially more than the five 
cases reported in both 2008 and 2009 (figure 1). 
Fewer viral encephalitis (NOS) cases occurred in males 
(n=9) than females (n=14), giving a male to female 
ratio of 1.0:1.6. Cases ranged in age from 21 to 84 
years with a median age of 58 years. The majority of 
the notifications occurred in the elderly aged 65 years 
and over (48%; n=11; 2.1/100,000 population) followed 
by the 25-44 years age group (30%; n=7; 0.5/100,000 
population) (table 1). 
In 2011, six HSE areas notified cases of viral encephalitis 
(NOS) (range 1-12), with HSE-E accounting for 52% 
(n=12/23) of cases. The national crude incidence rate 
in 2011 was 0.5 (95% CI 0.3–0.7) cases per 100,000 
population with the rate in HSE-E being 6.7 (95%CI 
0.3–1.1) cases/100,000 population.
Of the 23 cases reported in 2011, 21 were confirmed 
(91.3%) and one each was classified as probable and as 
possible (4.3%).
In recent years herpes simplex virus and varicella 
virus have been the two main causative agents of 
viral encephalitis notifications in Ireland (figure 2). 
Notifications due to herpes simplex virus have doubled 
between 2010 and 2011, but in contrast, only one 
varicella virus-related case was reported in 2011 
compared to 11 in 2010. Of the 20 herpes simplex 
virus (HSV) encephalitis cases notified in 2011, 13 were 
reported as HSV type 1, six were type 2 and the typing 
6.1 Viral Encephalitis
Summary
Number of cases 2011: 23
Number of cases 2010 22
Number of cases 2009: 5
Crude incidence rate, 2011: 0.5/100,000
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Table 1. Number, age-specific incidence rates and proportion of viral encephalitis (NOS) cases by 
age group, 2011
 Causative pathogen    
Age Group
Herpes 
simplex virus
Unknown Varicella virus Total ASIR % Proportion
<1 0 0 0 0 0.00 0.0
1-4 0 0 0 0 0.00 0.0
5-14 0 0 0 0 0.00 0.0
15-24 1 0 0 1 0.17 4.3
25-44 6 1 0 7 0.48 30.4
45-64 3 0 0 3 0.29 13.0
65+ 9 1 1 11 2.05 47.8
All ages 20 2 1 23 0.50 100
% total cases 87.0 8.7 4.3 100.0 138.1  
ASIR, age specific incidence rate per 100,000 population of total cases
details of the remaining case was not reported.
One patient with viral encephalitis in 2011 died with the 
cause of death not specified.
In summary the numbers of viral encephalitis 
notifications in Ireland in 2011 were similar to 2010. 
There was a marked decline in viral encephalitis 
notifications associated with varicella virus but a marked 
increase in those caused by HSV.
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 29th August, 2011. These 
figures may differ from those published previously due 
to ongoing updating of notification data in CIDR.
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Figure 1. Annual number of viral encephalitis (NOS) cases by age group, 1997-2011
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Figure 2. Annual number of viral encephalitis (NOS) cases by causative pathogen, 1997-2011
Meningitis due to viruses not otherwise specified (NOS) 
in the Irish Infectious Disease (Amendment) (No. 3) 
Regulations 2003 (SI No. 707 of 203) are notifiable 
under the disease viral meningitis. (Details of viral 
meningitis cases caused by other notifiable diseases 
are presented in other separate chapters in this report). 
Clinicians and laboratories (the latter since 2004) are 
legally obliged to notify all cases of viral meningitis.
In 2011, 220 cases of viral meningitis (NOS) were 
notified in Ireland, the highest number recorded since 
1997 (figure1). No deaths as a direct cause by viral 
meningitis (NOS) were reported in 2011. 
Of the 220 cases notified, 207 were classified as 
confirmed (94.1%), ten as probable (4.5%) and three as 
possible (1.4%). A similar number of cases occurred in 
males (n=114) as in females (n=105), giving a male to 
6.2 Viral Meningitis
Summary
Number of cases 2011: 220
Number of cases 2010 168
Number of cases 2009: 142
Crude incidence rate, 2011: 4.8/100,000
-102-HPSC Annual Report 2011 6. Other Infections
Table 1. Number, age-specific incidence rates and proportion of viral meningitis (NOS) notifications  by age group and type, 
2011
 Causative pathogen    
Age Group Enterovirus
Human Herpes 
virus type 6
Unknown
Herpes 
Simplex 
virus
Varicella 
zoster 
virus
Echovirus Total ASIR
% 
Proportion
<1 68 22 3 1 0 1 94 129.8 42.7
1-4 5 4 0 0 0 0 9 12.4 4.1
5-14 13 1 0 1 0 0 15 20.7 6.8
15-24 26 0 2 2 3 1 34 47.0 15.5
25-44 44 0 6 3 1 0 54 74.6 24.5
45-64 3 0 1 1 0 0 5 6.9 2.3
65+ 3 0 1 1 0 0 5 6.9 2.3
All ages* 164 28 13 9 4 2 220 303.8 100
% total cases 74.5 12.7 5.9 4.1 1.8 0.9 100.0 138.1  
ASIR, age specific incidence rate per 100,000 population of total case
* Includes three cases with unknown age details
Figure 1. Number of viral meningitis (NOS) cases by age group and year, 1997-2012 
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female ratio of 1.0:1.09. One case was reported with 
unknown gender details.
Children and young adults were most commonly 
affected with a median age of seven years (range one 
week to 72 years). Nearly 70% of cases occurred in 
those age under 25 years of age (figure 1, table 1). 
The highest age specific incidence rate (ASIR) was 
in infants <1 year of age (129.8/100,000; n=94). The 
next highest ASIR was in the 25-44 years age group 
(74.6/100,000; n=54). Lowest rates were reported in the 
older age groups (2.3/100,000; n=5 each) (table 1). 
The national crude incidence rate in 2011 was 4.8 (95% 
CI 4.2 – 5.4) cases per 100,000 population. This was a 
24% increase compared with 2010 when 168 cases were 
notified (3.7/100,000). The incidence rate in 2011 was 
highest in HSE-E at 6.7/100,000 (95%CI 5.5–7.9) cases 
and lowest in HSE-W at 2.9/100,000 (95%CI 1.3-4.5) 
(figure 2).
In 2011, enterovirus was the most common pathogen 
associated with viral meningitis, accounting for nearly 
75% (n=164/220) of all notifications (figure 3, table 
1). Human herpes virus 6 (HHV6) was the causative 
pathogen for 12.7% (n=28) notifications; herpes simplex 
virus (HSV) accounted for 4.1% (n=9) of notifications 
(figure 3, table 1).
Enterovirus meningitis was also most common in infants 
under one year of age with 68 of the 94 viral meningitis 
(NOS) cases in this age group in 2011 caused by this 
pathogen (72%) (figure 4). Between 2007 and 2011 
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Figure 2. Crude incidence rates per 100,000 population with 95% confidence 
intervals for viral meningitis (NOS) cases by HSE area, 2011
Figure 3. Number of viral meningitis (NOS) cases by organism type and year, 
1997-2011
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enteroviruses have accounted for 67% (n=450/672) of 
all viral meningitis (NOS) cases, with a distinct seasonal 
peak observed in the period June to August (figure 5).
 
The figures presented in this report are based on data 
extracted from the Computerised Infectious Disease 
Reporting (CIDR) system on 29th August, 2012. These 
figures may differ from those published previously due 
to ongoing updating of notification data in CIDR.
Figure 5. Three-month moving average of the annual number of enterovirus 
notifications, 2007-2011
Figure 4. Number of enterovirus cases notified by age group and gender, 2011
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Seven cases of Creutzfeldt-Jakob disease (CJD) were 
notified in 2011 compared to three cases in 2010.  All 
cases in 2011 were sporadic CJD cases.  The age profile 
of the cases is shown in figure 1.  Two cases were male 
and five were female.
In total, 58 cases of CJD were notified since CJD was 
first specified as a notifiable disease in December 1996.  
Figure 2 shows the 58 CJD notifications by age group.  
The majority (83%, n=48) of the cases were aged 
greater than 54 years.  Of the 58 cases, 31 were male 
and 27 were female.  Fifty-five cases were sporadic CJD, 
two were familial CJD and one was iatrogenic CJD.
Variant CJD (vCJD) is specified as a separate notifiable 
disease.  No cases of vCJD were notified in 2011.  Four 
cases of vCJD were notified since vCJD became notifi-
able in December 1996.  A summary of these four cases 
was provided in the 2006 HPSC annual report. 
Data presented in this summary are based on notifi-
cations from HSE Areas and from the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit.  Annual 
figures published here are based on the year the no-
tification was entered on the Computerised Infectious 
Disease Reporting (CIDR) system and consequently may 
differ from annual figures published by the Irish National 
Creutzfeldt-Jakob Disease Surveillance Unit.
6.3 Creutzfeldt-Jakob disease  
Summary
Number of cases, 2011: 7
Number of cases, 2010: 3
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Figure 1.  Number of CJD notifications (n=7) in 2011 by age group Figure 2.  Number of CJD notifications (n=58) from December 
1996 to 2011 by age group
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Infectious Disease Outbreaks
During 2011, 379 outbreaks of infectious diseases 
were reported with 4,418 associated cases of illness, 
including 874 (19.8%) cases hospitalised and seven 
deaths. Regional variation in outbreaks was observed 
between HSE areas with the highest rates observed 
in HSE-M (12.4/100,000 population) and HSE-NW 
(10.1/100,000 population) while the lowest rate was 
observed in HSE-MW at 6.1 per 100,000 population. 
Table 1 details the regional distribution of all outbreaks 
of infectious disease, outbreaks of infectious intestinal 
disease (IID) and outbreaks of non-IID.
General outbreaks accounted for 66.2% (n= 251) of 
all outbreaks notified during 2011. The remaining 
outbreaks (33.8%, n= 128) were reported as family/
household outbreaks. Similar to previous years, 
person-to-person spread* was reported as the mode 
of transmission for the majority of outbreaks in 2011 
(68.6%, n=260). Most of these outbreaks were due to 
norovirus, AIG, measles and VTEC. 
Private houses were the most frequently reported 
outbreak location in 2011, accounting for 28.5% (n=108) 
of all outbreaks while hospitals were the second most 
common outbreak location, accounting for 17.4% (n=66) 
of all outbreaks. The highest numbers ill were reported 
from outbreaks in hospitals (n=1,174), residential 
institutions (n=874), hotels (n=696) and community 
hospital/long stay units (n=693). Table 2 details the 
number of IID and non-IID outbreaks and numbers ill by 
outbreak location for outbreaks reported during 2011. 
Infectious intestinal disease (IID) outbreaks:
IID outbreaks accounted for 74.4% (n=282) of all 
outbreaks reported during 2011. This remains stable 
compared to the number of IID outbreaks reported 
during 2010 (n=286).Table 3 details the regional 
distribution of outbreaks of infectious intestinal disease 
(IID) 
Norovirus/ suspected viral outbreaks, accounted for 
57.4% of all IID outbreaks reported in 2011. Figure 1 
compares norovirus/ suspected viral outbreaks with 
non-norovirus IID outbreaks by year from 2001 to 2011. 
Norovirus/ suspected norovirus was also responsible 
for the 10 largest outbreaks during 2011. Numbers ill 
ranged from two cases to 584 cases. 
7. Outbreaks
Summary
Number of outbreaks: 379
Number of IID outbreaks: 282
Number of non-IID outbreaks: 97
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*  Including 79 outbreaks reported as person to person and airborne transmission and 4 person-to-person and animal contact
Table 1:  Number of outbreaks by HSE area, 2011
HSE area Number of 
outbreaks
Outbreak rate 
per 100,000
Number ill Number 
hospitalised
Number of 
deaths
Number of IID 
outbreaks
Number 
of Non-IID 
outbreaks
HSE-E 129 8.0 2,447 519 5 71 58
HSE-M 35 12.4 287 15 0 29 6
HSE-MW 23 6.1 106 68 0 21 2
HSE-NE 29 6.6 226 93 0 25 4
HSE-NW 26 10.1 139 42 0 25 4
HSE-SE 39 7.8 426 16 1 20 6
HSE-S 54 8.1 537 27 0 33 6
HSE-W 43 9.7 244 91 1 42 12
HPSC 1 - 6 3 0 1 0
Total 379 8.3 4,418 874 7 282 97
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‡ Includes all norovirus outbreaks and AIG outbreaks where organism was suspected norovirus, suspected viral or not specified
Norovirus/suspect viral IID Non-norovirus IID 
Figure 1: Number of norovirus/suspected viral outbreaks‡  and number of non-norovirus IID outbreaks by year, 2001-2011
Table 2: Number of IID and non-IID outbreaks and number ill by outbreak location, 2011
Outbreak location
IID Non-IID Total outbreaks
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Private house 84 198 24 77 108 275
Hospital 57 1,119 9 55 66 1,174
Comm. Hosp/ long-stay unit 48 664 1 29 49 693
Residential institution 45 852 3 22 48 874
Crèche 11 102 17 128 28 230
Hotel 9 696 0 0 9 696
Extended family 6 23 10 47 16 70
Community outbreak 5 53 8 67 13 120
Other 5 35 5 43 10 78
Travel related 4 16 2 7 6 23
School 2 10 13 84 15 94
Coach tour 1 6 0 0 1 6
University/ college 1 15 1 2 2 17
Restaurant / cafe 1 7 0 0 1 7
Workplace 1 30 1 2 2 32
Public house 0 0 1 3 1 3
Unknown 1 2 1 3 2 5
Not specified 1 13 1 8 2 21
Total 282 3,841 97 577 379 4,418
Table 3: IID outbreak summary by HSE area 2011
HSE area Number of outbreaks Outbreak rate per 
100,000
Number ill Number hospitalised Number of deaths
HSE-E 71 4.4 2,107 474 1
HSE-M 29 10.3 270 14 0
HSE-MW 21 5.5 99 66 0
HSE-NE 25 5.7 213 85 0
HSE-NW 20 7.7 107 38 0
HSE-SE 33 6.6 386 8 0
HSE-S 42 6.3 422 24 0
HSE-W 40 9.0 231 88 1
HPSC 1 - 6 3 0
Total 282 6.1 3,841 800 2
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† Including 53 IID outbreaks reported as person to person and airborne transmission and 4 reported as person-to-person and animal transmission 
§ Includes all norovirus outbreaks and AIG outbreaks where organism was suspected norovirus, suspected viral or not specified
IID Non IID 
Figure 2: Number of IID and non-IID outbreaks by month of notification, 2011
Table 4:  Number of general and family IID outbreaks by disease, 2011
Outbreak disease/pathogen
Family outbreak General outbreak Total IID outbreaks
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Number of 
outbreaks
Number ill
Acute infectious gastroenteritis 
(unspecified)
1 9 58 800 59 809
Campylobacter infection 7 16 0 0 7 16
Clostridium difficile infection 0 8 35 8 35
Cryptosporidiosis 27 71 3 23 30 94
Enterohaemorrhagic 
Escherichia coli (VT negative)
1 0 0 0 1 0
Giardiasis 3 8 0 0 3 8
Noroviral infection 1 4 102 2617 103 2621
Rotavirus infection 3 6 2 19 5 25
Salmonellosis 8 22 5 27 13 49
Shigellosis 1 3 1 3 2 6
Verotoxigenic Escherichia coli 
infection
39 82 12 96 51 178
Total 91 221 191 3620 282 3841
Table 5: Non-IID outbreak summary by HSE area, 2011
HSE area
Number of 
outbreaks
Outbreak rate per 
100,000
Number ill Number hospitalised Number of deaths
HSE-E 58 3.6 340 45 4
HSE-M 6 2.1 17 1 0
HSE-MW 2 0.5 7 2
HSE-NE 4 0.0 13 8 0
HSE-NW 6 2.3 32 4 0
HSE-SE 6 1.2 40 8 1
HSE-S 12 1.8 115 3 0
HSE-W 3 0.7 13 3 0
Total 97 2.1 577 74 5
After noroviral infection (n=103), the next most 
commonly reported IID outbreaks during 2011 were 
acute infectious gastroenteritis (not otherwise specified) 
(n=59), VTEC (n=51) and cryptosporidiosis (n=30). The 
number of general and family outbreaks of IID and 
numbers ill, are outlined in Table 4.  
The most frequently reported locations for IID 
outbreaks were private houses (n=84), hospitals (n=57), 
community hospital/long stay facilities (n=48) and 
residential institutions (n=45). The most commonly 
reported outbreak in hospitals was noroviral infection 
(n=45). In community hospital/long stay facilities the 
most commonly reported outbreaks were of AIG (n=24) 
and noroviral infection (n=22). In residential institutions 
the most commonly reported outbreaks were of 
norovirus (n=25) and AIG (n=18).
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Table 6: Number of family and general non–IID outbreaks by disease, 2011
Outbreak disease/pathogen Family outbreak General outbreak Total Non-IID outbreaks
Number 
outbreaks
Number ill Number 
outbreaks
Number ill Number 
outbreaks
Number ill
Measles 9 38 17 114 26 152
Pertussis 18 69 4 21 22 90
Hand, foot and mouth disease/ suspected 
HFMD
0 0 11 83 11 83
Tuberculosis 2 8 3 19 5 27
Influenza 1 3 3 25 4 28
Influenza-like illness 0 0 4 46 4 46
Enterovirus/ suspected enterovirus 0 0 4 19 4 19
Mumps 2 4 1 3 3 7
Varicella/ suspected varicella 1 2 2 7 3 9
Carbapenem resistant Enterobacteriaceae 
(CRE)
0 0 2 10 2 10
Scabies/ suspected scabies 0 0 2 49 2 49
Legionellosis 1 2 0 0 1 2
Viral meningitis 1 2 0 0 1 2
Malaria 1 5 0 0 1 5
Meningococcal disease 1 2 0 0 1 2
Staphylococcus aureus infection 0 0 1 10 1 10
Vancomycin Resistant Enterococci (VRE) 0 0 1 3 1 3
Suspected Coxsackie 16 0 0 1 15 1 15
Human metapneumovirus 0 0 1 11 1 11
Scarlet Fever 0 0 1 2 1 2
Klebsiella pneumoniae KPC 0 0 1 2 1 2
MRSA 0 0 1 3 1 3
Total 37 135 60 442 97 577
† Including 53 IID outbreaks reported as person to person and airborne transmission and 4 reported as person-to-person and animal transmission  
§Including 26 non-IID outbreaks reported as person to person and airborne transmission
Person-to-person (P-P) spread† was the most frequently 
reported mode of transmission implicated in IID 
outbreaks during 2011 (65.2%, n=184). 
In 2011, the number of IID outbreaks peaked during 
March, April and May with a second peak during 
December. The first peak was mainly due to high 
numbers of norovirus/ suspected norovirus outbreaks, 
with 19 norovirus/ suspected norovirus outbreaks 
reported during March, 14 during April and 16 during 
May. The second peak in December was also mainly 
due to norovirus/ suspected norovirus outbreaks (n=17) 
but also included eight VTEC outbreaks. Figure 2 
illustrates the number of IID and non-IID outbreaks by 
month of notification during 2011.
Non-IID outbreaks:
During 2011, 97 outbreaks of non-IID diseases were 
reported, representing 25.6% of all outbreaks notified 
nationally. The most common non-IID outbreak diseases 
were measles (26.8%, n=26), pertussis (22.7%, n=22) 
and hand, foot and mouth disease/suspected HFMD 
(11.3%, n=11). Table 5 details the regional distribution 
of non-IID outbreaks while the number of general and 
family outbreaks of non-IID disease and numbers ill are 
outlined in Table 6.  
The number of non-IID outbreaks also peaked during 
May and June and was due to was due to high numbers 
of hand, foot and mouth disease (HFMD)/ suspected 
HFMD outbreaks, measles and pertussis outbreaks 
reported. A smaller secondary peak was also observed 
in August and September which was due to measles 
and pertussis (figure 2). 
The most frequently reported locations for non-IID 
outbreaks were private houses (n=24), crèches (n=17) 
and schools (n=13) as shown in table 2. Non-IID 
outbreaks in these locations were most frequently 
caused by pertussis, measles and hand, foot and mouth 
disease (HFMD)/ suspected HFMD. 
Person-to-person (P-P) spread§ was the most frequently 
reported mode of transmission implicated in non-IID 
outbreaks during 2011 (78.4%, n=76). 
The information gathered from outbreaks reported 
is used to inform public health professionals on the 
causes and factors contributing to outbreaks, to target 
prevention strategies and to monitor the effectiveness 
of prevention programmes.
For further information on disease specific outbreaks, 
please refer to the individual disease chapter.
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Immunisation Uptake
In 2011, the HSE Areas provided HPSC with quarterly 
immunisation uptake data for their Area and for 
each of the Local Health Offices (LHOs) in their Area.  
HPSC collated these data and quarterly reports were 
produced which are available on the HPSC website.  
The annual immunisation uptake rates presented 
here represent the collation of the 2011 quarterly 
data.  The proportion of children who completed the 
recommended childhood immunisation schedule by 12 
months (born between 01/01/2010 and 31/12/2010) 
and 24 months (born between 01/01/2009 and 
31/12/2009) of age in 2011 are reported.  
Since September 1st 2008 the new primary childhood 
immunisation schedule has been implemented for 
children born on or after July 1st 2008 (table 1).  These 
children should receive one dose of vaccine against 
tuberculosis (BCG vaccine) at birth or by one month of 
age; three doses of vaccines against diphtheria (D3), 
tetanus (T3), pertussis (P3),  Haemophilus influenzae type 
b (Hib3), polio (Polio3) and Hepatitis B (HepB3) with one 
dose of each given at two, four and six months of age; 
three doses of pneumococcal conjugate vaccine (PCV3) 
given at two, six and 12 months of age and three doses 
of meningococcal group C (MenC3) vaccine given at 
four, six and 13 months of age.  Also at 12 months of 
age a dose of MMR (MMR1) is recommended and at 13 
months a booster dose of Hib (Hibb) is recommended.  
Further vaccinations are recommended for older 
children and adults; please see 
www.immunisation.ie for complete information 
on the Irish immunisation schedule.
In children who reached 12 months of age in 2011 (born 
between 01/01/2010 and 31/12/2010) uptake of BCG, 
D3, T3, P3, Hib3, Polio3, HepB3 and two doses of PCV 
(PCV2) and MenC (MenC2) were measured.  In children 
who reached 24 months of age in 2011 (born between 
01/01/2009 and 31/12/2009) uptake of D3, T3, P3, Hib3, 
Polio3, HepB3, MenC3, PCV3, MMR1 and Hibb were 
measured.  
The immunisation uptake rates are reported here by 
HSE Area and LHO.  While there are 32 LHOs the 
immunisation uptake rates for the LHOs of North Lee 
and South Lee are reported as a combined figure.
Caveats to 2010 and 2011 data
Not all HSE Areas were able to provide data during 
2010 and 2011. 
•  BCG uptake data were available for the HSE-MW, 
HSE-NW and HSE-SE Areas in Quarters 1-4 2010 
and 2011, for the HSE-M in Quarters 3 and 4 2010 
and Quarters 1-4 2011, for the HSE-S in Quarter 4 
2010 and in Quarters 1-4 2011 and the HSE-W in 
Quarters 3-4 2011.  In Quarters 3 and 4 2011 the 
HSE-W reported BCG uptake data (4%), for children 
at 12 months of age for the first time, resulting in a 
low national uptake rate (85%) compared to previous 
years.  This is not a true decline as uptake rates are 
based on available data and the HSE-W BCG data 
were not available previously. Traditionally BCG was 
given at age 10 - 12 years in the HSE-W.  HSE-W BCG 
data were not available by LHO. The available national 
BCG cohort data may be around 31% of the national 
birth cohort in 2010 and 48% of the national birth 
cohort in 2011 (these figures are estimates only).  
8. Immunisation Uptake
Summary
Among children 12 months of age in 2011 uptake of:
D3, T3, P3, Hib3, Polio3, HepB3, MenC2 and PCV2 was 
90% 
Among children 24 months of age in 2011 uptake of:
D3, T3, P3, Hib3, Polio3 and HepB3 reached the target 
of 95% for the first time
MMR1 was 92%
PCV3 was 90%
Hibb was 88%
MenC3 was 84%  
MenC3 and Hibb uptake are considerably lower than 
the uptake of the other recommended vaccines, 
both of which should be given to children at 13 
months of age, suggesting that children are less 
likely to get the necessary vaccines at this age.  
-112-HPSC Annual Report 2011 8. Immunisation Uptake
•  Data in 2011 are compared here to data in 2010.  As a 
new childhood immunisation schedule was introduced 
in 2008, for those born on or after July 1st 2008, the 
2010 HepB3 and PCV3 data at 24 months are for those 
born between July 1st and December 31st 2008 (i.e. 
Quarters 3 and 4 2010 data) only.  As not all HSE 
Areas were able to provide data for each quarter in 
2010 a number of figures in 2010 are incomplete, this 
is detailed in the 2010 annual report.  For both these 
reasons some figures for 2010 may reflect data from 
less than four quarters and in some cases reflect data 
from one quarter only.  The available 2010 national 
12 month D3, T3, P3, Hib3, Polio3, HepB3 and PCV2 
cohort data may be around 87% (this figure is an 
estimate only) of the 2010 national birth cohort and 
the available MenC2 cohort may be around 85% (this 
figure is an estimate only) of the 2010 national birth 
cohort.  The available 2010 national 24 month cohort 
data may be around 89-90% (this figure is an estimate 
only) of the 2010 national birth cohort. 
Immunisation uptake rates at 12 months
National immunisation uptake rates, in children 12 
months of age in 2011, were 90% for D3, T3, P3, Hib3, 
Polio3, HepB3, MenC2 and PCV2 and 85% (based on 
available data) for BCG (table 2).  Compared with 2010, 
the uptake rates for D3, P3, T3, Hib3, Polio3, HepB3, 
MenC2 and PCV2 increased by one percent in 2011.  
In Quarters 3 and 4 2011, the HSE-W reported BCG 
uptake data (4%) for the first time, resulting in a low 
national uptake rate (85%) compared to the national 
uptake in 2010 (95%).  This is not a true decline as 
national uptake rates are based on available data and 
the HSE-W BCG data were not available previously.
Among the HSE Areas, uptake rates for D3, T3, P3, Hib3, 
Polio3 and HepB3 ranged from 89% to 95%, MenC2 
ranged from 86% to 94% and PCV2 ranged from 
85% to 94% (table 2).  The target uptake of 95% was 
reached during 2011 in the HSE-M for D3, T3, P3, Hib3, 
Polio3 and HepB3. This is the first time a HSE Area has 
reached the target of 95% for these vaccines in children 
at 12 months of age. Among the LHOs, uptake rates 
for D3, T3, P3, Hib3, Polio3, HepB3 and MenC2 ranged 
from 81% to 96% and PCV2 ranged from 81% to 97% 
(appendix 2.1).  The target uptake of 95% was reached 
or exceeded in Longford/Westmeath and Roscommon 
for D3, T3, P3, Hib3, Polio3, HepB3, MenC2 and PCV2 and 
reached in Sligo/Leitrim for PCV2 (appendix 2.1).  The 
target uptake of 95% was reached or exceeded for BCG 
in ten LHOs reporting data (appendix 2.1).
Immunisation uptake rates at 24 months
National immunisation uptake rates, in children 24 
months of age in 2011, reached the target of  95% for 
D3, T3, P3, Hib3, Polio3 and HepB3 for the first time and 
were 92% for MMR1, 90% for PCV3, 88% for Hibb and 
84% for MenC3 (table 2).  Compared with 2010, the 
uptake rates for MenC3 declined by two percent, Hibb 
increased by three percent, MMR1 and PCV3 increased 
by two percent and D3, T3, P3, Hib3, Polio3 and HepB3 
increased by one percent (figure 1).  
Since September 1st 2008 the new primary childhood 
immunisation schedule has been implemented for 
children born on or after July 1st 2008 (table 1); children 
who were 24 months of age in Quarter 3 2010 were 
born between July 1st and September 31st 2008 
and were the first children recommended the new 
immunisation schedule.  Under the new immunisation 
schedule children are now recommended HepB vaccine 
and PCV.  In addition, there is a change in timing of the 
MenC and Hibb vaccines (table 1). The changes to the 
schedule mean that three injections (6 in 1, PCV and 
MenC vaccines) are now recommended at six months 
of age and two GP visits are required on or after 12 
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Age Children born before  01/07/2008        Children born on or after 01/07/2008
Birth BCG BCG
2 months DTaP/Hib/IPV (5 in 1) + MenC DTaP/Hib/IPV/HepB (6 in 1) + PCV
4 months DTaP/Hib/IPV (5 in 1) + MenC DTaP/Hib/IPV/HepB (6 in 1) + MenC
6 months DTaP/Hib/IPV (5 in 1) + MenC DTaP/Hib/IPV/HepB (6 in 1) + PCV + MenC
12 months MMR + Hib MMR + PCV
13 months - MenC + Hib
Please see www.immunisation.ie for complete information on the Irish childhood immunisation schedule including vaccinations for older 
children and adults
BCG Bacille Calmette Guerin vaccine 
DTaP Diphtheria, Tetanus and acellular Pertussis vaccine
Hib Haemophilus influenzae type b vaccine
IPV Inactivated Polio Virus vaccine
MenC  Meningococcal group C vaccine
HepB Hepatitis B vaccine
PCV Pneumococcal Conjugate Vaccine
MMR Measles, Mumps and Rubella vaccine
Table 1.  Change in primary childhood immunisation schedule (introduced on September 1st 2008)
months; the first dose of MMR and the third dose of 
PCV should be given at 12 months of age and at 13 
months of age the third dose of MenC vaccine and Hibb 
should be given (table 1).  MenC3 uptake was 93% in 
Quarter 1 2010 but declined to 80% in Quarter 3 2010 
and was 82% in Quarter 4 2010 (figure 2).  During 2011, 
MenC3 increased from 83% in Quarters 1 and 2 to 85% 
in Quarters 3 and 4.  Hibb was 87% in Quarters 1 and 
2 2010 but declined to 84% in Quarters 3 and 4 2010 
(figure 2). During 2011 Hibb uptake increased from 86% 
in Quarter 1 to 90% in Quarter 4.  There was also low 
uptake of PCV3 in 2010 (combined Quarters 3 and 4 
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Table 2.  Annual immunisation uptake rates (based on available data) by HSE Area for children 12 and 24 months of age in 2011
% Uptake at 12 months
Cohort born 01/01/2010 - 31/12/2010
% Uptake at 24 months
Cohort born 01/01/2009 - 31/12/2009
D3 HepB3 MenC2 PCV2 BCG D3 Hibb HepB3 MenC3 PCV3 MMR1
HSE-E 89 89 89 89 na 94 87 94 82 89 90
HSE-M 95 95 94 94 94 97 95 97 89 94 96
HSE-MW 92 92 92 93 97 96 89 96 86 92 93
HSE-NE 90 90 89 89 na 96 88 96 85 92 92
HSE-NW 94 93 93 94 95 97 93 96 86 90 94
HSE-SE 92 92 92 92 96 95 94 95 86 91 93
HSE-S 89 89 86 85 90 96 82 95 84 91 93
HSE-W 91 91 91 91 4 94 81 94 81 89 90
Ireland 90 90 90 90 85 95 88 95 84 90 92
na=not available
Since T3, P3, Hib3 and Polio3 uptake identical to D3 uptake only D3 uptake figures presented
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Figure 1.  National annual immunisation uptake rates (based on available data) at 24 months, 1999-2011
Since T3 and Polio3 uptake identical to D3 uptake only D3 uptake figures presented.
P3 uptake could not be calculated accurately during 1999-2001 as DTaP/DT uptake was reported as a combined value for the HSE-NE during 1999, Quarters 3 and 
4 2000 and Quarter 1 2001 and the HSE-NW in 2000 and 2001. The 2002 MenC3  figure is based on uptake rates for Quarter 3 and Quarter 4 2002 only. The 2005 
MMR1 uptake figure is incomplete as the HSE-E was unable to provide MMR data for Quarter-4 2005, due to technical problems with extraction of MMR1 data 
from the HSE-E database.  The 2006 MMR1 figure includes the Quarter-1 2006 HSE-E figure, which is an estimate only due to technical problems with extraction of 
MMR1 data from the HSE-E database.  The 2007 national Hibb figure is incomplete, as the HSE-W data for Quarter 1 2007 and the HSE-NW data for Quarter 3 2007 
were not available.  The 2007 national Hibb figure also includes the HSE-SE data which are an underestimate due to data extraction methods.  The 2008 Hibb figure 
is incomplete as the HSE-SE data for Q2 2008 and the HSE-MW data for Quarter 3 2008 were not available.  The 2008 national MenC3 figure is incomplete as the 
HSE-E and HSE-MW MenC3 data for Quarter 3 2008 were not available. The 2009 data are incomplete as the following were unavailable: the Quarter 1 2009 HSE-E 
D3, T3, P3 and Polio3 data for those born on the 31/03/2007; the Quarter 2 2009 HSE-E Dublin North Hibb uptake data and; the Quarter 4 2009 HSE-MW data, HSE-E 
Dublin North Hibb data and HSE-SE Hibb data for those given a Hib dose as part of the five in one or six in one vaccine after 12 months of age.  The 2010 data are 
incomplete as the following were unavailable: the Quarter 1 2010 HSE-M and HSE-S data and the HSE-E Dublin North Hibb data; the Quarter 2 2010 HSE-M data 
and; the Quarter 4 2010 HSE-NE data. As a new childhood immunisation schedule was introduced in 2008, for those born on or after July 1st 2008, the 2010 HepB3 
and PCV3 data at 24 months are for those born between July 1st and December 31st 2008 (i.e. Quarters 3 and 4 2010 data) only.  
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data was 88%).  During 2011, PCV3 increased from 90% 
during Quarters 1 and 2 to 91% during Quarters 3 
and 4.
Uptake rates among the HSE Areas, for children at 24 
months of age in 2011, for D3, T3, P3, Hib3, Polio3 and 
HepB3 ranged from 94% to 97%, MMR1 ranged from 
90% to 96%, PCV3 ranged from 89% to 94%, Hibb 
ranged from 81-95% and MenC3 ranged from 81% to 
89% (table 2).  The target uptake of 95% was reached 
or exceeded during 2011 in the HSE-M for D3, T3, P3, 
Hib3, Polio3, HepB3, Hibb and MMR1 and in the HSE-MW, 
HSE-NE, HSE-NW, HSE-SE and HSE-S for D3, T3, P3, 
Hib3, Polio3 and HepB3 (table 2).
D3, Hibb, MenC3 and MMR1 uptake rates are mapped 
by LHO in figure 3.  Among the LHOs the uptake rates 
ranged from 90% to 98% for D3, T3, P3 and Polio3, 89% 
to 98% for Hib3 and HepB3, 85% to 97% for MMR1, 83% 
to 98% for PCV3, 76% to 96% for MenC3 and 75% to 
97% for Hibb (appendix 2.2).  The target uptake of 95% 
was reached or exceeded in 22 LHOs for D3, T3, P3 and 
Polio3, in 21 LHOs for Hib3, in 19 LHOs for HepB3, in six 
LHOs for MMR1, in four LHOs for Hibb and in one LHO 
for MenC3 and PCV3 (appendix 2.2).  Roscommon was 
the only LHO to reach and exceed the target of 95% for 
all vaccines at 24 months.   
There was a large decline in MenC3 and a decline in 
Hibb uptake at 24 months in Quarters 3 and 4 2010 
i.e. children who were born between July 1st and 
December 31st 2008 and were the first recommended 
the new immunisation schedule.  There is a change 
in timing of the MenC and Hibb vaccines under the 
new immunisation schedule (table 1).  During 2011 a 
joint study was carried out in four of the HSE Areas to 
identify reasons for the apparent decline in uptake. 
As part of the study work was done to determine if  
the local immunisation databases accurately reflected 
immunisation uptake for the group of children who 
were 24 months of age in Quarter 3 2010 as well as 
to identify possible reasons for children missing the 
recommended vaccines.1  A key finding of this study 
was that most parents did not know their children were 
incompletely vaccinated and were unaware of the need 
for their child to visit  the GP at 13 months for the 
MenC and Hibb vaccination. The findings were used to 
inform communication to GPs and practice nurses as 
well as the development of new information materials 
by the National Immunisation Office for parents.2 The 
information campaign highlighted the importance 
of completing five GP visits to ensure children are 
fully vaccinated. While the quarterly uptake of these 
vaccines increased in 2011 compared to 2010 MenC3 
and Hibb uptake are still considerably lower than the 
uptake of the other recommended vaccines, both of 
which should be given at 13 months of age suggesting 
that children are less likely to get the necessary vaccines 
at this age.  In addition, MMR1 (92%) and PCV3 (90%) 
uptake are lower than the target uptake of 95%.
Figure 2.  National quarterly immunisation uptake rates at 24 months
Note scale ranges from 60-100%
P3 uptake could not be calculated accurately during 1999-2001 as DTaP/DT uptake was reported as a combined value for the HSE-NE during 
1999, Quarters 3 and 4 2000 and Quarter 1 2001 and the HSE-NW in 2000 and 2001. The Q4-2005 MMR1 figure is based on data from seven 
of the eight HSE-Areas.  The Q1-2006 MMR1 figure includes the HSE-E figure that is an estimate only.  The Q1-2007, Q3-2007, Q2-2008 and 
Q3-2008 Hibb figures are based on data from seven of the eight HSE Areas.  In Q1-2008 the HSE-SE changed their Hibb data extraction method 
compared to previous quarters; in Q1-2008 the uptake of Hibb in the HSE-SE was 83% compared to 53% in Q4-2007.  The Q3-2008 MenC3 
figure is based on data from six of the eight HSE Areas.  The Q1-2009 HSE-E D3, P3, T3, Polio3 and MMR1 uptake figures exclude those born on 
the 31/03/2007.  The Q2-2009 HSE-E Hibb uptake figures exclude uptake figures from Dublin North.  The Q4-2009 figures are based on data 
from seven of the eight HSE Areas.  The Q4-2009 Hibb figures also exclude uptake figures from Dublin North and HSE-SE Hibb data for those 
given a Hib dose as part of the five in one or six in one vaccine after 12 months of age.   The Q1-2010 figures are based on data from six of the 
eight HSE Areas.  The Q1-2010 Hibb figures also exclude uptake figures from HSE-E Dublin North.  The Q2-2010 and Q4-2010 figures are based 
on data from seven of the eight HSE Areas.  
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In contrast in 2011, national uptake rates at 24 months 
for D3, T3, P3, Hib3, Polio3 and HepB3 reached the target 
rate of 95% for the first time.  Among the HSE Areas 
the target uptake of 95% was reached or exceeded for 
those at 24 months during 2011 in the HSE-M for D3, 
T3, P3, Hib3, Hibb, Polio3, HepB3 and MMR1 and in the 
HSE-MW, HSE-NE, HSE-NW, HSE-SE and HSE-S for D3, 
T3, P3, Hib3, Polio3 and HepB3.  Roscommon exceeded the 
target of 95% for all vaccines at 24 months.  
The 2011 immunisation uptake rates for each LHO are 
presented in appendix 2.  The immunisation reports for 
Quarters 1 to 4 2011 are available on the HPSC website 
in Topics A-Z under the heading vaccination. 
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Figure 3.  D3 (A), Hibb (B), MenC3 (C) and MMR1 (D) immunisation uptake rates (%) in those 24 months of age in 2011 by Local 
Health Office (LHO)
LHOs in Dublin are highlighted separately for ease of viewing
North Lee and South Lee are separate LHOs, however, their combined (labelled NSL on the map) immunisation uptake rate is reported here
Please see appendix 2.3 to translate LHO codes
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1. 
9.1.1 Clostridium difficile Infection
Notifiable C. difficile infection: New cases
New cases of CDI in persons two years or older have 
been notifiable in Ireland under the disease category 
“acute infectious gastroenteritis” (AIG) since May 2008. 
In 2011, recurrent CDI cases were not notifiable.  
There were 1,848 cases of new CDI notified to Public 
Health Departments via the Computerised Infectious 
Diseases Reporting (CIDR) system in 2011.  All cases 
were laboratory confirmed. This represents a national 
crude incidence rate (CIR) of 40.3 new CDI cases per 
100,000 population, an increase of 9.2% from 36.9 
cases per 100,000 population reported in 2010 (Table 
1). Regional variation was observed in the incidence 
of CDI (Table 1). However, this most likely reflects 
differences in laboratory diagnosis and reporting rather 
than true variation in disease incidence. Identification of 
seasonal patterns in the CIDR data is hindered by late 
and batch notifications from laboratories.
As in 2010, the majority of new cases were in female 
patients (60.2%) and in older age groups.  The mean 
age of cases was 67.6 years (range 2-98 years) (Figure 
1) with 1,223 cases (66%) reported in patients aged 
over 65 years.  Of note, the 75-84 year age group had 
the highest number of cases (n=504), representing 
40.8% of the over 65 year age group. 
The majority of cases were classified as ‘hospital 
inpatient’ (76%), with 11% classified as general practice 
patients, 3.8% as hospital outpatients or day patients, 
9.1.0  Healthcare-associated infections 
(HCAI)
Key Points
•   In 2011, 1,848 new cases of Clostridium difficile-
infection (CDI) were notified.  This represents a 
national crude incidence rate of 40.3 new cases 
per 100,000 population, an increase of 9.2% 
from 2010
•   Of the 1,848 new CDI cases, 1,223 (66%) were 
reported from patients aged over 65 years
•   In the voluntary enhanced surveillance scheme, 
1,511 CDI cases [1,396 (92.3%) new and 107 
(7.1%) recurrent] were reported from 41 acute 
hospitals. The national CDI incidence rate was 
3.1 cases per 10,000 bed days used, which 
represents an increase from 2.8 in 2010.  Twenty 
percent of all CDI cases were associated with 
the community and 9.5% were associated with 
nursing homes. While the majority of patients 
experienced onset of symptoms in healthcare 
facilities, 27% had onset of symptoms in the 
community
•   Of the 204 specimens (14% of all samples) for 
which ribotyping data were available (from ten 
hospitals), the most common ribotypes reported 
were: 027 and 078 (n=26, 13% each), 014 (n=23, 
11%), 005 (n=21, 10%), and 002 (n=17, 8%) 
Table 1.  Number of notified cases, crude incidence rate of 
CDI in Ireland by HSE area, 2011, and total number with crude 
incidence rate for 2010 (Source, CIDR)
HSE Area No. of cases *CIR incl. 95% C.I.
East 781 48.2 (44.8 - 51.6)
Midlands 50 17.7 (12.8 - 22.6)
Mid West 96 25.3 (20.2 - 30.4)
North East 81 18.4 (14.4 - 22.4)
North West 79 30.6 (23.9 - 37.3)
South East 262 39.4 (34.6 - 44.2)
South  293 58.9 (52.2 - 65.6)
West 206 46.3 (40 - 52.6)
Total 2011 1848 40.3 (38.5 - 42.1)
Total 2010 1693 36.9 (35.1 - 38.7)
* Rates calculated using 2011 census data
5% as Emergency Department patients, and 4.1% as 
either ‘other’, ‘not specified’ or ‘unknown’. However, 
this data does not provide information on the origin 
or onset of CDI, rather it represents the location of the 
patient at the time of CDI diagnosis.  Information on 
the origin and onset of CDI cases is collected as part of 
the enhanced surveillance system. 
Notifiable C. difficile infection: Outbreaks
In 2011, eight outbreaks of C. difficile infection, all 
healthcare-associated and involving 35 patients, were 
notified to Public Health Departments (Table 2). Four 
were linked to hospitals, two to nursing homes and two 
to long-term care facilities.
Enhanced surveillance of C. difficile infection
Although the notifiable CDI data provides important 
preliminary information on the burden of new cases of 
CDI in Ireland in 2011, it represents an underestimate 
of the true burden of CDI, as recurrent CDI cases are 
not captured and it does not capture information on 
the origin, onset or severity of CDI. National collation 
of C. difficile enhanced surveillance commenced on 
a voluntary basis on 1st August 2009. Information on 
case type, origin, onset and severity of CDI is collected 
using the European Society for Clinical Microbiology 
and Infectious Diseases Study Group on C. difficile 
(ESCMID-ESGCD) case definitions.  By the end of 2011, 
41 hospitals participated in the voluntary enhanced 
surveillance CDI scheme, comprising 35 acute public 
hospitals (24 general, eight tertiary and three specialist 
hospitals) and six private hospitals. 
In 2011, 1,511 cases of CDI were reported to the 
enhanced surveillance scheme. Of these, 1,396 (92.3%) 
were classified as new CDI cases (representing 76% 
of all the new CDI cases notified to Public Health 
Departments via CIDR) and 107 (7.1%) as recurrent with 
eight (0.6%) of unknown case type. Of the reported 
cases, 57% (n=862) originated within the reporting 
healthcare facility, which corresponds to an overall 
national CDI incidence rate of 3.1 cases per 10,000 
bed days used. The CDI rate has remained relatively 
stable since August 2009 with small fluctuations 
that are likely to be largely as a result of changes in 
laboratory testing protocols for C. difficile (Figure 2). 
(See Laboratory Survey of C. difficile Diagnostic and 
Reporting Practices below). The rate is based only 
on the number of new and recurrent CDI cases that 
originated in the participating healthcare facility and 
is calculated using acute public hospital activity data 
from the Business Intelligence Unit, Corporate Planning 
and Corporate Performance (CPCP) at the Health 
Services Executive (HSE). There was a wide range in 
the incidence of CDI among participating hospitals in 
2011 (range, 0 – 7.8 cases per 10,000 bed days used; 
median, 2.2 cases). Tertiary hospitals (n=8) showed a 
higher median incidence rate compared to general 
hospitals (n = 24) (CDI rate = 2.8 versus 1.75 CDI cases 
per 10,000 BDU)). These differences in CDI median 
incidence rates may reflect inter-hospital variations 
in patient case mix, C. difficile ribotypes, laboratory 
testing protocols, antimicrobial prescribing policies, 
antimicrobial stewardship interventions and surveillance 
resources. No obvious seasonal trend for CDI in Ireland 
is distinguishable for 2011. 
Severe CDI
A severe case of CDI is defined as a patient requiring 
admission to an intensive care unit (ICU) for treatment 
of CDI or its complications, a patient requiring 
colectomy or death within 30 days after diagnosis, if 
CDI is either the primary or contributory cause of death. 
Twenty-one (1.4%) severe cases were reported in 2011, 
which is similar to 2010 (1.6%); three patients required 
both surgery and ICU admission, five required surgery 
only and 13 required ICU admission without surgery. 
As for notifiable CDI, most cases reported through the 
enhanced surveillance scheme were female (61%) and in 
the over 65 age group (69%). Forty-three deaths were 
reported, of which two were directly attributed to CDI 
and 24 were not directly attributed to CDI. The cause 
of death for the remainder was either unknown or not 
specified.
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Figure 1: Age and Sex distribution of CDI in Ireland, 2011 
(Source, CIDR)
* Rates calculated using 2011 census data 
Female Male 
Table 2. CDI outbreaks reported in Ireland in 2011 by HSE 
area (Source, CIDR)
HSE Region Outbreak location Total 
number ill
East Residential Home 3
East Community Hospital/ Long Stay Unit 4
East Hospital 6
East Residential Home 2
East Hospital 8
North East Community Hospital/ Long Stay Unit 2
South Hospital 2
West Hospital 8
Figure 2. The quarterly rate of C. difficile infection in Ireland: 
2009 - 2011)
Female Male 
Onset & origin of CDI
Onset: Patient location when symptoms of CDI 
commenced
Seventy-one percent (n=1,078) of patients had onset 
of CDI symptoms in a healthcare facility – healthcare 
onset (HCO), with 78% (n=841) of these occurring in the 
reporting hospital, 6% (n=69) in another hospital and 
14% (n=149) in a nursing home (Figure 3). The remainder 
(n=19) had onset in another unspecified healthcare 
facility or of unknown onset. However, 27% (n=405) of 
all CDI cases had onset of symptoms in the community 
– community onset (CO), with 92% of these reported as 
unknown location of onset. A similar profile was reported 
in 2010 (Figure 3).
Origin: Location where the patient acquired the CDI
The majority of CDI cases, 74% (n=1,112) were 
healthcare-associated (HCA). Community-associated (CA) 
cases accounted for 20% (n = 300). The origin of 3% (n = 
44) of CDI cases was unknown (i.e. the patient had been 
discharged from a healthcare facility between 4 and 12 
weeks prior to CDI onset) and for the remaining 3% (n = 
55) cases no information on case origin was provided.
Of the 1,112 HCA CDI cases, 76% (n=862) originated 
in the reporting hospital, 8% (n=89) originated in other 
hospitals, 13% (n=143) originated in nursing homes and 
3% (n=18) originated in another unspecified healthcare 
facility or were of unknown origin (Figure 3).
Of the 1,112 HCA CDI patients:
•   92% (n=1,025) experienced onset of CDI symptoms 
at least 48 hours following admission to a healthcare 
facility (healthcare-onset, healthcare-associated)
•   7.5% (n=81) patients experienced symptom onset in 
the community within four weeks of discharge from 
a healthcare facility (community-onset, healthcare-
associated)
•   0.5% (n = 6) of patients had no information recorded 
on symptom onset
Of the 300 CA CDI cases: 
•   88% (n=265) patients experienced onset of CDI 
symptoms while outside a healthcare facility and 
without a history of discharge from a healthcare facility 
within the previous 12 weeks
•   11% (n=33) patients experienced symptom onset 
within the first 48 hours of admission to a healthcare 
facility, without a history of admission to or residence 
in a healthcare facility within the previous 12 weeks 
No origin facility information was collected on the 
community-associated cases as this information is too 
resource-intensive to follow up on outside of the accute 
hospital setting.
In the second half of 2011, information was captured 
on the location where the patient’s faecal specimen was 
taken. The reporting hospital accounted for the majority 
(65%) of patient specimens (n=483), whilst 3.5% (n=26) 
were taken in the GP practice, 5% (n=38) were taken in 
nursing homes, and 4% (n=21) were taken in a hospital 
other than the reporting hospital. For the remaining 24% 
(n=177) of specimens, no information was provided.
The collation of national data on C. difficile through 
CIDR notifications of new CDI cases and the enhanced 
CDI surveillance system, which captures both new and 
recurrent cases has provided a valuable insight into the 
burden of CDI in Ireland. There was an increase in the 
number of new CDI cases reported in 2011 compared 
to 2010. However, this underlying reason for this may 
be due to changes in laboratory testing protocols 
for C. difficile. (See Laboratory Survey of C. difficile 
Diagnostic and Reporting Practices below). In 2011, 
7% of all CDI cases reported through the enhanced 
surveillance scheme were recurrent infections compared 
with 8% in 2010 and 14% in 2009. This may represent 
an improvement in infection prevention and control 
strategies and management of patients with CDI.  
However, it may also reflect changes in laboratory testing 
protocols. Recurrent CDI is difficult to manage clinically 
and just like new CDI, can result in severe infection, 
places a burden on limited isolation resources and results 
in significant patient morbidity. Therefore, knowledge of 
the burden of recurrent CDI in Ireland is essential to help 
guide preventative strategies.
During 2011 and 2010, 20% of all CDI cases were 
associated with the community and 10% of cases were 
associated with nursing homes, an increase from 8% 
in 2010. Moreover, 27% of all CDI cases had onset 
of symptoms in the community, consistent with the 
figure reported in 2010. This indicates that C. difficile 
infection is not confined to hospitals and is increasingly 
common in community and nursing home settings.  It 
is essential that CDI is considered in the differential 
diagnosis of all patients presenting with diarrhoea 
and that specimens are sent in a timely fashion for 
laboratory diagnosis.  Patients with CDI in healthcare 
facilities must be isolated with contact precautions as 
outlined in national guidelines. http://www.hpsc.ie/
hpsc/A-Z/Gastroenteric/Clostridiumdifficile/Publications/
File,2936,en.pdf.  All healthcare professionals must 
promote practices known to reduce the incidence of 
CDI including; compliance with infection prevention 
and control measures, awareness of local CDI 
surveillance data and prudent use of antimicrobials. 
The national guidelines for antimicrobial stewardship 
in hospitals in Ireland are available at: http://www.
hpsc.ie/hpsc/A-Z/MicrobiologyAntimicro 
bialResistance/strategyforthecontrolofAntimicrobial 
ResistanceinIrelandSARI/AntibioticStewardship/  
Publications/
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Figure 3. CDI Origin and Onset by Location where CDI Case 
Originated, 2011
CO: Community-onset; HCO: Healthcare-onset; CA: 
Community-associated CDI; HCA: Healthcare-associated CDI
C. difficile PCR ribotyping
As part of the voluntary C. difficile enhanced surveillance 
scheme, participating hospitals are requested to provide 
C. difficile PCR ribotyping information, where available. 
Ireland does not have a national C. difficile reference 
laboratory or ribotyping service. Therefore, laboratories 
submit specimens abroad for ribotyping. In 2011, 
ribotyping data was provided for 204 C. difficile isolates 
(14% of all samples) submitted from ten hospitals. The 
most common ribotypes reported were: 027 and 078 
(n=26, 13% each), 014 (n=23, 11%), 005 (n=21, 10%), 
and 002 (n=17, 8%). In 2011, one hospital reported that 
74% of healthcare-associated C. difficile isolates from 
2011 were ribotyped. The most common ribotypes 
reported from that hospital were: 005 (n=14), 014 
(n=12), 002 and 078 (n=11 each), 020 (n=8) and 027 
(n=5).
Laboratory Survey of C. difficile diagnostic and 
reporting practices: 2011 
Twenty-five of 29 Irish microbiology laboratories 
responding to a 2006 laboratory survey on C. difficile 
diagnostic practices performed on-site testing for 
C. difficile and all 25 reported use of an enzyme 
immunoassay for toxin detection. In all but one 
laboratory, the assay in use detected both toxin A and 
toxin B. 
In May 2008, all new CDI cases became notifiable 
under the category of ‘Acute Infectious Gastroenteritis’ 
(AIG).  In August 2009, the national voluntary C. difficile 
enhanced surveillance scheme commenced, collecting 
information on CDI case type (both new and recurrent 
cases), origin, onset and severity.  Changes in the 
recommended C. difficile laboratory testing practice 
were proposed in 2009 and 2010 by the European 
Society for Clinical Microbiology and Infectious Diseases 
(ESCMID) and the United Kingdom (UK) National Health 
Service (NHS). 
The Irish laboratory survey was repeated in 2011. Of the 
37 laboratories responding, 33 performed on-site testing 
for C. difficile and 58% reported a change to their 
testing algorithm in the past two years. The majority 
of laboratories (74%) reporting changed testing had 
moved from a one-step to a two-step testing algorithm.  
Seventeen (52%) continued to use a one-step test, whilst 
16 (48%) used a two-step testing algorithm. For two-step 
algorithms, a variety of testing methodologies were in 
use (Table 3). Owing to considerable variations in current 
Irish laboratory C. difficile testing methodologies, inter-
hospital comparison of CDI rates is not recommended as 
the data in the national quarterly enhanced surveillance 
reports are not adjusted for differences in the 
sensitivities of the different diagnostic methodologies 
used across the different laboratories.
With regard to PCR ribotyping of C. difficile isolates, 
the 2006 laboratory survey found that none of the 
laboratories surveyed routinely requested ribotyping 
and only 28% requested ribotyping in the setting of a 
suspected CDI outbreak. The 2011 repeat laboratory 
survey reported that 24 of 33 (73%) laboratories 
performing C. difficile testing reported having referred 
specimens for ribotyping. The criteria for referral varied 
between laboratories with 15 (62.5%) doing so in the 
event of an outbreak, 11 (46%) upon request and 
nine for severe infection (38%). Only four of 24 (17%) 
laboratories responding to the 2011 survey reported 
routine referral of specimens abroad for PCR ribotyping. 
The 2011 microbiology laboratory survey also sought 
information regarding reporting practices for positive 
C. difficile laboratory results. Of the 37 laboratories, 35 
(95%) provided information. The responses indicated 
local variation in the approach to notification with 19 
laboratories (51%) routinely notifying all positive C. 
difficile laboratory results. Sixteen laboratories (43%) 
indicated that positive results were checked to ensure 
that the patient met the CDI case definition prior 
to notification and, for 12 of those 16 laboratories 
(75%), there was also local discussion of patients with 
positive C. difficile laboratory results in conjunction 
with the infection prevention and control team prior 
to notification. Twenty laboratories (54%) reported the 
existence of a mechanism to ensure correlation between 
CDI cases notified via CIDR and cases reported via the 
voluntary CDI enhanced surveillance scheme.
Conclusion
The first national C. difficile guidelines were published 
in May 2008. Since publication, there have been new 
developments in diagnosis and patient management and 
thanks to CIDR notification of new cases of CDI and the 
excellent participation in the voluntary CDI enhanced 
surveillance scheme, there has been a significant amount 
of information collected regarding the burden of CDI 
on the Irish healthcare system.  There was an increase in 
the number of new CDI cases notified to CIDR between 
2010 and 2011, which may partly be due to changes 
in laboratory testing protocols. Of the 1,511 CDI cases 
notified via enhanced surveillance, 92% were new and 
7% were recurrent CDI. Twenty-seven percent of patients 
with CDI had symptom onset in the community. 
For the purposes of CDI notification to public health 
and CDI enhanced surveillance, it is important that all 
positive C. difficile laboratory results are discussed with 
the clinician responsible for the patient to ascertain the 
following information:
1. That the patient with the positive laboratory test 
result for C. difficile meets the CDI case definition – 
if the case definition is not met, the laboratory result 
is not notifiable
2. Whether the patient has previously had a positive C. 
difficile test result within the past eight weeks:
a. If yes, and the patient’s diarrhoea had resolved 
but has subsequently returned, this represents 
recurrent CDI
b. If yes, and the patient’s diarrhoea has not yet 
resolved, this is a repeat positive specimen from 
the same CDI episode
The C. difficile Sub-Committee of the Health Protection 
Surveillance Centre reconvened in October 2011 to 
commence work on updating the 2008 C. difficile 
guideline document. 
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Table 3: Two-step testing algorithms in use in Irish 
microbiology laboratories – 2011   
Step One Step Two Number of Laboratories
GDH TOXIN EIA 11
GDH TOXIN GENE PCR 4
TOXIN EIA TOXIGENIC 
CULTURE
1
9.1.2 HCAI Surveillance
Key Points
Key points:
•   This study provided an important baseline for CRE 
epidemiology in Irish critical care units.
•   Thirty-five acute hospitals (30 public and five 
private) representing all regions of Ireland and 
incorporating 40 critical care units (37 adult and 
three paediatric) participated in this voluntary four-
week pilot study. Eighty-four percent of public 
hospital critical care beds were captured in this 
study.
•   Patients admitted to critical care units were 
screened weekly for rectal carriage of CRE. There 
were 839 opportunities to perform weekly rectal 
swabs for CRE carriage and 760 rectal swabs were 
taken, reflecting a compliance rate of 91% with the 
study screening protocol.
•   The CRE screening swabs were processed 
according to a common laboratory protocol at 27 
microbiology laboratories. Suspected CRE isolates 
were referred for confirmatory testing to the 
Antimicrobial Resistance and Microbial Ecology 
(ARME) Laboratory at NUI, Galway.
•   CRE was not detected in 40 Irish critical care units 
during this four-week study. Five suspected CRE 
isolates were referred to ARME and none were 
confirmed as CRE.
9.1.2.1  Carbapenem Resistant Enterobacteriaceae 
(CRE) in Critical Care Units in Ireland: National 
Pilot Study – June 2011
Carbapenem resistant Enterobacteriaceae (CRE) are 
multi-drug resistant organisms for which extremely 
limited treatment options exist. CRE have emerged 
in Ireland since late 2010, including case reports and 
outbreaks. In June 2011, a national prevalence study 
systematically examined if patients admitted to Irish 
critical care units were colonised with carbapenemase-
producing, carbapenem resistant Enterobacteriaceae. 
Recommendations
•  It is of critical importance that all senior healthcare 
facility management and healthcare workers ensure 
that systems are in place to detect and screen patients 
who are at risk of CRE, in accordance with the national 
CRE screening guidelines. 
•   Appropriate antimicrobial prescribing and good 
infection prevention and control practices by all 
are essential to prevent the emergence of CRE 
and other multi-drug resistant organisms. Hospitals 
should ensure that they have active antimicrobial 
stewardship programmes in line with national 
guidelines.
•   A national reference laboratory service for 
confirmation and typing of antimicrobial-resistant 
Gram-negative bacilli, including CRE, should be 
established as a matter of urgency. In the interim, 
it is recommended that a service level agreement 
with an Irish laboratory is established to ensure that 
suspected CRE specimens are investigated and 
reported in a timely fashion.
The complete national report is available on the HPSC 
website:  http://www.hpsc.ie/hpsc/A-Z/Microbiology
AntimicrobialResistance/strategyforthecontrolof
AntimicrobialResistanceinIrelandSARI/Carbapenem
ResistantEnterobacteriaceaeCRE/Nationalpilotstudy
ofCREinCriticalCareUnitsJune2011/
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9.1.2.2  Healthcare-Associated Infections in Long Term 
Care Facilities in Ireland: 2011 Study
Key Points
•   In total 5,922 residents were surveyed in 108 
LTCFs, 84 of which were public and 24 private, 
an increase from 69 LTCFs that participated in 
the 2010 survey (Table 1). The majority of the 
LTCFs were classified as general care type (63 
LTCFs, 58%), with 14% classified as intellectually 
disabled (n = 15), 5% as psychiatric (n = 5) and 
4% as either residential (n = 1, 1%), physical (n 
= 1, 1%), rehabilitation (n = 1, 1%) or palliative 
care (n = 1, 1%). Twenty - one were a mix of care 
types, (19%).
•   The median number of beds per LTCF was 50 
with a range of 10 to 226 beds. Only 21% 
(median) of the beds were in single rooms 
(range: 0 to 100%). 
•   Over a third of the residents (39.3%) were over 
85 years of age, 48.6% were disorientated, 
49.7% had impaired mobility and 59% were 
incontinent.
In May 2010, a national point prevalence survey (HALT) 
on healthcare-associated infection and antibiotic 
use in Irish long term care facilities (LTCFs) was 
conducted as part of a European initiative coordinated 
by the European Centre for Disease Prevention and 
Control. The 2010 national report and protocol can 
is available on the HPSC website.http://www.hpsc.
ie/hpsc/A-Z/MicrobiologyAntimicrobialResistance/
InfectionControlandHAI/Surveillance/
HCAIinlongtermcarefacilities/HALTproject2010/Results/
The HALT survey was repeated in Ireland in May 2011. 
Healthcare-Associated Infection (HCAI):
•   In total, 4.1% (242) of residents had an infection on the 
day of the survey, (range 0 – 26.1%, median = 4.3%) 
as defined by the adapted McGeer definitions (where 
physical diagnosis was included as a criterion in each 
category of infection). This represents an increase from 
3.6% in 2010 (Table 2). 
•   The most common infections were respiratory (1.4%, 
83 residents), urinary (1.3%, 79 residents) and skin 
infections (1%, 57 residents), (Table 2).
•   Residents with an infection were more likely to be older 
(over 85 years), have a medical device (e.g., urinary 
catheter) in place and recently had surgery.  Urinary 
infections were associated with the presence of a 
urinary catheter, skin infections with the presence of 
pressure sores and respiratory infections with older age 
(over 85 years).
Antimicrobial use:     
•   Antimicrobials were prescribed for 601 (10.1%) 
residents. Prescriptions were for treatment of infection 
in 340 residents, (58%), for prophylaxis in 244 
residents, (39%), and for an unspecified reason in 22 
residents (3%) of residents.  This is a similar profile to 
2010 (Figure 3).
•   Co-amoxiclav and trimethoprim were the most 
frequently prescribed antibiotics. 
•   Respiratory, urinary and skin infections were the 
most common indications for therapeutic antibiotic 
prescriptions. Only 45% (n = 55) of residents that were 
prescribed antibiotics for a urinary infection had a 
specimen taken for culture. 
•   Prophylactic antibiotics were predominantly prescribed 
for the prevention of urinary infection (81% of all 
prophylactic antibiotics prescribed).
Medical Care and Coordination
•   Medical care for residents was provided by general 
practitioners (GPs) in 46% (50) of LTCFs, by medical 
staff employed by the facility in 41% (43) and by both 
in 12% (13) of LTCFs.
•   In 39% (42) of LTCFs, a designated medical doctor was 
responsible for standardisation of practices and policies 
and coordination of medical activities.  This included 
staff education, development of infection prevention 
and control and antibiotic stewardship policies and 
coordination of medical rotas and staff vaccination. 
Infection Prevention and Control:
•   In 37% (40) of LTCFs there was no infection prevention 
and control practitioner in place whereas 63% (68) had. 
In 62% (42) of LTCFs with an infection prevention and 
control practitioner, this person was not working in the 
facility. 
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Table 1. Breakdown of LTCFs by region and ownership
Category
Number of 
LTCFs
Total residents 
surveyed
Median residents 
surveyed/LTCF  
(range)
Median single rooms/100 
beds  
(range)
Median bed 
occupancy/100 beds
By Ownership
Public 84 4400 35 (3 - 221) 18 (0 - 100) 93
Private 24 1522 57 (23 - 134) 64 (3 - 100) 96
By HSE Region
HSE - Dublin North East 10 604 48 (20 - 126) 13 (0 - 100) 95
HSE - Dublin Mid-Leinster 35 2308 54 (8 - 221) 53 (3 - 100) 96
HSE - South 24 1530 57 (3 - 153) 18 (1 - 93) 93
HSE - West 39 1480 28 (9 - 133) 20 (4 - 90) 95
National 108 5922 43 (3 - 221) 21 (0 - 100) 95
Antibiotic Stewardship:
•   Only 12% of LTCFs surveyed had an antibiotic 
committee, 8% of facilities provided regular training 
on appropriate antibiotic prescribing and 19% had 
written guidelines.
•   Presence of a coordinating doctor was significantly 
associated with the availability of written antibiotic 
guidelines (P = 0.004) and presence of an antibiotic 
committee was more likely to occur in public rather 
than private LTCFs (P = 0.03). 
This study provides an important baseline on HCAI, 
antimicrobial stewardship activities and antimicrobial 
consumption in Irish LTCFs to inform future preventative 
strategies. The prevalence of HCAI risk factors in the 
population surveyed reflects a high dependency level in 
Irish LTCFs. The low rate of pressure sores and urinary 
catheter use despite a high proportion of incontinent 
and/or immobile residents reflects high quality nursing 
and medical care provided within in the facilities.  
The HCAI prevalence reported in this study increased 
from 3.6% in 2010 (69 LTCFs) to 4.1% (108 LTCFs) in 
2011. This may be due to improved case finding and the 
increased number of participating LTCFs. 
The antibiotic use reported in both years of this survey 
(10.1%), corresponds with the 2009 Irish ESAC results 
(overall prevalence 10.9%), which is higher than the 
European overall prevalence of 5.9%. 
The proportion of antibiotics that were prescribed for 
prophylactic use (39%) is of concern, specifically in the 
prevention of urinary tract infection highlighting the 
need for national antimicrobial stewardship guidelines 
for LCTFs and education of prescribers. Antimicrobial 
guidelines for primary care and guidelines on the 
diagnosis and management of urinary tract infection in 
elderly residents of LTCFs were published in 2011. 
The HALT study will be repeated throughout Europe 
in May 2013 and will provide an opportunity for 
participating Irish LTCFs to assess local and national 
initiatives undertaken since 2011.
The national report for the Republic of Ireland was 
published in August 2011. http://www.hpsc.ie/
hpsc/A-Z/MicrobiologyAntimicrobialResistance/
InfectionControlandHAI/Surveillance/
HCAIinlongtermcarefacilities/HALTproject2011/Results/
File,12869,en.pdf
-124-HPSC Annual Report 2010 Healthcare Associated Infections
Figure 3: Breakdown of Antibiotics by Treatment type
Table 2. HCAI prevalence by infection type using the Adapted  McGeer definition 
Infection Type 2010 2011
Number of infections % of residents with infectiona
Number of 
infections
% of residents with 
infectiona
Urinary Tract Infection 62 1.5% 79 1.3%
Respiratory Tract Infection 44 1% 88 1.4%
Cold 15 0.4% 32 0.5%
Flu 0 0% 2 0.03%
Pneumonia 6 0.1% 11 0.2%
Otherb 23 0.6% 43 0.7%
Skin 31 0.7% 57 1%
Cellulitis 29 0.7% 54 0.9%
Fungal 2 0.05% 1 0.02%
Herpes 0 0% 2 0.03%
Eye, Ear, Nose, Mouth 11 0.3% 25 0.4%
Eye 6 0.1% 14 0.2%
Ear 2 0.05% 4 0.1%
Mouth 3 0.1% 7 0.1%
Total 149 3.6% 242 4.1%
a The percentage of residents with an infection is calculated as the number of infected residents per total eligible residents.
b Other: Other lower respiratory tract infections (e.g. bronchitis, tracheobronchitis
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9.1.3 Hand Hygiene
9.1.3.1 Alcohol Hand Rub Surveillance
Key Points
• The median rate of alcohol hand rub consumption 
in acute hospital in Ireland increased to 21.3 
litres per 1,000 bed-days used in 2011, from the 
updated figure of 19.2 in 2010
Hand hygiene is one of the most important ways 
to prevent HCAI.  Alcohol hand rubs (AHR) are an 
effective and rapid method of hand hygiene, and 
recommended as the primary means of hand hygiene 
in national and international guidelines. Measurement 
of hospital-level consumption of AHR, expressed as 
volume used per 1,000 bed-days, has been shown to 
correlate with overall hand hygiene activity in hospitals. 
It is a recommended process measure of hand hygiene 
activity by both the World Health Organisation (WHO) 
and the US Centers for Disease Control & Prevention 
(CDC). 
HPSC has collated data on AHR consumption in 
acute public hospitals in Ireland since 2006. The data 
collected represent the total volume of AHR dispensed 
to wards, clinics and other hospital areas per quarter 
for hospitals that provide the data via their pharmacy 
department, and total volume purchased per quarter 
for hospitals that provide the data via their supplies 
department. Quantities used for peri-operative surgical 
hand hygiene were excluded. The rate of usage per 
hospital is calculated as the total volume of AHR 
consumed in litres per 1,000 bed-days used (Table 1). 
In 2011 the median rate of AHR consumption increased 
to 21.3 litres per 1,000 bed-days used, from the 
updated figure of 19.2 in 2010. This represents a 10% 
increase in national consumption since 2010. Although 
the rate has decreased since its peak in 2009 (22.1), it 
is now double the consumption rate since surveillance 
began in 2006 (Table 1). The peak in the rate in 2009 
is probably related to the influenza pandemic in 2009, 
when there was an increased awareness of hand 
hygiene.
The wide variation in levels of AHR consumption 
between hospitals (10.6 - 129.4 litres per 1,000 bed-
days used) may, in part, be explained by differences in 
methodologies for collecting and reporting the data, 
and difference in types and range of hand hygiene 
agents used. The main limitation of this surveillance 
system is that the data refer to the use of AHR only, 
and do not take account of other hand hygiene 
agents (e.g. medicated liquid soap) that may also be 
in use in hospitals (although the latter should account 
for only a small proportion of routine hand hygiene 
activity in hospitals). In addition, the data do not 
give an indication of the frequency with which hand 
decontamination is carried out at a given hospital nor 
distinguish between who has used the AHR (visitor, 
patient or healthcare worker). 
The data are also prone to reporting artefacts, 
particularly for hospitals that report supplies (rather 
than pharmacy dispensing) data. For example, the 
hospital with the highest rate in 2011 had undergone 
a change in suppliers and the products had been 
restocked in all areas of the hospital over a relatively 
short period of time.  It is expected that there will be 
outliers of this nature from time to time.
Using the median consumption figure provides a stable 
indicator of the national AHR rate over time. However, 
the volume of AHR consumed remains a crude measure 
of hand hygiene activity at individual hospital level and 
must be viewed with other indicators such as direct 
observation of hand hygiene compliance.
Further information may be found at: http://www.hpsc.
ie/hpsc/A-Z/Gastroenteric/Handwashing/
Table 1. National data on AHR consumption in acute public hospitals in Ireland by year, 2006 – 2011. 
2006 2007 2008 2009 2010 2011
Number of participating hospitals 52 50 50 49 45 43
National consumption rate* 10.5 15 18.7 22.1 19.2 21.2
Range for participating hospitals in litres per 
1,000 bed-days used
0.5 - 29.0 5.2 - 47.1 5.9 - 52.5 7.8 - 47.7 7.6 - 36.4 10.6 - 129.4
* The consumption rate is the total volume of AHR consumed in the defined time period in litres per 1,000 bed-days used. The national rate 
represents the median of the national sample for each time period.
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9.1.3.2 Hand Hygiene Compliance Audit
Key Points
• 	Two national hand hygiene compliance audits took 
place in 2011, following the publication of a revised 
protocol and lead auditor training
•  For Period 1 (June), 36 hospitals participated. In 
total, 7,515 opportunities for hand hygiene were 
observed; achieving an average compliance of 
74.7%, range 54.8% to 91.9%
•  For Period 2 (October), 42 hospitals participated. 
In total, 8,765 opportunities for hand hygiene were 
observed; achieving an average compliance of 
79.6%, range 67.1% to 89.5%
•  The overall compliance for the combined periods 
was 77.3%, which is significantly above the HSE 
target for 2011 of 75%, however, a few individual 
hospitals and a number of compliance measures 
were significantly below the target
Hand hygiene is one of the most important ways to 
prevent HCAI.  Measuring hand hygiene compliance 
by direct observation is described by the World Health 
Organisation (WHO) as the gold standard. In 2009, 
a hand hygiene observational standard operating 
procedure (SOP) was developed by the HPSC and 
Infection Protection Society and used in acute hospitals. 
Following an evaluation, a multidisciplinary steering 
group was established and a revised SOP was published 
in 2011. 
Healthcare workers were observed for their compliance 
against the WHO ‘5 moments of hand hygiene’. 
National workshops for training lead auditors were 
held in March and September 2011, and each auditor’s 
inter-rater reliability was assessed using the Kappa 
statistic. Two national audits were conducted in 2011, 
one in June 2011 (Period 1) and one in October 
(Period 2). Acute hospitals were required to measure 
healthcare worker compliance against 30 hand hygiene 
opportunities for each of the seven randomly selected 
wards in their facility resulting in a maximum of 210 
opportunities per hospital per period.
For Period 1, 36 hospitals participated. In total, 
7,515 opportunities for hand hygiene were observed; 
achieving an average compliance of 74.7%, range 
54.8% to 91.9%. For Period 2, 42 hospitals participated. 
In total, 8,765 opportunities for hand hygiene were 
observed; achieving an average compliance of 
79.6%, range 67.1% to 89.5%. Of the 34 hospitals 
with comparable results for both periods, 15 had 
significantly improved from one period to the next, two 
had significantly worst compliance and 17 had shown 
no significant change.
Results for the two periods are combined in a summary 
in Table 1 and Figure 1. The overall compliance was 
77.3%, which is significantly above the HSE target for 
2011 of 75%. Of the four HSE regions, HSE-West had 
the lowest compliance at 73.6% and HSE-Dublin Mid-
Leinster had the highest at 79.4%. Of the four major 
healthcare worker categories, medical staff had the 
lowest compliance at 65.0% and nurse/midwife staff 
the highest at 82.3%. Based on the WHO ‘5 moments 
for hand hygiene’, compliance for moment 5 (after 
touching patient surroundings) was the lowest at 
72.2% and the highest for moment 3 (after body fluid 
Table 1:  Summary of hand hygiene compliance in acute hospitals in Ireland combined for the two national audit periods in 2011
 
Hand Hygiene 
Opportunities
Hand Hygiene 
Actions
Percent 
Compliance
Lower 95% 
Confidence 
Interval
Upper 95% 
Confidence 
Interval
Overall 16,280 12,585 77.3% 76.7% 77.9%
HSE – South 3,344 2,598 77.7% 76.2% 79.1%
HSE - Dublin North-East 3,547 2,770 78.1% 76.7% 79.4%
HSE - Dublin Mid-Leinster 5,250 4,170 79.4% 78.3% 80.5%
HSE – West 4,139 3,047 73.6% 72.2% 75.0%
Nurse/Midwife 9,340 7,691 82.3% 81.6% 83.1%
Auxiliary 2,363 1,747 73.9% 72.1% 75.7%
Medical 3,437 2,235 65.0% 63.4% 66.6%
Other 1,137 910 80.0% 77.6% 82.3%
Moment 1 4,205 3,185 75.7% 74.4% 77.0%
Moment 2 992 746 75.2% 72.4% 77.9%
Moment 3 1,631 1,382 84.7% 82.9% 86.4%
Moment 4 6,054 4,983 82.3% 81.3% 83.3%
Moment 5 4,612 3,329 72.2% 70.9% 73.5%
Intensive Care Unit Wards 1,829 1,482 81.0% 79.2% 82.8%
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Figure 1:  Summary of hand hygiene compliance in acute hospitals in Ireland 
combined for the two national audit periods in 2011. Vertical black bars 
represent the 95% confidence intervals.
Staff category: “Auxiliary” includes healthcare assistants, porters, catering and 
household services; “Other” includes physiotherapists, radiologists, dieticians, 
social workers and pharmacists
Moment 1: Before touching a patient; Moment 2: Before clean/aseptic 
procedure; Moment 3: After body fluid exposure risk; Moment 4: After 
touching a patient; Moment 5: After touching patient surroundings
exposure risk) at 84.7%. Compliance within intensive 
care units was 81.0%. The proportion of hand hygiene 
actions that were undertaken using soap and water was 
41.4% as opposed to hand rub at 58.6%. At individual 
hospital level, compliance for the combined periods 
ranged from 65.6% to 88.8%, with only five hospitals 
having compliance significantly below the target of 
75%.
The results may not be reflective of healthcare worker 
compliance at all times. Compliance with hand 
hygiene is measured by auditors observing healthcare 
workers undertaking patient care who may change 
their behaviour if aware that they are being observed. 
However, it is also known that this effect (known as the 
Hawthorne effect) diminishes over time and healthcare 
workers under observation may not be aware of the 
presence of the auditor due to the many competing 
demands on their attention. In addition, the purpose of 
auditing is to improve practice, therefore any action that 
improves compliance increases patient safety. Auditors 
are requested to give immediate feedback to ward staff 
following an audit, thereby increasing awareness and 
knowledge of hand hygiene. Furthermore, all auditors 
measured compliance in the facility in which they work; 
therefore there may be an element of bias in the results. 
This risk of bias should be balanced by the benefits of 
increasing local staff’s knowledge and awareness of 
hand hygiene. 
While there was a significant improvement in hand 
hygiene compliance in 2011 from Period 1 to Period 
2, meeting the target for 2011 of 75%, a few of the 
hospitals and a number of compliance measures 
were significantly below the target. There are many 
factors that can contribute to improving healthcare 
workers hand hygiene compliance including improved 
infrastructure (e.g. access to alcohol gel at the point of 
care), increased awareness through education, audit 
and feedback, support from senior management/
clinicians and an informed patient population. 
Ireland participates in the European Surveillance of 
Antimicrobial Consumption (ESAC) project which aims 
to collect systemic antimicrobial usage data from the 
outpatient (ambulatory, community or primary care) 
setting and from the hospital (inpatient) setting. The 
management of ESAC was taken over by ECDC in 2011 
and the project is now called ESAC-Net. Antimicrobial 
consumption is measured in Defined Daily Dose (DDD), 
which is the assumed average maintenance dose per 
day for a drug used for its main indication in adults. 
Rates are calculated in DDD per 1000 inhabitants per 
day (DID) for outpatients and DDD per 100 bed-days 
used (DBD) for inpatients. Please see “Antimicrobial 
consumption” and “Denominator data” parts of the 
explanatory notes section for further details.
Outpatient Antimicrobial Consumption
The overall outpatient antimicrobial consumption for 
Ireland in 2011 was 22.7 DID, a 15% increase from the 
previous year’s rate of 19.8 DID. In the latest interim 
ESAC-Net report (2010 data), the reported range 
of outpatient antimicrobial usage among European 
countries was 11.1 to 39.4 DID. The median for all 26 
European countries with reliable data was 18.3 DID.
Since outpatient antimicrobial usage in Ireland has been 
19.2 – 22.7 DID for the last ten years, the overall rate in 
Ireland is mid-to-high in Europe.  The underlying trend 
(Figure 1) showed that consumption increased steadily 
to a peak in 2007 and in 2009 declined to reach a level 
similar to that in 2004, however the rate has been 
increasing since 2009. There is still marked seasonal 
fluctuation in use, with highest levels occurring during 
periods of increased influenza activity. Consumption 
for 2011 was in line with expected use, as modelled on 
previous years’ trend and seasonality (Figure 2).
In Ireland in 2011, outpatient consumption of 
penicillins accounted for the largest class used (54% 
of total at 12.2 DID), followed by macrolides (18%, 
4.2 DID), tetracyclines (12%, 2.8 DID), cephalosporins 
(5%, 1.2 DID), sulphonamides (5%, 1.2 DID) and 
fluoroquinolones (4%, 0.9 DID). Other antimicrobial 
classes accounted for less than 2% of total use. 
Penicillin in combination with a beta-lactamase inhibitor 
(such as co-amoxiclav) accounted for the largest 
proportion of penicillins (54%) at 6.6 DID. Broad-
spectrum penicillin (such as amoxicillin) usage was also 
high at 29% of all penicillins (3.6 DID).
There was considerable variability in the overall 
outpatient antimicrobial usage at county level (18.4 to 
30.6 DID) as shown in Figure 3. 
Hospital Antimicrobial Consumption
Forty-two public acute hospitals provided valid 
antimicrobial usage data for 2011. The median rate of 
antimicrobial consumption was 83.7 DBD (range 22.7 – 
135.4 DBD). This was a 6% increase from the previous 
year’s revised rate of 79.3 DBD. These levels are again 
mid-to-high in Europe.
The largest group of antimicrobials, penicillins, 
which represent 51% of all inpatient antimicrobial 
9.2.0 Antimicrobial Consumption 
Key Points
•  The overall outpatient antimicrobial consumption in 
Ireland for 2011 was 22.7 DID, a 15% increase from 
2010. This rate is mid-to-high in comparison with 
other European countries.
•  The median rate of hospital antimicrobial 
consumption in Ireland for 2011 was 83.7 DBD 
(range 22.7 – 135.4 DBD), a 6% increase from 2010. 
This rate is again mid-to-high in comparison with 
other European countries. Forty-two public acute 
hospitals contributed the data in 2011.
•  Thirty-three hospitals participated in a point 
prevalence study in 2011, facilitated by the Irish 
Antimicrobial Pharmacists Group. The median 
prevalence of antimicrobial use in participating 
hospitals was 40.7% in 2011, compared with 36.5% 
in 2010 and 34.4% in 2009.
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usage, showed an increased in consumption by 7% 
in 2011 to 42.3 DBD. The use of fluoroquinolones 
such as ciprofloxacin (representing 7% of all inpatient 
antimicrobial usage) increased by 2% in 2011 to 5.8 
DBD. Fluoroquinolone usage had been decreasing 
since 2007 however this trend reversed in 2011. 
Consumption of cephalosporins, monobactams 
and carbapenems (representing 8% of all inpatient 
antimicrobial usage) increased by 1% in 2011 to 
6.9 DBD. Consumption of glycopeptides such as 
intravenous vancomycin, imidazoles such as intravenous 
metronidazole and nitrofurans (representing 10% of all 
inpatient antimicrobial usage) increased by 4% in 2011 
to 8.4 DBD. Consumption of erythromycin and related 
agents (representing 14% of all inpatient antimicrobial 
usage) increased by 10% in 2011 to 11.8 DBD. Less 
frequently used agents in hospitals are tetracyclines, 
sulphonamides/trimethoprim, aminoglycosides and 
other systemic antimicrobials; collectively these drugs, 
representing 10% of all inpatient antimicrobial usage, 
increased by 6% in 2011 to 8.4 DBD. 
Hospital function was the main driver for the differences 
in the rates of antimicrobial consumption between 
hospitals. The rates for regional/tertiary and general 
hospitals (medians 82.9 and 89.9 DBD) centred just 
above the median for Ireland, while the rate for single 
specialist facilities (maternity, orthopaedic or paediatric) 
10
15
20
25
30
Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011
D
ef
in
ed
 D
ai
ly
 D
os
es
 p
er
 1
00
0 
In
ha
bi
ta
nt
s 
pe
r 
D
ay
 (
D
ID
)
Observed Use Underlying Trend
Figure 1. Outpatient antibiotic consumption in Ireland by quarter, 2000-2011.
Figure 2. Outpatient antibiotic consumption in Ireland by month, 2000-2011. 
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was much lower (median 28.9 DBD). The lower median 
consumption in single speciality hospitals probably 
reflects differences in case-mix, compared to other 
hospitals. However it may also reflect the fact that 
DDDs are based on adult dosing and may therefore 
underestimate antimicrobial consumption in paediatric 
settings. 
There was continued reduction in the proportionate use 
of intravenously administered specific antimicrobials 
(those with good oral bioavailability) over total use, 
from a median of 6.9% in 2010 to 6.6% in 2011. This 
measure reflects patient acuity and also the hospital 
function. The change in the level of this measure 
may also reflect local antimicrobial stewardship 
interventions.
Hospitals Care Point Prevalence Survey (PPS) 2011
Thirty-three hospitals participated in a point prevalence 
study in September and October of 2011 which was 
facilitated by the Irish Antimicrobial Pharmacists Group 
(IAPG). Similar surveys had previously been carried out 
in 2009 and 2010. Clinical records on 7,468 patients 
were reviewed, of whom 2,586 received systemic 
antimicrobial therapy. The median prevalence of 
antimicrobial use in participating hospitals was 40.7% in 
2011 compared with 36.5% in 2010 and 34.4% in 2009. 
The data collected included patient demographics 
and antibiotic allergy status, details of systemic 
antimicrobial therapy, diagnoses and indication, 
compliance with local guidelines and documentation of 
reason for therapy. In most respects practices in Ireland 
were broadly in line with other European hospitals in 
previous years, though the prevalence of antimicrobial 
use was much higher in 2011. The PPS in 2011 had 
taken place at a time (autumn) when antimicrobial use 
is expected to be higher than in the summer months, 
which is when it took place in 2009 and 2010. The 
increase in the number of participating hospitals in 
the 2011 study is an indication of the value of this 
methodology to monitor antimicrobial prescribing 
patterns and to identify targets for antimicrobial 
stewardship interventions. 
More detailed analyses of antimicrobial usage data can be found on 
the www.hpsc.ie website, through “Topics A-Z”, under “Antibiotic 
Consumption Surveillance”. Details of the WHO ATC/DDD system 
of classifying and measuring drug consumption can be found at 
www.whocc.no/atc_ddd_index/. The figures presented in this report 
may vary from previously published levels owing to methodological 
changes.
Figure 3. Outpatient antibiotic consumption in Ireland by 
county, in DDD per 100 inhabitants per day for 2011.
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9.3.0 Antimicrobial Resistance
Key Points
•  There were 2,210 reports of invasive E. coli infection 
submitted to the European Antimicrobial Resistance 
Surveillance Network (EARS-Net) in Ireland, an 
increase of 5% from 2,170 reports in 2010  
  The proportions of reported invasive E. coli with 
resistance to 3rd-generation cephalosporins (3GCs) 
(9.3%), ciprofloxacin (23.8%) and aminoglycosides 
(12.2%), that produce extended-spectrum beta-
lactamases (ESBLs) (7.5%) and with multi-drug 
resistance (13.0%) were at their highest levels since 
surveillance began
•  There were 1,096 reports of S. aureus bloodstream 
infection (BSI), a decrease of 12%. Of these, 263 
(24. 0%) were meticillin-resistant S. aureus (MRSA), a 
decrease of 14% from 305 reported in 2010
  For acute hospitals, the rate of MRSA BSI was 0.067 
cases per 1,000 patient bed days used, a decrease 
from 0.078 in 2010. Over the same period, the 
rate of meticillin-susceptible S. aureus (MSSA) BSI 
decreased from 0.238 to 0.210
  Enhanced surveillance data revealed that 23% of 
the all S. aureus BSI isolates were associated with 
CVCs and 3% with peripheral venous catheters
•  There were 364 reports of E. faecium BSI compared 
with 392 in 2010, a decrease of 7%
  Vancomycin-resistant E. faecium (VREfm) accounted 
for 37.4% of reports, which was the highest 
proportion among countries reporting to EARS-Net 
•  There were 312 reports of invasive K. pneumoniae 
infections compared to 326 in 2010, a decrease of 
4%
  ****Five isolates (1.6%) were carbapenem-
resistant. Of these, four were due to 
carbapenemase-producing enzymes (CPE) (three, 
from one hospital, with the OXA-48 enzyme and 
one, from another hospital, with a KPC) and one 
was due to a combination of ESBL production 
and impermeability. The four CPE carbapenem-
resistant isolates represent the first reports of 
invasive infection due to these organisms in 
Ireland****
•  There were 327 reports of invasive S. pneumoniae 
infection compared to 314 in 2010, an increase 
of 3%.  Of these, 64 (19.6%) were penicillin-non-
susceptible S. pneumoniae (PNSP), an increase from 
18.2% in 2010; the proportion of isolates with high-
level resistance to penicillin increased from 4.8% in 
2010 to 6.1% in 2011 
  The national rate of invasive infection was 7.1 
compared to 6.8 per 100,000 population in 2010. 
A reduction in numbers of reports and rates of 
infection were seen in children <1year, the target 
population for the conjugate vaccines introduced 
since September 2008
  Serotype data were available on 295 of 327 
isolates (90%) and results indicate good coverage 
for both the 23-valent polysaccharide (PPV23) 
and 13-valent conjugate (PCV13) vaccines in their 
target populations: 74% (adults ≥65 years) and 54% 
(children <2 years), respectively
•  There were 184 reports of invasive P. aeruginosa 
infections compared to 222 in 2010, a decrease of 
17% 
•  Enhanced surveillance data were provided on  1,875 
cases from 12 laboratories, representing 40% of all 
cases submitted to EARS-Net in 2011
•  See http://www.hpsc.ie for further details of EARS-
Net, antimicrobial resistance and enhanced BSI 
surveillance in Ireland
•  European data are available at http://ecdc.europa.
eu/en/activities/surveillance/EARS-Net/Pages/
Database.aspx
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Introduction
The European Antimicrobial Resistance Surveillance 
Network (EARS-Net), previously the European 
Antimicrobial Resistance Surveillance System (EARSS), 
in Ireland collects routinely-generated antimicrobial 
susceptibility testing data on seven important bacterial 
pathogens using the EARS-Net case definition. 
Participating laboratories submit data on the “primary” 
or first isolate from blood or cerebrospinal fluid (CSF) 
per patient per quarter.  EARS-Net does not distinguish 
clinically significant isolates from contaminants and 
primarily serves as a surveillance system to measure 
national levels of antimicrobial resistance (AMR).  In 
2011, all 41 microbiology laboratories participated in 
EARS-Net resulting in complete coverage of the Irish 
population.
Escherichia coli
There were 2,210 reports of invasive E. coli infection 
(2,209 from blood and one from CSF) from 2,169 
patients, an increase of 5.1% from 2,170 reports in 
2010.  See table 1 for the proportion of E. coli isolates 
resistant to the four “indicator” antibiotics/antibiotic 
classes [ampicillin, third-generation cephalosporins 
(3GCs; cefotaxime, ceftriaxone, ceftazidime or 
cefpodoxime), fluoroquinolones (ciprofloxacin or 
ofloxacin) and aminoglycosides (gentamicin, amikacin or 
tobramycin)] by year since 2004.  
Two hundred and six (9.3%) of 2,208 isolates were 
resistant to 3GCs, of which 155 were ESBL-positive 
and 50 were ESBL-negative; 524 (23.8%) of 2,203 
were ciprofloxacin-resistant; and 191 (8.7%) of 2,203 
were gentamicin-resistant [269 (12.2%) of 2,205 were 
aminoglycoside-resistant (i.e. resistant to gentamicin, 
tobramycin or amikacin)]. 
In 2011, resistance to 3GCs, ciprofloxacin and 
aminoglycosides were at their highest levels since 
surveillance began (figure 1). Between 2008 and 2011, 
the trend in 3GC resistance was upwards, however this 
was not significant (Chi2 trend=6.386, P=0.094).
Ireland had moderately high levels (10 to <25%) of 
ciprofloxacin and aminoglycoside resistance (ranking 
15th and 12th, respectively, out of 29 countries reporting 
to EARS-Net) and moderately low levels (5 to <10%) 
of 3GC resistance (ranking 19th out of 29 countries) in 
2011.
Extended spectrum beta-lactamases (ESBLs) were 
detected in 164 (7.5%) of 2,196 isolates tested. In 
2011, ESBL production among E. coli isolates was at its 
highest level since surveillance began. Between 2008 
and 2011, ESBL production increased from 5.0% to 
7.5%, which is statistically significant (Chi2 trend=11.31, 
P=0.01). ESBLs are enzymes that confer resistance 
to most penicillins and cephalosporins (including 
3GCs). ESBL-producing bacteria (including E. coli and 
K. pneumoniae) are often resistant to other classes of 
antibiotics and have emerged as important causes of 
infections in hospitals.
Of 2,199 isolates tested against all four “indicator” 
antibiotics, 286 (13.0%), from 49 hospitals/institutions, 
were identified as multi-drug resistant (MDR; defined as 
resistance to three or more of these), an increase from 
11.7% in 2010:
•  95 with resistance to ampicillin, 3GCs, ciprofloxacin 
and aminoglycosides (81 ESBL-positive, 14-negative)
•  69 with resistance to ampicillin, 3GCs and 
ciprofloxacin (57 ESBL-positive, 12 -negative)
•  118 with resistance to ampicillin, ciprofloxacin and 
aminoglycosides (three ESBL-positive, 115 -negative)
•  Four with resistance to ampicillin, 3GCs and 
aminoglycosides (two ESBL-positive, one -negative)
In 2011, MDR E. coli was at its highest level since 
surveillance began. 
Females were approximately 1.2-times more likely to 
have an invasive E. coli infection than males (z=3.84, 
P=0.0001).  The frequency of invasive E. coli infection 
increased with age with the majority of infections 
(n=1,607; 73%) occurring in adults over 60 years.  The 
median age was 71 years (95%CI, 71-72).
Staphylococcus aureus
There were 1,096 reports of S. aureus bloodstream 
infection (BSI) from 1,058 patients, of which 263 (24.0%) 
were meticillin-resistant S. aureus (MRSA) (table 1).  
This represents the lowest annual proportion since 
surveillance began in 1999.  In 2010, the proportion was 
24.4%, which was the first time Ireland had <25% MRSA 
and thus changed from a red to an orange colour on 
the EARS-Net map.  The decrease observed between 
2010 and 2011 was not significant (z=0.217, P=0.83). 
This is the fifth successive year in which a decrease has 
been observed and the overall downward trend over 
this time period is highly significant (Chi2trend=164.4, 
P<0.0001) (figure 2).  Overall, there was a 13.7% 
reduction in the number of MRSA BSI reports compared 
with 2010 (263 vs. 305). The total number of meticillin-
susceptible S. aureus (MSSA) BSI reports decreased by 
11.9% in 2011 compared to 2010 (833 vs. 946). 
Despite the decrease in numbers and proportion of 
MRSA, Ireland still had one of the higher proportions 
of MRSA in Europe in 2011 (see http://ecdc.europa.eu/
en/activities/surveillance/EARS-Net/Pages/Database.
aspx for European data, including EARS-Net tables, 
charts and maps) (figure 3). Ireland ranked 10th out of 
28 countries reporting to EARS-Net. All of the countries 
with higher proportions of MRSA than Ireland are in 
Southern and Central Europe.
No MRSA isolates with reduced susceptibility to 
vancomycin were detected at the National MRSA 
Reference Laboratory.  
The MRSA rate for all acute hospitals in 2011 was 0.067 
cases per 1,000 patient bed days used, representing 
a decrease from 0.078 in 2010, while the MSSA rate 
also decreased from 0.238 in 2010 to 0.210 to 2011 
[Note: the rates are calculated taking into account 
the denominator data (bed days used) obtained 
from the Business Intelligence Unit at the Health 
Services Executive for all acute public hospitals; and 
directly from the hospitals for private hospitals where 
available, where both numerator (MRSA numbers) and 
denominator data have been provided]. 
In patients with laboratory-confirmed S. aureus BSI, 
the probability that the infecting organism was MRSA 
as compared to MSSA was approximately 1.9-times 
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Table 1. Summary of EARS-Net data by pathogen and year, 2004-2011
Pathogen 2004 2005 2006 2007 2008 2009 2010 2011
Number laboratories by year-end 40 41 42 44 42 43 40† 41††
E. coli
Number of isolates 1256 1445 1656 1785 1926 2064 2170 2210
Ampicillin-R* 65.0% 67.6% 70.7% 68.3% 70.4% 68.7% 68.4% 71.9%
3GC-R* 2.6% 4.1% 4.2% 6.7% 7.4% 7.5% 8.3% 9.3%
ESBL-producers* 1.1% 2.4% 2.5% 4.1% 5.0% 5.8% 6.1% 7.5%
Ciprofloxacin-R* 12.6% 17.3% 21.5% 22.1% 23.3% 22.3% 23.6% 23.8%
Gentamicin-R* 5.7% 8.5% 7.7% 9.9% 10.2% 7.7% 9.4% 8.7%
Gentamicin/Amikacin/Tobramycin-R* 6.1% 8.6% 8.6% 10.6% 11.0% 9.3% 11.8% 12.2%
Carbapenem‡-R* 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
MDR* 5.6% 7.7% 9.0% 11.4% 12.1% 10.4% 11.7% 13.0%
Number laboratories by year-end 41 42 42 44 43 43 40† 41††
S. aureus
Number of isolates 1323 1424 1412 1393 1303 1309 1251 1096
Number Meticillin-R (or MRSA) 553 592 592 536 439 355 305 263
Meticillin-R (or MRSA) 41.8% 41.6% 41.9% 38.5% 33.7% 27.1% 24.4% 24.0%
Number VISA 0 0 2 1 0 0 0 0
VISA* 0.0% 0.0% 0.1% 0.1% 0.0% 0.0% 0.0% 0.0%
Number laboratories by year-end 40 41 42 44 42 43 40† 41††
E. faecium
Number of isolates 187 224 265 330 406 397 392 364
Ampicillin-R* 95.7% 92.3% 93.9% 93.1% 95.1% 92.9% 95.6% 95.9%
Vancomycin-R 23.2% 31.7% 37.1% 33.4% 35.7% 38.3% 39.3% 37.4%
HLG-R* 58.0% 51.4% 44.3% 35.2% 28.1% 39.1% 39.6% 36.8%
MDR* 18.5% 25.6% 25.6% 22.7% 16.2% 26.7% 24.9% 21.1%
Number laboratories by year-end 41 42 42 44 42 43 40† 41††
S. pneumoniae
Number of isolates 400 401 407 438 447 356 314 327
Penicillin-NS* 10.3% 11.7% 15.7% 17.4% 23.1% 20.2% 18.2% 19.6%
of which:   HLR 1.8% 3.0% 2.9% 5.7% 6.0% 5.6% 4.8% 6.1%
 Int 7.0% 8.7% 12.5% 11.0% 16.8% 13.8% 12.7% 13.5%
Erythromycin-R* 14.4% 12.1% 16.1% 16.4% 16.7% 17.3% 15.7% 18.9%
%Penicillin-NS/Erythromycin-R 3.1% 3.2% 7.4% 7.9% 10.2% 11.9% 12.6% 13.8%
Number laboratories by year-end 36 39 41 42 40† 41††
K. pneumoniae
Number of isolates
No data No data
217 244 310 323 326 312
Ampicillin-R* 97.7% 99.2% 99.7% 99.7% 99.1% 100.0%
3GC-R* 10.2% 9.9% 11.4% 11.2% 10.5% 8.0%
ESBL-producers* 8.6% 3.7% 7.7% 8.2% 5.0% 5.6%
Ciprofloxacin-R* 15.3% 18.1% 12.8% 13.0% 10.5% 13.2%
Gentamicin-R* 7.8% 9.9% 10.7% 11.1% 6.8% 7.4%
Gentamicin/Amikacin/Tobramycin-R* 9.2% 11.1% 10.7% 11.1% 7.1% 8.3%
Carbapenem‡-R* 0.0% 0.6% 0.0% 0.0% 0.0% 1.6%
MDR* 11.2% 11.9% 10.6% 11.9% 8.0% 8.4%
Number laboratories by year-end 40 41 42 44 42 43 40† 41††
E. faecalis
Number of isolates 242 290 294 280 301 289 298 265
Ampicillin-R* 0.8% 3.5% 4.5% 2.2% 0.7% 2.1% 2.0% 0.8%
Vancomycin-R 1.3% 2.5% 3.7% 2.9% 3.7% 0.7% 0.3% 4.9%
HLG-R* 41.3% 44.4% 42.4% 36.9% 30.5% 36.7% 29.7% 29.1%
Number laboratories by year-end 36 39 41 42 40† 41††
P. aeruginosa
Number of isolates
No data No data
128 177 199 248 222 184
Pipericillin/tazobactam-R* 9.4% 12.6% 9.7% 8.9% 10.0% 2.8%
Ceftazidime-R* 10.6% 11.8% 8.7% 11.8% 9.2% 8.2%
Imipenem/meropenem-R* 11.8% 12.2% 9.3% 10.2% 8.3% 12.0%
Ciprofloxacin-R* 18.0% 22.9% 21.8% 12.1% 13.2% 12.6%
Gentamicin-R* 10.2% 13.3% 9.0% 7.7% 8.7% 6.5%
MDR* 9.5% 12.4% 11.1% 6.4% 6.5% 4.0%
R, Resistant; NS, Non-Susceptible [includes isolates with intermediate (Int) and high-level resistance (HLR)]
MRSA, Meticillin-Resistant S. aureus; VISA, Vancomycin-Intermediate S.  aureus
HLG, High-Level Gentamicin; 3GC, 3rd-Generation Cephalosporin (includes cefotaxime, ceftriaxone, ceftazidime 
and cefpodoxime); ESBL, Extended-Spectrum Beta-Lactamase; MDR, Multi-Drug Resistant
* Not all isolates tested
† In 2010, 3 laboratories stopped processing blood cultures, however coverage of acute hospitals remained at 100%
††  In Q3 2011, one additional laboratory started reporting data
‡ Carbapenems include imipenem, meropenem and ertapenem
greater in patients aged ≥65years than in those aged 
<65 years (RR=1.9, z=5.312, P<0.0001).
Males were approximately 1.8-times more likely to 
get an invasive S. aureus infection (1.6-times for 
MRSA, z=3.87, P=0.0001; 1.8-times for MSSA, z=8.88, 
P<0.0001) than females (z=9.63, P<0.0001).  The 
frequency of invasive S. aureus infection increased 
with age, with the majority of infections (n=646; 59%) 
occurring in adults over 60 years.  The median age for 
patients with an MRSA infection was 72 years (95%CI, 
69-74) while the median age for patients with MSSA 
was 63 years (95%CI, 61-65).  This was considered to be 
a significant difference as the confidence intervals did 
not overlap. 
Enterococcus faecium
There were 364 reports of E. faecium BSI from 354 
patients, a decrease of 7% from 392 reports in 2010. 
See table 1 for the annual proportions of E. faecium 
isolates resistant to the three “indicator” antibiotics 
(ampicillin, vancomycin and high-level gentamicin) by 
year since 2004.  
One hundred and thirty-six (37.4%) of 364 were 
resistant to vancomycin and 131 (36.8%) of 356 isolates 
were resistant to high-level gentamicin (figure 4). The 
proportion of isolates that were vancomycin-resistant 
E. faecium (VREfm) decreased from 39.3% in 2010, but 
this was not a significant finding (z=0.537; P=0.59).
Since 2008, Ireland has had the highest proportion of 
VREfm in Europe. This remained the case in 2011, with 
the next highest proportions reported by Greece (23%), 
Portugal (20%) and Germany (11%) (figure 5). 
Table 2. Age and gender breakdown of patients by organism with major resistance profiles (data from 12 laboratories participating 
in enhanced surveillance for 2011). Proportion of isolates detected <48 hours and >5 days post-admission is also shown. 
Total 2011 Female Mean age 
(years)
Detected <48 
hours after 
admission
Detected >5 
days after 
admission
Staphylococcus 
aureus
Meticillin Resistant Staphylococcus aureus (MRSA) 109 32% 66 50% 38%
Meticillin Susceptible S. aureus 307 33% 58 56% 25%
Streptococcus 
pneumoniae
Penicillin Non-Susceptible S. pneumoniae 21 33% 69 95% 0%
Penicillin Susceptible S. pneumoniae 107 41% 60 93% 5%
Escherichia coli
Fluoroquinolone Resistant E. coli 199 41% 72 63% 30%
Fluoroquinolone Susceptible E. coli 663 59% 66 69% 21%
Enterococci
Vancomycin Resistant Enterococci (VRE) 64 45% 61 17% 72%
Vancomycin Sensitive Enterococci 198 38% 66 40% 54%
Klebsiella pneumoniae 137 39% 65 42% 43%
Pseudomonas aeruginosa 70 36% 70 57% 33%
Figure 1. Trends for E. coli – total numbers of E. coli and percentage resistance to 3GCs, 
ciprofloxacin/ofloxacin (CIP/OFX) and gentamicin/amikacin/tobramycin (GEN/AMK/TOB), 
and percentage ESBL-positive with 95% confidence intervals.
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Of 355 isolates tested against all three “indicator” 
antibiotics, 75 (21.1%), from 20 hospitals, were resistant 
to all three and therefore classed as MDR.  This 
represents a decrease from 24.9% in 2010. 
Males were approximately 1.4-times more likely to 
have an invasive E. faecium infection than females 
(z=3.08, P=0.002).  The frequency of invasive E. faecium 
infection increased with age with the majority of 
infections (n=237; 65%) occurring in adults over 60 
years.  The median age was 67 years (95%CI, 65-69).
Klebsiella pneumoniae
There were 312 reports of invasive K. pneumoniae 
infection (311 from blood and one from CSF) from 
304 patients, a decrease of 4% from 326 reports in 
2010).  See table 1 for the proportion of K. pneumoniae 
isolates resistant to the four “indicator” antibiotics 
(as for E. coli above), plus carbapenems (imipenem, 
meropenem or ertapenem), since 2006. 
Twenty-five (8.0%) of 312 isolates were resistant to 
3GCs, 15 of which were ESBL-positive; 41 (13.2%) 
of 311 were ciprofloxacin-resistant; and 23 (7.4%) of 
312 were gentamicin-resistant [26 (8.3%) of 312 were 
aminoglycoside-resistant (i.e. resistant to gentamicin, 
tobramycin or amikacin)]. 
There were no significant changes in the proportions 
compared with 2010 and there were no significant 
trends over the past four years. 
No isolates were reported as ampicillin-susceptible, 
which is as expected as all klebsiellae are inherently 
resistant to this antibiotic.
ESBLs were detected in 17 (5.6%) of 305 isolates tested, 
representing an increase from 5.0% in 2010. 
Five carbapenem-resistant isolates were reported in 
2011. Four of these were due to a carbapenemase-
producing enzyme, or CPE - three OXA-48 from one 
hospital and one KPC from another hospital - while 
one was not due to a CPE, with the resistance due 
to a combination of ESBL production and porin loss 
resulting in impermeability. The four CPE carbapenem-
resistant isolates represent the first reports of invasive 
infection due to these organisms in Ireland.
Twenty-six, or 8.4%, of 311 isolates tested against all 
four “indicator” antibiotics, from 14 hospitals, were 
identified as MDR, a slight increase from 8.0% in 2010:
•   16 with resistance to ampicillin, 3GCs, ciprofloxacin 
and aminoglycosides (9 ESBL-positive, 7 -negative)
•   Three with resistance to ampicillin, 3GCs and 
ciprofloxacin (all ESBL-positive)
•   one with resistance to ampicillin, 3GCs and 
gentamicin (ESBL negative)
•   Six with resistance to ampicillin, ciprofloxacin and 
aminoglycosides (one ESBL-positive, 5 -negative) 
Notably, the number with resistance to all four 
“indicator” antibiotics increased from 8 in 2010 to 16 in 
2011.
Antimicrobial resistance levels among K. pneumoniae 
isolates in Ireland are among the lowest in Europe, with 
Ireland ranking 23rd or 24th out of 29 countries for 3GC, 
fluoroquinolone and aminoglycoside resistance. Ireland 
ranked 7th out of 28 countries reporting carbapenem 
resistance in 2011, however, this does not distinguish 
carbapenem resistance due to CPE from other 
resistance mechanisms.
Males were approximately 1.5-times more likely 
to have an invasive K. pneumoniae infection than 
females (z=3.37, P<0.001).  The frequency of invasive 
K. pneumoniae infection increased with age with the 
majority of infections (n=153; 63%) occurring in adults 
over 60 years.  The median age was 66 years (95%CI, 
64-68).
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Figure 2. Trends for S. aureus – total numbers of S. aureus/MRSA and percentage 
MRSA with 95% confidence intervals
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Streptococcus pneumoniae
There were 327 reports of invasive S. pneumoniae 
infection (322 from blood and five from CSF) from 324 
patients, an increase of 2.8% from 314 reports in 2010.  
See table 1 for the annual proportions of S. pneumoniae 
isolates non-susceptible/resistant to penicillin and 
erythromycin by year since 2004.  
Penicillin-non-susceptible S. pneumoniae (PNSP) 
accounted for 19.6% (n=64) of all isolates tested against 
penicillin (n=327) in 2010 (table 1).  Of the 64 PNSP 
isolates, 44 were intermediately-resistant (Int; MIC=0.1-
1.0mg/L) and 20 were high-level resistant (HLR; MIC 
>1.0mg/L) to penicillin.  No antimicrobial susceptibility 
testing data were provided for one isolate. Fifty-nine 
(18.9%) of 312 isolates were resistant to erythromycin.  
The proportion of PNSP in Ireland decreased from 
23.1% in 2008 to 18.2% in 2010 but increased to 19.6% 
in 2011 (figure 6).  The proportion of isolates that were 
HLR to penicillin increased from 4.8% in 2010 to 6.1% in 
2011.  
In 2011, Ireland once again had one of the highest 
proportions of PNSP (ranking 7th out of 27 countries, 
and 3rd   out of 19 countries reporting 50 isolates or 
more) and high-level resistance to penicillin among 
S. pneumoniae (ranking 10th out of 27 countries, and 
4th out of 19 countries reporting 50 isolates or more), in 
countries reporting to EARS-Net, although comparisons 
with other EARS-Net countries is problematic due to 
the possibility of different interpretive criteria being 
applied to the data [Note: The Clinical Laboratory 
Standards Institute (CLSI) now provides three sets of 
breakpoints for interpreting penicillin susceptibility of 
S. pneumoniae isolates: meningitis, non-meningitis and 
oral. In Ireland, EARS-Net data are reported using the 
“oral” breakpoints (which correspond to the original 
CLSI breakpoints) for epidemiological purposes, and 
thus consistency].
Moderately high levels of erythromycin resistance were 
seen (with Ireland ranking 11th out of 27 countries, and 
7th out of 18 countries reporting 50 isolates or more), 
similar to the situation observed in much of Southern 
and Central Europe. 
Of isolates tested against both penicillin and 
erythromycin (n=312), 43 (13.8%) were simultaneously 
PNSP (25 Int, 11 HLR, 1 NS) and erythromycin-resistant 
in 2011.
Prior to the introduction of the 7-valent pneumococcal 
conjugate vaccine (PCV7) into the childhood 
immunisation schedule in September 2008, a national 
pilot project was established early in 2007 as a result 
of a collaborative initiative between RCSI/Beaumont 
Hospital, Children’s University Hospital, Temple St and 
HPSC with the aim of providing baseline serotyping 
data on invasive S. pneumoniae isolates.  PCV13 
replaced PCV7 as of September 2010. Serotype data 
were available on 295 pneumococcal isolates from 
29 laboratories (of 32 that reported pneumococcal 
isolates to EARS-Net in 2011) representing 90% of all 
pneumococcal isolates reported in 2011.  Overall, 232 
(79%) isolates belonged to serotypes covered by the 
pneumococcal polysaccharide vaccine (PPV23; target 
population: adults ≥65 years and at risk groups), while 
168 (57%) were covered by the conjugate vaccine 
(PCV13; target population: children <2 years).  From 
adults  ≥65 years, 108 of 146 (74%) isolates were 
covered by PPV23, while from children <2 years, 7 of 
13 (54%) isolates were covered by PCV13.  Of the 60 
PNSP isolates for which serotyping data were available, 
17 of 31 (55%) from adults ≥65 years were covered 
by PPV23 while the five isolates from children <2 
years were covered by PCV13. On-going surveillance 
of the predominant serotypes is required as strains 
with serotypes other than those in the vaccine have 
been reported to increase in prevalence following 
Figure 3. Distribution of MRSA in EARS-Net countries in 2011
Map downloaded from ECDC’s TESSy database on 22/10/2012:
http://ecdc.europa.eu/en/activities/surveillance/EARS-Net/Pages/Database.aspx
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introduction of PCV7 in other countries, hence the need 
for a fully resourced reference facility.  
The rate of invasive pneumococcal disease (IPD) in 
Ireland in 2011 was estimated to be 7.1 cases per 
100,000 population compared with 6.8 in 2010 (note: 
both calculated using the 2011 census data).  The 
highest rates of IPD were observed in children <1 year 
(13.1 cases per 100,000) and adults aged 65-74 years 
(22.9), 75-79 years (34.6) and ≥80 years (62) (figure 7).  
The rates in all age groups were broadly similar to the 
data for 2010 with the exception of the <1 year age 
group, which decreased from 24.6 to 13.1.  
Males were approximately 1.2-times more likely to have 
an invasive S. pneumoniae infection [1.7-times for PNSP, 
z=2.07, P=0.04; 1.1-times for penicillin-susceptible 
S. pneumoniae (PSP), z=1.11, P=0.27] than females 
(z=1.95, P=0.05). The median age was 64 years (95%CI, 
60-68).
Figure 5. Distribution of Vancmycin-resistant E. faecium in EARS-Net countries in 2011
Map downloaded from ECDC’s TESSy database on 22/10/2012: http://ecdc.europa.eu/en/activities/
surveillance/EARS-Net/Pages/Database.aspx
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Figure 4. Trends for E. faecium – total numbers of E. faecium and percentage resistance 
to high-level gentamicin (HLG) and vancomycin (VAN) with 95% confidence intervals
Enterococcus faecalis
There were 265 reports of E. faecalis BSI from 255 
patients, a decrease of 11% from 298 reports in 2010.  
See table 1 for the annual proportions of E. faecalis 
isolates resistant to the three “indicator” antibiotics (as 
for E. faecium above) by year since 2004.  
Thirteen (4.9%) of 264 isolates were resistant to 
vancomycin and 74 (29.1%) of 254 isolates were 
resistant to high-level gentamicin. 
The increase in the proportion of isolates that were 
vancomycin-resistant E. faecalis (VREfa) from 0.3% 
in 2010 to 4.7% in 2011was found to be statistically 
significant (z=3.5; P=0.0005). This represents the 
highest proportion of VREfa since surveillance began 
in 2002. This is also one of the highest proportions in 
Europe, with Ireland ranking 4th out of 29 countries 
reporting to EARS-Net in 2011.
Two isolates were reported as ampicillin-resistant, which 
suggests that these isolates were either misidentified 
as E. faecalis or misclassified as ampicillin-resistant, as 
resistance to ampicillin is rare in E. faecalis.
Males were approximately 1.85-times more likely to 
have an invasive E. faecalis infection than females 
(z=5.08, P<0.0001).  The frequency of invasive 
E. faecalis infection increased with age with the majority 
of infections (n=174; 66%) occurring in adults over 60 
years.  The median age was 68 years (95%CI, 65-71).
Pseudomonas aeruginosa
There were 184 reports of invasive P. aeruginosa 
infection (183 from blood and one from CSF) 
from 181 patients, a decrease of 17% from 222 
reports in 2010.  See table 1 for the proportion of 
P. aeruginosa isolates resistant to the five “indicator” 
antibiotics/antibiotic classes [piperacillin-tazobactam, 
ceftazidime, carbapenems (meropenem or imipenem), 
fluoroquinolones (ciprofloxacin or ofloxacin) and 
gentamicin] since 2006.  
Five (2.8%) of 272 isolates were resistant to piperacillin-
tazobactam; 15 (8.2%) of 184 were resistant to 
ceftazidime; 22 (12.0%) of 161 were resistant to 
imipenem or meropenem; 23 (12.6%) of 183 were 
resistant to ciprofloxacin; and 12 (6.5%) of 184 were 
resistant to gentamicin [no additional isolates were 
resistant to the other aminoglycosides (amikacin or 
tobramycin)]. 
In 2011, resistance to piperacillin-tazobactam, 
ceftazidime and gentamicin were at their lowest levels 
since surveillance began. Between 2008 and 2011, 
resistance to ciprofloxacin decreased significantly from 
21.8% to 12.6% (Chi2 trend=5.47, P=0.02).
Seven (4.0%) of 175 isolates tested against all five 
“indicator” antibiotics, from five hospitals, were MDR 
(2010, 6.5%), which is the lowest since surveillance 
began:
•  Five with resistance to 4 of the 5 required antibiotics 
classes
•  Two with resistance to 3 of the 5 required antibiotics 
classes
Antimicrobial resistance levels among P. aeruginosa 
isolates in Ireland are among the lowest in Europe, 
with Ireland ranking between 22nd and 24th out of 29 
countries for 3GC, fluoroquinolone and aminoglycoside 
resistance.
Males were approximately 1.9-times more likely to 
have an invasive P. aeruginosa infection than females 
(significant; z=4.33, P<0.0001).  The frequency of 
invasive P. aeruginosa infection increased with age 
with the majority of infections (n=136; 74%) occurring 
in adults over 60 years.  The median age was 70 years 
(95%CI, 66-73).
Enhanced Bloodstream Infection Surveillance
The enhanced surveillance programme was established 
in 2004 and involves voluntary participation by hospitals 
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Figure 6. Trends for S. pneumoniae – total numbers of S. pneumoniae/PNSP and 
percentage PNSP with 95% confidence intervals
HLR, High-level resistant; I, Intermediately resistant
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Figure 7. Numbers and age-specific incidence rates of patients with invasive 
S. pneumoniae infection in 2011 compared with 2010
that provide additional demographic, risk factor and 
clinical data on invasive pathogens causing BSI. In 
2011, there were 1,875 individual records (cases or 
isolates under the EARS-Net definition) submitted 
from 12 participating laboratories (compared to 2,562 
submitted in 2010). The total number of records thus 
far for 2011 represents 40% of the total core EARS-Net 
dataset. Demographic and other basic data for the 
major resistance profiles of EARS-Net pathogens are 
shown in Table 2. 
As vancomycin resistance among E. faecium BSI in 
Ireland is the highest reported in Europe, a detailed 
analysis of the changes over time of the factors 
affecting enterococcal BSI was undertaken in 2011. 
The six years’ enhanced data (2006-2011) showed that 
most vancomycin-resistant enterococci (VRE) BSI were 
hospital-acquired: 87% of E. faecium VRE BSI and 67% 
of E. faecalis VRE BSI were acquired in the reporting 
hospital. The rate of hospital-acquired E. faecium VRE 
BSI rose during 2006-2010, and declined slightly in 
2011, whilst the rate for vancomycin susceptible E. 
faecium (VSE) BSI generally increased. Intra-abdominal/
gastro-intestinal tract and central venous catheters 
accounted for about half of all primary sources for E. 
faecium. Urinary tract with or without catheter was 
also an important source for E. faecalis. The most 
common risk factors included underlying malignancy/
immunosuppression, intensive care unit stay and 
recent surgery. Recent surgery as risk factor had been 
increasing in VRE since 2006, however, this decreased 
sharply in 2011.
Of the MRSA BSI, 23% were noted as having central 
venous catheter and 3% as peripheral venous catheter 
as primary source. Of the fluoroquinolone-resistant E. 
coli BSI, 18% were noted as having urinary catheter as 
primary source of the bacteraemia.
For further details, go to the HPSC website (http://
www.hpsc.ie) and click on “Topics A-Z”, then 
“Enhanced Bacteraemia Surveillance.
Enhanced Surveillance of Carbapenem 
resistant Enterobacteriaceae (CRE) in Ireland
Key Points
•  In 2011, 39 cases of CRE colonisation or infection 
were notified
•  Only two patients had a history of hospitalisation 
abroad 
•  Detection of CRE represented colonisation in the 
majority of patients (68%) and CRE infection was 
reported for 30%
Carbapenem resistant Enterobacteriaceae (CRE) are 
multiple-drug resistant Gram-negative bacteria that can 
be easily spread between patients in healthcare settings 
and have the ability to cause infections for which 
effective antibiotic therapy may be lacking. Most CRE 
produce carbapenemase, an enzyme that breaks down 
the carbapenem class of antibiotics (e.g. imipenem, 
meropenem). Carbapenemase production has spread 
worldwide in the past 15 years and is now a prominent 
resistance mechanism reported in many countries. 
In 2011, carbapenemase-producing CRE were 
confirmed and reported from 39 patients in Ireland. The 
reported carbapenemase enzyme types were OXA-48 
(21 cases), KPC (17 cases) and NDM-1 (one case). There 
were four reported CRE outbreaks [KPC type (2) and 
OXA-48 type (2)]. Both KPC outbreaks were confirmed 
to be directly linked, using molecular methods. 
Completed enhanced surveillance forms were received 
from seven laboratories on 37 patients (95%). The 
average patient age was 63 years (range – 6 months 
to 95 years). Twenty-seven patients (73%) had been 
admitted from home, eight (21%) were transfers from 
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another acute hospital, one patient (3%) had been 
admitted from a long-term care facility and one (3%) 
was not an inpatient. 
At the time of detection of CRE, 16 patients (43%) were 
already known to be colonised or infected with one or 
more other multi-drug resistant organisms (MDRO). 
Two patients (5%) had a history of recent hospitalisation 
abroad. Nineteen patients (51%) reported no foreign 
travel in the last 12 months. Travel history was unknown 
for 15 patients (41%) and three patients had a history of 
foreign travel within the past 12 months [India [NDM-1], 
Greece [KPC] and Spain [OXA-48]. Of note, the latter 
patient had not been hospitalised abroad.
Twenty-eight patients (76%) had a history of 
hospitalisation in the past 12 months, 15 (41%) had a 
history of surgery in the past six months, nine (24%) 
had a history of admission to intensive care in the last 
12 months. Thirteen patients (35%) had underlying co-
morbidities [chronic lung, liver or renal disease, diabetes 
mellitus, urological abnormality or immunocompromise]. 
Four patients had no identifiable risk factors for CRE 
colonisation or infection.
Of the 37 patients, the antimicrobial exposure history 
prior to isolation of CRE was provided for 33 (89%). 
Twenty-six (79%) had received β lactam/β lactamase 
inhibitor combination agents, 11 (33%) had received 
fluoroquinolones, 9 (27%) had received carbapenems, 
7 (21%) had received aminoglycosides and four had 
received cephalosporins (12%).  One patient each 
had received co-trimoxazole and chloramphenicol 
respectively.  
For 25 patients (68%), the isolation of CRE represented 
colonisation and 11 patients (30%) developed CRE 
infection. The significance of isolation of CRE was 
unknown for one patient (2%). Of the 11 CRE infections, 
six (55%) were classified as intra-abdominal, three 
(27%) as urinary tract and there were two bloodstream 
infections (18%).  
The majority of the CRE (21; 57%) were detected from 
rectal screening swabs. One patient had CRE isolated 
from both sputum and urine. Two patients (5%) had CRE 
isolated from blood cultures. 
Of the 37 patients, outcome was reported for 33 
(89%) and of those, 15 (45%) were discharged home. 
Eleven patients (33%) died in hospital and seven (21%) 
remained inpatients at the time the surveillance form 
was returned. For five of the eleven deaths, the patient 
was reported to have had CRE infection. For the 
remaining six patients who died, CRE colonisation was 
reported. However, it is not known whether or not CRE 
colonised patients subsequently went on to develop 
CRE infection later in the hospital admission and the 
potential contribution of CRE was not reported for the 
eleven deaths.
Of the 15 patients who were discharged home, length-
of-stay could be calculated for 14. The median length-
of-stay was 44 days (range – 7 to 340 days).
Klebsiella pneumoniae accounted for all 37 CRE 
isolates reported by the seven laboratories. Reported 
minimum inhibitory concentrations for meropenem and 
ertapenem ranged from 0.25 to >32 mg/L. Gentamicin 
resistance was reported for 14 of 37 (38%) isolates and 
fluoroquinolone resistance for 21 of 29 (72%) isolates. 
Of the 25 isolates tested against tigecycline, 18 (72%) 
were reported to be either resistant or of intermediate 
susceptibility. Of the 16 isolates tested against colistin, 
15 (94%) were reported as susceptible. 
In response to the emergence of CRE in Ireland, interim 
CRE screening guidelines were issued and an enhanced 
surveillance scheme for CRE was launched. 
Latest available information on CRE in Ireland is avail-
able on the HPSC website at the following link:  http://
www.hpsc.ie/hpsc/A-Z/MicrobiologyAntimicrobialRe-
sistance/strategyforthecontrolofAntimicrobialResistan-
ceinIrelandSARI/CarbapenemResistantEnterobacteriace-
aeCRE/
Conclusion
Improvements in infection prevention and control 
resources and interventions in recent years, along 
with hospital antibiotic stewardship programmes, 
have probably contributed to reducing the burden of 
MRSA BSI in Ireland since 2006. The introduction of 
pneumococcal conjugate vaccines into the childhood 
immunisation programme since September 2008 has 
already resulted in a reduction in the burden of invasive 
pneumococcal disease in children.  Despite these 
successes, however, AMR remains a major problem 
this country, in particular VREfm, fluoroquinolone-
resistant E. coli, penicillin non-susceptible and 
erythromycin-resistant S. pneumoniae and increases 
in ESBL-production in E. coli and K. pneumoniae. The 
increasing number of reported invasive infections due 
to multi-drug resistant strains of these pathogens is of 
particular concern.  It should also be noted that AMR is 
an issue in other bacterial species as well as in infections 
occurring at sites other than blood and/or CSF for which 
national surveillance data are not currently available in 
Ireland. While data from invasive infections is extremely 
valuable in comparing national levels of AMR, it may 
underestimate the true burden of infections caused by 
drug-resistant pathogens. 
Thirty nine cases of CRE colonisation or infection 
were reported in 2011. In addition, four cases of 
carbapenemase-producing K. pneumoniae bloodstream 
infection were reported in 2011, marking the first 
appearance of this emerging resistance mechanism 
from invasive infections in this country. In Greece, 71% 
and 1.4% of invasive K. pneumoniae and E. coli isolates, 
respectively, were resistant to carbapenems in 2011, 
both of which are the highest proportions in Europe. In 
Italy, the proportion of invasive K. pneumoniae isolates 
that are carbapenem-resistant increased from 3% in 
2008 to 30% in 2011. The situation in Greece and Italy 
should act as a warning signal for countries where this 
particular resistance has yet to emerge or is still at a 
very low incidence. Increases in the prevalence of CRE 
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are largely related to broad spectrum antibiotic use, 
particularly in hospital and long-term care settings, 
and aggressive infection prevention and control 
interventions are required to prevent their spread 
between patients. In Ireland, initial steps have been 
taken to halt the spread of CRE and it is important 
that these are maintained and further initiatives are 
implemented, particularly in relation to hospital-based 
infection prevention and control and antimicrobial 
stewardship programmes. 
The enhanced EARS-Net surveillance data are 
particularly useful in informing infection prevention 
and control programmes both nationally and in those 
hospitals that participate in the surveillance scheme. 
Participation in enhanced surveillance can also help 
to identify risk factors and potentially preventable 
infections that can be targeted as part of such 
programmes.
The high levels of penicillin non-susceptibility and 
erythromycin resistance among invasive pneumococcal 
infections in Ireland are also cause for concern. 
Pneumococcal infections are largely community-
acquired, and AMR in this pathogen is largely related to 
antibiotic use outside of hospitals. As shown in countries 
such as France and Belgium, continued prescriber, 
patient and public education can reduce inappropriate 
antibiotic use in the community, and lead to reductions 
in the level of drug-resistant pneumococcal infections. 
Infections caused by drug-resistant bacteria result in 
excess mortality, morbidity and costs to the healthcare 
system. Rising levels of AMR threaten many aspects 
of healthcare that we currently take for granted. It is 
critical that comprehensive infection prevention and 
control and antimicrobial stewardship programmes 
continue to be developed and maintained at all 
levels and settings within the health service, and 
that these are supported by appropriately resourced 
reference laboratory services. To this end, it is vital that 
recommendations and guidelines produced by the 
HSE/RCPI AMR and HCAI Clinical Advisory Group are 
implemented. 
HPSC thanks all the microbiology laboratories for their 
continued participation and enthusiasm for the EARS-
Net project.
The data presented in this report were taken from the 
EARS-Net database on 19th October 2012.
For further details of EARS-Net and antimicrobial 
resistance in Ireland see http://www.hpsc.ie 
European data are available at http://ecdc.europa.eu/
en/activities/surveillance/EARS-Net/Pages/Database.
aspx
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Computerised Infectious Disease 
Reporting System (CIDR)
The text in red below is not to be included – 
CIDR OPERATIONS
2011 saw an upgrade of the CIDR application at the 
end of March from version 2.3.1 to version 2.4. This 
upgrade included the addition of some new core CIDR 
data items and some minor application enhancements 
and bug fixes. The value of relocating the CIDR 
development environment from our support supplier to 
HPSC was underscored when a critical bug associated 
with one of the new data items needed to be fixed 
quickly and this was achieved by mid-April. 
CIDR Implementation
2011 was a very significant year as it saw the completion 
of the national implementation of CIDR at both Public 
Health level and hospital microbiology laboratories and 
reference laboratories across the country.
This means that all eight Public Health Departments 
across the country now use CIDR on a daily basis 
to enter statutory notifications of infectious disease 
from clinicians and receiving notifications from 38 
laboratories across the country electronically, including 
5 reference laboratories.
The increase in the number of laboratories using CIDR 
has been accompanied by a similar increase in the 
volume of laboratory records reported through CIDR.
CIDR training
The completion of CIDR implementation was 
accompanied by a major training effort. The were six 
basic CIDR training courses held for Public Health staff 
resulting in 30 users being trained. Two advanced Public 
Health training courses were delivered to 3 trainees 
whilst two training courses on ad hoc reporting from the 
CIDR system were provided for 5 people.  Three CIDR 
training courses for laboratory users were held for 15 
trainees during 2011.
10. Computerised Infectious Disease 
 Reporting (CIDR)
Figure 1. The volume of  statutory infectious disease 
notifications since CIDR implementation commenced in 
2004.
Figure 2. The increased number of laboratories using CIDR 
year on year.
Summary
•  2011 represented the 8th year of CIDR operation
•  CIDR implementation in the last remaining regional 
Department of Public Health completed
•  Implementation in all CIDR labs completed
•  TB notifications on CIDR from the beginning of 
2011
•  Syphilis notifications on CIDR from May 2011
•  CIDR ready for new notifiable diseases from the 
beginning of 2012
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Notifications
No. of Labs Using CIDR
Records from Labs
Notifications
No. of Labs Using CIDR
Records from Labs
MORE DISEASES REPORTED USING CIDR
TB
The go-live of TB notifications from January 2nd 2011 
was achieved as planned.  This involved all new TB 
notifications now being notified using CIDR and 
included an extensive enhanced disease-specific dataset 
in addition to the core CIDR data items. This extended 
dataset included 115 TB-specific questions in relation to 
additional patient, sociodemographic and clinical details 
as well as diagnostic, outcome, contact and outbreak 
information. 
Syphilis
Clinical syphilis notifications using CIDR went live from 
May 3rd 2011. Like TB this involved both the core CIDR 
dataset as well as a significant number (32) of syphilis-
specific enhanced data items.
New notifiable diseases (2011)
The new schedule of notifiable infectious disease 
was published in September and required extensive 
work to prepare for these notifications using CIDR. 
This included adding 18 new diseases to CIDR and 
a number of disease-specific enhanced data fields.  
It also involved assessing, in conjunction with the 
relevant HPSC disease-specific teams, how best 
to address those diseases such as Acute Infectious 
Gastroenteritis (AIG) with data already recorded within 
CIDR but now reportable separately as Clostridium 
difficile or as Rotavirus. This involved reclassifying 
historic notifications in line with the causative organism 
identified. Similarly Enterohaemorrhagic Escherichia 
coli (EHEC - E.coli of serogroup known to be toxin 
producing) had been notifiable since January 2004 but 
from September 2011, EHEC was no longer notifiable 
and verotoxigenic E.coli (VTEC) only notifiable under 
current legislation. In both instances there was a desire 
to ensure that it remained possible to analyse trends 
across years.
INFORMATION GOVERNANCE
HPSC, including CIDR, continued to be successfully 
audited through 2011 against the ISO 27001 standard 
for Information Security Management. This accreditation 
provides reassurance to both healthcare professionals 
and data subjects that the security and confidentiality 
of information recorded through CIDR is managed 
appropriately. This was especially helpful in enabling 
syphilis notifications to be implemented on CIDR and to 
allow HIV notifications to commence on CIDR from the 
beginning of 2012.
CIDR COMMUNICATIONS
The CIDR National Steering Group met on four 
occasions through 2011 and continues to provide 
oversight and governance for CIDR.  Similarly the CIDR 
National User Group met four times in 2011 to discuss 
operational aspects of using CIDR to provide feedback 
to the CIDR team within HPSC.
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Figure 3. The number of laboratory records notified to 
Departments of Public Health through CIDR (the peak in 
2009 was attributable in part to the influenza pandemic that 
year).
Notifications
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Appendix 1
Notifiable Infectious Diseases in Ireland
Notes:
Figures for the year 2011 presented in this appendix were extracted from the Computerised Infectious Disease 
Reporting (CIDR) system in September 2012. These figures may differ from those published previously due to 
ongoing updating of notification data on CIDR.
Figures on EARS-Net pathogens and sexually transmitted infections are not presented here, since these diseases 
were not reported via the CIDR system during 2011. Separate databases are used to collate data on these diseases. 
Syphilis data were reported via CIDR from May 2011 but are excluded from this appendix as they represent only a 
portion of the cases notified in 2011. 
Table  A1.1. List of notifiable infectious diseases and their respective causative pathogens (relevant to 2011) under Infectious 
Diseases (Amendment) (No. 3) Regulations 2003 (S.I. No. 707 of 2003)
Infectious Disease Causative Pathogen(s)
Acute anterior poliomyelitis Polio virus
Acute infectious gastroenteritis
Ano-genital warts
Anthrax Bacillus anthracis
Bacillus cereus food-borne infection/intoxication Bacillus cereus
Bacterial meningitis (not otherwise specified)
Botulism Clostridium botulinum
Brucellosis Brucella species
Campylobacter infection Campylobacter species
Chancroid Haemophilus ducreyi
Chlamydia trachomatis infection (genital) Chlamydia trachomatis
Cholera Vibrio cholerae
Clostridium perfringens (type A) food-borne disease Clostridium perfringens
Creutzfeldt Jakob disease
Creutzfeldt Jakob disease (new variant)
Cryptosporidiosis Cryptosporidium parvum
Diphtheria Corynebacterium diphtheriae
Echinococcosis Echinococcus species
Enterococcal bacteraemia Enterococcus species (blood)
Enterohaemorrhagic Escherichia coli Escherichia coli of serogroup known to be toxin-producing
Escherichia coli infection (invasive) Escherichia coli (blood, CSF)
Giardiasis Giardia lamblia
Gonorrhoea Neisseria gonorrhoeae
Granuloma inguinale
Haemophilus influenzae disease (invasive) Haemophilus influenzae (blood, CSF or other normally sterile site)
Hepatitis A (acute) Hepatitis A virus
Hepatitis B (acute and chronic) Hepatitis B virus
Hepatitis C Hepatitis C virus
Herpes simplex (genital) Herpes simplex virus
Influenza Influenza A and B virus
Legionellosis Legionella species
Leptospirosis Leptospira species
Listeriosis Listeria monocytogenes
Lymphogranuloma venereum
Malaria Plasmodium falciparum, P. vivax, P. ovale, P. malariae
Measles Measles virus
Meningococcal disease Neisseria meningitidis
Mumps Mumps virus
Non-specific urethritis
Noroviral infection Norovirus
Paratyphoid Salmonella paratyphi
Pertussis Bordetella pertussis
Plague Yersinia pestis
Q fever Coxiella burnetii
Rabies Rabies virus
Rubella Rubella virus
Salmonellosis Salmonella enterica
Severe Acute Respiratory Syndrome (SARS) SARS-associated coronavirus
Shigellosis Shigella species
Smallpox Variola virus
Staphylococcal food poisoning Enterotoxigenic Staphylococcus aureus
Staphylococcus aureus bacteraemia Staphylococcus aureus (blood)
Streptococcus group A infection (invasive) Streptococcus pyogenes (blood, CSF or other normally sterile site)
Streptococcus pneumoniae infection (invasive) Streptococcus  pneumoniae (blood, CSF or other normally sterile site)
Syphilis Treponema pallidum
Tetanus Clostridium tetani
Toxoplasmosis Toxoplasma gondii
Trichinosis Trichinella species
Trichomoniasis Trichomonas vaginalis
Tuberculosis Mycobacterium tuberculosis complex
Tularemia Francisella tularensis
Typhoid Salmonella typhi
Typhus Rickettsia prowazekii
Viral encephalitis
Viral haemorrhagic fevers Lassa virus, Marburg virus, Ebola virus, Crimean-Congo haemorrhagic fever virus
Viral meningitis
Yellow fever Yellow fever virus
Yersiniosis Yersinia enterocolitica, Yersinia pseudotuberculosis
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Table A1.2 Number of notifiable infectious diseases, 2009-2011 and crude incidence rates of diseases, 2011
Infectious Disease 2009 2010 2011 CIR* 2011
Acute infectious gastroenteritis (unspecified) 108 95 88 1.92
Bacillus cereus food-borne infection or intoxication 1 0 0 0.00
Bacterial meningitis (not otherwise specified) 40 42 35 0.76
Botulism 0 0 1 0.02
Brucellosis 0 2 1 0.02
Campylobacter infection 1807 1660 2427 52.90
Clostridium difficile infection 1895 1693 1848 40.28
Clostridium perfringens (type A) food-borne disease 1 0 0 0.00
Creutzfeldt Jakob disease 5 3 7 0.15
Cryptosporidiosis 445 294 428 9.33
Echinococcosis 1 1 0 0.00
Enterohaemorrhagic Escherichia coli (VT negative) 14 25 23 0.50
Giardiasis 61 57 57 1.24
Haemophilus influenzae disease (invasive) 43 28 44 0.96
Hepatitis A (acute) 50 46 19 0.41
Hepatitis B (acute and chronic) 793 640 525 11.44
Hepatitis C 1236 1228 1257 27.39
Influenza 5055 275 2077 45.27
Legionellosis§ 9 11 7 0.15
Leptospirosis 24 17 16 0.35
Listeriosis 10 10 7 0.15
Malaria 90 82 61 1.33
Measles 162 403 267 5.82
Meningococcal disease 147 114 94 2.05
Mumps 3619 292 165 3.60
Noroviral infection 1633 1926 990 21.58
Paratyphoid 10 5 2 0.04
Pertussis 78 114 229 4.99
Q fever 17 9 5 0.11
Rotavirus infection 2354 2501 2451 53.42
Rubella 19 24 4 0.09
Salmonellosis 332 356 311 6.78
Shigellosis 70 60 42 0.92
Staphylococcal food poisoning 1 0 0 0.00
Streptococcus group A infection (invasive) 60 68 67 1.46
Streptococcus pneumoniae infection (invasive) 432 391 425 9.26
Toxoplasmosis 37 36 32 0.70
Tuberculosis‡ - - 424 9.24
Typhoid 9 8 14 0.31
Typhus 0 0 1 0.02
Verotoxigenic Escherichia coli infection 241 199 284 6.19
Viral encephalitis 5 22 23 0.50
Viral meningitis 142 168 220 4.79
Yersiniosis 3 3 6 0.13
Total 21059 12908 14984  
*CIR, Crude incidence rate per 100,000 total population
‡Tuberculosis only notifiable in CIDR since 2011 
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
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Table A1.3 Number of notifiable infectious diseases by HSE area, 2011
Infectious Disease HSE-E HSE-M HSE-MW HSE-NE HSE-NW HSE-SE HSE-S HSE-W Total
Acute infectious gastroenteritis (unspecified) 50 0 2 0 15 20 0 1 88
Bacterial meningitis (not otherwise specified) 16 2 2 2 3 6 3 1 35
Botulism * * * * * * * * 1
Brucellosis * * * * * * * * 1
Campylobacter infection 804 182 227 193 124 327 320 250 2427
Clostridium difficile infection 781 50 96 81 79 262 293 206 1848
Creutzfeldt Jakob disease 0 0 0 3 0 1 2 1 7
Cryptosporidiosis 12 50 60 30 33 76 64 103 428
Enterohaemorrhagic Escherichia coli (VT 
negative)
1 0 15 0 5 1 0 1 23
Giardiasis 20 3 5 2 1 9 11 6 57
Haemophilus influenzae disease (invasive) 18 3 2 7 2 4 2 6 44
Hepatitis A (acute) 9 1 1 1 1 3 3 0 19
Hepatitis B (acute and chronic) 327 17 31 30 13 18 51 38 525
Hepatitis C 957 47 36 63 18 43 60 33 1257
Influenza 743 125 257 171 89 239 166 287 2077
Legionellosis§ 3 0 0 0 0 3 1 0 7
Leptospirosis 3 1 5 2 0 0 5 0 16
Listeriosis 2 0 0 1 1 0 1 2 7
Malaria 32 6 1 7 0 1 9 5 61
Measles 232 5 5 8 1 2 6 8 267
Meningococcal disease 32 8 10 9 8 10 11 6 94
Mumps 72 11 15 11 20 12 7 17 165
Noroviral infection 398 70 149 140 14 98 69 52 990
Paratyphoid * * * * * * * * 2
Pertussis 108 15 7 12 32 12 24 19 229
Q fever 0 1 0 1 0 1 1 1 5
Rotavirus infection 456 300 172 222 153 378 412 358 2451
Rubella * * * * * * * * 4
Salmonellosis 112 23 40 24 15 35 27 35 311
Shigellosis 20 2 9 1 1 3 4 2 42
Streptococcus group A infection (invasive) 29 5 6 1 2 7 12 5 67
Streptococcus pneumoniae infection (invasive) 133 14 38 25 31 87 61 36 425
Toxoplasmosis 14 1 1 2 0 1 11 2 32
Tuberculosis 193 20 24 25 14 30 87 31 424
Typhoid 4 0 5 1 0 1 1 2 14
Typhus * * * * * * * * 1
Verotoxigenic Escherichia coli infection 30 64 56 23 24 23 41 23 284
Viral encephalitis 12 1 0 2 0 4 1 3 23
Viral meningitis 108 10 21 14 10 19 25 13 220
Yersiniosis 2 0 0 0 2 0 1 1 6
*Data not reported to HSE area level when total number in Ireland <5 cases
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
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Table A1.4 Number of notifiable infectious diseases by HSE region, 2011
Infectious Disease HSE Mid-Leinster HSE-North East HSE-West HSE-South Total
Acute infectious gastroenteritis (unspecified) 14 36 18 20 88
Bacterial meningitis (not otherwise specified) 9 11 6 9 35
Botulism * * * * 1
Brucellosis * * * * 1
Campylobacter infection 731 448 601 647 2427
Clostridium difficile infection 583 329 381 555 1848
Creutzfeldt Jakob disease 0 3 1 3 7
Cryptosporidiosis 62 30 196 140 428
Enterohaemorrhagic Escherichia coli (VT negative) 1 0 21 1 23
Giardiasis 18 7 12 20 57
Haemophilus influenzae disease (invasive) 13 15 10 6 44
Hepatitis A (acute) 7 4 2 6 19
Hepatitis B (acute and chronic) 172 202 82 69 525
Hepatitis C 618 449 87 103 1257
Influenza 568 471 633 405 2077
Legionellosis§ 2 1 0 4 7
Leptospirosis 2 4 5 5 16
Listeriosis 2 1 3 1 7
Malaria 26 19 6 10 61
Measles 75 170 14 8 267
Meningococcal disease 27 22 24 21 94
Mumps 65 29 52 19 165
Noroviral infection 323 285 215 167 990
Paratyphoid * * * * 2
Pertussis 88 47 58 36 229
Q fever 1 1 1 2 5
Rotavirus infection 624 354 683 790 2451
Rubella * * * * 4
Salmonellosis 93 66 90 62 311
Shigellosis 13 10 12 7 42
Streptococcus group A infection (invasive) 18 17 13 19 67
Streptococcus pneumoniae infection (invasive) 91 81 105 148 425
Toxoplasmosis 9 8 3 12 32
Tuberculosis 143 95 69 117 424
Typhoid 1 4 7 2 14
Typhus * * * * 1
Verotoxigenic Escherichia coli infection 82 35 103 64 284
Viral encephalitis 8 7 3 5 23
Viral meningitis 84 48 44 44 220
Yersiniosis 2 0 3 1 6
*Data not reported to HSE region level when total number in Ireland <5 cases     
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
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Table A1.6 Number of notifiable infectious diseases by gender, 2011
Infectious Disease Male Female Unknown Total
Acute infectious gastroenteritis (unspecified) 44 42 2 88
Bacterial meningitis (not otherwise specified) 15 20 0 35
Botulism 1 0 0 1
Brucellosis 1 0 0 1
Campylobacter infection 1302 1120 5 2427
Clostridium difficile infection 735 1112 1 1848
Creutzfeldt Jakob disease 2 5 0 7
Cryptosporidiosis 230 198 0 428
Enterohaemorrhagic Escherichia coli (VT negative) 11 12 0 23
Giardiasis 21 35 1 57
Haemophilus influenzae disease (invasive) 25 19 0 44
Hepatitis A (acute) 10 9 0 19
Hepatitis B (acute and chronic) 275 241 9 525
Hepatitis C 824 428 5 1257
Influenza 893 1172 12 2077
Legionellosis§ 6 1 0 7
Leptospirosis 14 2 0 16
Listeriosis 2 5 0 7
Malaria 41 20 0 61
Measles 147 119 1 267
Meningococcal disease 57 37 0 94
Mumps 89 76 0 165
Noroviral infection 420 566 4 990
Paratyphoid 1 1 0 2
Pertussis 92 136 1 229
Q fever 3 2 0 5
Rotavirus infection 1246 1189 16 2451
Rubella 2 2 0 4
Salmonellosis 161 149 1 311
Shigellosis 25 17 0 42
Streptococcus group A infection (invasive) 28 39 0 67
Streptococcus pneumoniae infection (invasive) 230 195 0 425
Toxoplasmosis 8 24 0 32
Tuberculosis 243 181 0 424
Typhoid 6 8 0 14
Typhus 1 0 0 1
Verotoxigenic Escherichia coli infection 138 145 1 284
Viral encephalitis 9 14 0 23
Viral meningitis 114 105 1 220
Yersiniosis 3 3 0 6
Total 7475 7449 60 14984
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
 Table A1.7 Number of notifiable infectious diseases by case classification, 2011
Infectious Disease Confirmed Probable Possible Total
Acute infectious gastroenteritis (unspecified) 2 86 0 88
Bacterial meningitis (not otherwise specified) 19 3 13 35
Botulism 1 0 0 1
Brucellosis 1 0 0 1
Campylobacter infection 2425 2 0 2427
Clostridium difficile infection 1848 0 0 1848
Creutzfeldt Jakob disease 7 0 0 7
Cryptosporidiosis 413 15 0 428
Enterohaemorrhagic Escherichia coli (VT negative) 23 0 0 23
Giardiasis 56 1 0 57
Haemophilus influenzae disease (invasive) 44 0 0 44
Hepatitis A (acute) 18 0 1 19
Hepatitis B (acute and chronic) 525 0 0 525
Hepatitis C 1257 0 0 1257
Influenza 2067 1 9 2077
Legionellosis§ 6 1 0 7
Leptospirosis 16 0 0 16
Listeriosis 7 0 0 7
Malaria 61 0 0 61
Measles 211 0 56 267
Meningococcal disease 88 1 5 94
Mumps 70 3 92 165
Noroviral infection 976 14 0 990
Paratyphoid 2 0 0 2
Pertussis 113 31 85 229
Q fever 4 1 0 5
Rotavirus infection 2451 0 0 2451
Rubella 0 0 4 4
Salmonellosis 311 0 0 311
Shigellosis 42 0 0 42
Streptococcus group A infection (invasive) 65 2 0 67
Streptococcus pneumoniae infection (invasive) 349 8 68 425
Toxoplasmosis 32 0 0 32
Tuberculosis 288 50 86 424
Typhoid 14 0 0 14
Typhus 1 0 0 1
Verotoxigenic Escherichia coli infection 272 11 1 284
Viral encephalitis 21 1 1 23
Viral meningitis 207 10 3 220
Yersiniosis 6 0 0 6
Total 14319 241 424 14984
Case classifications are assigned to notifications as per the Case Definitions for Notifiable Diseases during 2011
The case definitions booklet, available at http://www.hpsc.ie has been updated since 2012
*As per the case definitions, meningococcal disease notifications are classified as definite, presumed and possible. For convenience 
they are reported in this table as confirmed, probable and possible, respectively
§Legionellosis figures include both Legionnaires’ disease and Pontiac fever cases
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Table A2.1 Immunisation uptake (%) at 12 months of age in 2011 (i.e. cohort born 01/01/2010-31/12/2010)
HSE Area Local Health Office/HSE Area
Number in co-
hort for BCG *
Number in 
cohort for D3, T3 
& P3 †
Immunisation Uptake (%)
BCG D3 Hib3 HepB3 MenC2 PCV2
HSE-E
Dublin South na 1733 na 91 91 91 91 91
Dublin South East na 1719 na 89 89 89 89 89
Dublin South City na 1834 na 94 94 94 94 94
Dublin South West na 2693 na 92 92 92 92 93
Dublin West na 2945 na 81 81 81 81 81
Dublin North West na 4078 na 82 82 82 82 82
Dublin North Central na 1827 na 90 90 90 89 89
Dublin North na 4431 na 92 92 92 92 92
Kildare/West Wicklow na 4409 na 91 91 91 91 91
Wicklow na 2147 na 89 89 89 89 89
HSE-E Total na 27816 na 89 89 89 89 89
HSE-M
Laois/Offaly 2840 2840 95 94 94 94 94 94
Longford/Westmeath 2117 2117 94 96 96 96 96 96
HSE-M Total 4957 4957 94 95 95 95 94 94
HSE-MW
Clare 1718 1740 98 92 92 92 93 92
Limerick 2105 2072 97 91 91 91 92 92
Tipperary NR/East Limerick 2069 2125 96 93 93 93 93 93
HSE-MW Total 5892 5937 97 92 92 92 92 93
HSE-NE
Cavan/Monaghan na 2218 na 92 92 92 90 90
Louth na 2131 na 91 91 91 90 90
Meath na 3690 na 88 88 87 87 87
HSE-NE Total na 8039 na 90 90 90 89 89
HSE-NW
Donegal 2378 2378 95 93 93 93 93 93
Sligo/Leitrim 1438 1438 96 94 94 94 93 95
HSE-NW Total 3816 3816 95 94 94 93 93 94
HSE-SE
Carlow/Kilkenny 2158 2158 96 90 90 90 90 91
South Tipperary 1405 1405 95 94 94 94 93 93
Waterford 2083 2083 96 93 93 93 93 93
Wexford 2248 2248 97 91 91 91 91 92
HSE-SE Total 7894 7894 96 92 92 92 92 92
HSE-S
North Cork 1627 1596 79 90 90 89 87 86
North South Lee 6130 6049 92 90 90 89 86 86
West Cork 761 763 89 86 86 86 82 81
Kerry 1983 1939 92 87 87 86 83 83
HSE-S Total 10501 10347 90 89 89 89 86 85
HSE-W
Galway na 4129 na 90 90 90 90 90
Mayo na 1803 na 92 92 92 91 92
Roscommon na 952 na 96 95 96 96 97
HSE-W Total 3538* 6884 4* 91 91 91 91 91
Ireland 36598 75690 85* 90 90 90 90 90
na=not available 
* In Quarters 3 and 4 2011 the HSE-W reported BCG uptake data (4%), for children at 12 months of age for the first time, resulting in a low 
national uptake rate (85%) compared to previous years.  This is not a true decline as national uptake rates are based on available data and the 
HSE-W BCG data were not available previously. Traditionally BCG was given at age 10 - 12 years in the HSE-W.  HSE-W BCG data were not 
available by LHO. The available national BCG cohort data may be around 48% (this figure is an estimate only) of the national birth cohort in 2011.  
†As the denominator/number in cohort varied slightly according to vaccine the most commonly used number is reported here. 
Since T3, P3 and Polio3 uptake identical to D3 uptake only D3 uptake figures are presented 
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here 
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Table A2.2 Immunisation uptake (%) at 24 months of age in 2011 (i.e. cohort born 01/01/2009-31/12/2009)
HSE Area
Local Health Office/HSE 
Area
Number in 
cohort for D3, 
T3, P3 & Polio3*
Immunisation Uptake (%)
D3 Hib3 Hibb HepB3 MenC3 PCV3 MMR1
HSE-E
Dublin South 1724 93 93 86 92 81 87 89
Dublin South East 1527 92 92 85 92 81 87 89
Dublin South City 1737 96 96 88 96 83 90 93
Dublin South West 2696 95 95 89 94 83 89 92
Dublin West 2958 93 93 84 93 76 86 89
Dublin North West 3935 91 91 81 91 77 85 85
Dublin North Central 1734 95 95 89 95 82 87 90
Dublin North 4508 95 95 91 95 87 91 92
Kildare/West Wicklow 4241 97 97 93 97 88 93 95
Wicklow 2100 93 93 81 93 77 87 88
HSE-E Total 27160 94 94 87 94 82 89 90
HSE-M
Laois/Offaly 2828 97 97 94 97 89 94 96
Longford/Westmeath 2101 97 97 95 97 90 94 96
HSE-M Total 4929 97 97 95 97 89 94 96
HSE-MW
Clare 1912 96 96 93 96 89 93 94
Limerick 2103 94 94 87 94 84 91 92
Tipperary NR/East Limerick 2044 96 96 89 96 85 92 93
HSE-MW Total 6059 96 96 89 96 86 92 93
HSE-NE
Cavan/Monaghan 2220 97 97 90 97 88 94 94
Louth 2148 94 94 89 94 85 91 92
Meath 3660 96 96 87 96 84 91 91
HSE-NE Total 8028 96 96 88 96 85 92 92
HSE-NW
Donegal 2485 97 97 91 95 86 91 93
Sligo/Leitrim 1469 97 97 95 96 86 88 96
HSE-NW Total 3954 97 97 93 96 86 90 94
HSE-SE
Carlow/Kilkenny 2121 95 95 94 95 85 89 93
South Tipperary 1569 97 97 97 96 86 92 93
Waterford 2124 95 95 94 95 88 92 93
Wexford 2406 95 95 94 95 87 91 93
HSE-SE Total 8220 95 95 94 95 86 91 93
HSE-S
North Cork 1562 95 94 82 94 83 90 90
North South Lee 5970 98 97 83 96 86 93 95
West Cork 815 90 89 75 89 76 83 86
Kerry 2148 96 95 82 94 84 91 92
HSE-S Total 10495 96 96 82 95 84 91 93
HSE-W
Galway 4085 93 93 78 93 78 87 88
Mayo 1793 95 95 80 95 80 89 89
Roscommon 970 98 98 97 98 96 98 97
HSE-W Total 6848 94 94 81 94 81 89 90
Ireland 75693 95 95 88 95 84 90 92
*As the denominator/number in cohort varied slightly according to vaccine the most commonly used number is reported here. 
Since T3, P3 and Polio3 uptake identical to D3 uptake only D3 uptake figures are presented
Please note while North Lee and South Lee are two separate Local Health Offices their combined immunisation uptake data are reported here 
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Table A2.3 Local Health Office (LHO) abbreviations used in the immunisation uptake chapter 
of this document
Local Health Office Abbreviations Local Health Office
CE Clare
CN/MN Cavan/Monaghan
CW/KK Carlow/Kilkenny
DL Donegal
DN Dublin North
DNC Dublin North Central
DNW Dublin North West
DS Dublin South
DSC Dublin South City
DSE Dublin South East
DSW Dublin South West
DW Dublin West
G Galway
KE/WW Kildare/West Wicklow 
KY Kerry
L Limerick
LD/WD Longford/Westmeath
LH Louth
LS/OY Laois/Offaly
MH Meath
MO Mayo
NC North Cork
NSL* North South Lee*
RN Roscommon
SO/LM Sligo/Leitrim
TN/EL Tipperary North /East Limerick
TS South Tipperary
WC West Cork
WD Waterford
WX Wexford
WW Wicklow 
*Please note while North Lee and South Lee are two separate LHOs their combined 
immunisation uptake data are reported
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Explanatory Notes
Glossary of Terms
Notifiable Infectious Diseases
Computerised Infectious Disease Reporting (CIDR) 
system
For the majority of the notifiable infectious diseases 
(see Appendix 1), data were collated using the 
Computerised Infectious Disease Reporting (CIDR) 
system. During 2011, notification data were inputted 
directly by areas using the system. For areas not yet on 
CIDR, data were forwarded weekly to HPSC for input to 
CIDR. Enhanced surveillance was undertaken for certain 
diseases and these data collated on CIDR. Outbreak 
data were also collated on CIDR using the same process 
outlined above.  Since 4th May 2008, new cases of 
Clostridium difficile-associated disease (CDAD) were 
notified on CIDR under the category ‘acute infectious 
gastroenteritis’ (AIG). Weekly Reports on infectious 
disease notifications (including a separate report for AIG 
with the emphasis on C. difficile) and outbreaks were 
produced by HPSC and published on the HPSC website, 
www.hpsc.ie. Throughout the year data were cleaned 
and validated on an ongoing basis and final data checks 
and cleaning were undertaken following year end by 
HPSC and the Departments of Public Health.  Data 
analysis was performed using CIDR Business Objects 
Reporting and MS Excel. Figures for the relevant 
chapters within this report were extracted from CIDR 
between July and October 2012. These figures may 
differ from those previously published due to ongoing 
updating of data on CIDR.
Data on the notifiable infectious diseases not yet on 
CIDR were collated as follows:
National Tuberculosis Surveillance System (NTBSS)
TB notification data (including enhanced information) 
for 2010 were collated in the regional Departments of 
Public Health, where data were entered on the Epi2000 
NTBSS database. Each HSE Area provided finalised 
2010 data (with outcome information). Data were 
validated and cleaned with each area and the national 
data were collated. Validation of the 2010 TB data was 
concluded during September 2012.
Sexually Transmitted Infections (STIs)
Clinicians and laboratories notified their respective 
Departments of Public Health of probable and 
confirmed cases of STIs. Data for 2010 and 2011 were 
collated and analysed by Departments of Public Health 
and aggregated data were reported to HPSC. National 
data were collated on an MS Access database, analysis 
preformed and reports produced by HPSC.
Case-based syphilis records have been collated 
nationally since 2000. Case-based syphilis data provided 
by some clinicians is a subset of aggregate syphilis 
notification data. Forms are completed by Departments 
of Public Health in conjunction with the clinician and are 
then forwarded to HPSC. An MS Access database was 
used at HPSC for collation and analysis of the national 
syphilis case-based data.
Since 1st May, 2011, the Computerised Infectious 
Disease Reporting (CIDR) system has been used to 
record notifications of syphilis, thereby allowing the 
replacement of the case-based and aggregate syphilis 
databases previously in use in Departments of Public 
Health and at HPSC.
Other Surveillance Systems
Influenza/Influenza-like illness Surveillance Systems
Since 2000, HPSC has worked in collaboration with 
the National Virus Reference Laboratory (NVRL), the 
Irish College of General Practitioners (ICGP) and 
the Departments of Public Health on the influenza 
sentinel surveillance project. Sixty general practices 
(located in all HSE-Areas and representing 5.7% of the 
population) were recruited to report electronically, on 
a weekly basis, the number of patients who consulted 
with influenza-like illness (ILI).  ILI is defined using 
the Irish case definition for ILI which is sudden onset 
of symptoms AND at least one of the following four 
systemic symptoms: fever, malaise, headache, myalgia; 
AND at least one of the following three respiratory 
symptoms: cough, sore throat, shortness of breath. 
Sentinel GPs were requested to send a combined nasal 
and throat swab on one ILI patient per week to the 
NVRL. The NVRL also tested respiratory non-sentinel 
specimens, referred mainly from hospitals. Other 
surveillance systems set up to monitor influenza/ILI 
activity include a network of sentinel hospitals reporting 
admissions data. The Departments of Public Health also 
notified HPSC weekly of all cases of influenza (including 
hospitalisation status), all influenza/ILI outbreaks and 
enhanced surveillance data on all hospitalised cases of 
confirmed influenza in 0-14 year olds. HPSC was notified 
of all registered deaths on a daily basis from the General 
Register Office.
Several surveillance projects that were initiated/
augmented during the 2009 influenza pandemic were 
continued during subsequent influenza seasons:
•  Surveillance of all calls to GP out-of-hours (OOHs) 
centres were monitored for self-reported influenza. 
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These data were provided by HSE-NE.  
•  Intensive Care Society of Ireland (ICSI) enhanced 
surveillance of all critical care patients with confirmed 
influenza in all critical care units and enhanced 
surveillance of all severe acute respiratory infections 
(SARI) in two pilot ICU sites.  
•  Enhanced surveillance of all confirmed influenza 
deaths.
At HPSC, data were collated from the various sources, 
analysed and routine reports were produced. Influenza 
surveillance reports were posted on the HPSC website 
www.hpsc.ie. Aggregated clinical and virological data 
and annonymised data on confirmed influenza cases 
admitted to ICU and influenza-associated deaths were 
reported weekly to the European Centre for Disease 
Prevention and Control (ECDC).
HIV
HIV and AIDS surveillance in Ireland is voluntary 
and anonymised and operates in co-operation with 
laboratories, clinicians and Departments of Public 
Health.  In 2011, clinicians completed surveillance forms 
on newly diagnosed HIV cases, AIDS cases and AIDS 
related deaths and forwarded these to the appropriate 
Department of Public Health who in turn forwarded 
them to HPSC where national data were collated on an 
MS Access database.  Bi-annual analysis of these data 
were performed at HPSC and reports produced.  
Immunisation Uptake
Each HSE Area maintains a childhood immunisation 
database. In 2011, HSE Areas provided HPSC with 
immunisation uptake data for their area and for each 
of the Local Health Offices in their area on a quarterly 
basis. National data were collated and analysed at 
HPSC using a MS Excel database.  Quarterly reports 
were produced and are available on the HPSC website. 
For further details on methods used, please see the 
immunisation uptake chapter within this report.
European Antimicrobial Resistance Surveillance 
Network (EARS-Net)
Data were collected by participating EARS-Net (formerly 
the European Antimicrobial Resistance Surveillance 
System, EARSS) laboratories in 2011 on the first invasive 
isolate per patient per quarter on Staphylococcus 
aureus and Enterococcus faecalis from blood only 
and on Streptococcus pneumoniae, Escherichia coli, 
Klebsiella pneumoniae and Pseudomonas aeruginosa 
from blood and cerebrospinal fluid (CSF).  Data were 
reported quarterly to HPSC, via WHONET software, 
and collated in an MS Access database. Quarterly and 
annual reports were produced.
Note: Invasive infections due to K. pneumoniae and 
P. aeruginosa became notifiable as of 13th September 
2011.
Antimicrobial consumption
Community (outpatient) consumption data were 
obtained from IMS Health and represent wholesaler 
to retail pharmacy sales figures for Ireland. Hospital 
(inpatient) consumption data were obtained directly 
from clinical pharmacies and validated with the support 
of the Irish Antimicrobial Pharmacists Association. 
Quarterly and annual consumption trends by named 
public acute hospitals are published on the HPSC 
website. All data were stored at the HSPC in an MS 
Access database, and interpreted using the WHO 
Anatomical Therapeutic Chemicals index (www.whocc.
no/atcddd/) in line with European Surveillance of 
Antimicrobial Consumption (ESAC) methodology. See 
relevant section for notes on the denominator data.
Healthcare associated infections
•  Clostridium difficile: Data on C.difficile enhanced 
surveillance were collected by participating hospitals, 
reported quarterly to the HPSC and stored in an MS 
Access database. Quarterly and annual reports were 
produced. 
•  Healthcare associated infections in long term 
care facilities (HALT): Participating Long Term Care 
Facilities (LTCFs) of the HALT project were asked to 
survey residents on one day only, thereby providing 
a snapshot of HCAI and antimicrobial use on that 
particular day. Data was entered by each LTCF onto a 
standalone Access-based IT tool developed by ECDC 
and sent to HPSC for analysis.
•  Data were also collected on the total volume of 
alcohol-based hand rub used per hospital per year/
quarter, excluding that used for pre-operative surgical 
“scrub”.  See relevant section for notes on the 
denominator data. The rate of usage per hospital was 
calculated as the total volume of hand rub consumed 
(in litres) per 1000 bed days used, and quarterly and 
annual reports were produced for publication on the 
HPSC website.
Denominator Data
To calculate disease incidence rates, Census of 
Population data were used as the denominator 
(available from the Central Statistics Office, http://www.
cso.ie).  Population figures were applied as follows: 
Census 2011 for analysis of 2009-2011 data 
Census 2006 for analysis of 2004-2008 data
Census 2002 for 2000-2003 data 
Census 1996 for 1999 data 
Monthly population changes were estimated between 
1993 and 2011 using a curve interpolation method for 
the calculation of outpatient antibiotic consumption 
rate. 
Bed-days used and other activity data for public acute 
hospitals were provided by the Performance Monitoring 
Unit of the HSE and used to calculate rates of MRSA, 
hospital antibiotic consumption and rates used in other 
hospital-based surveillance systems. Similar activity data 
were obtained directly from private acute hospitals.
HSE Areas
Although organisational changes have taken place 
in the Health Services, the term HSE Areas are used 
in this report when analysing and presenting data by 
geographical area (equating to the eight former health 
-159-HPSC Annual Report 2011 Explanatory Notes
board regions/areas). This is because operationally 
the surveillance, prevention and control of infectious 
diseases are still managed by eight Departments of 
Public Health, one in each HSE Area.
Regional Directors of Operations (RDO’s)
The range of health and personal social services 
provided by the HSE and its funded agencies are 
managed within four regions known as RDOs. Details of 
the four RDOs and their relationship with the eight HSE 
areas are shown below.
1. Dublin Mid Leinster (HSE-Midland plus CCA1-5 and 
CCA9-10 of HSE-East)
2. Dublin North East (HSE-North East plus CCA6-8 of 
HSE-East)
3. South (HSE-South and HSE-South East)
4. West (HSE-Midwest, HSE-North West and HSE-West)
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Glossary of Terms 
CIDR Computerised Infectious Diseases Reporting
DoHC Department of Health and Children
EARS-Net European Antimicrobial Resistance Surveillance Network 
ECDC European Centre for Disease Prevention and Control
EISN European Influenza Surveillance Network
FSAI Food Safety Authority of Ireland
FSPB Food Safety Promotion Board
ICGP Irish College of General Practitioners
IDU Injecting Drug User
IMMRL Irish Meningococcal and Meningitis Reference Laboratory
IPD Invasive pneumococcal disease
HCAI Healthcare associated infections
HPSC Health Protection Surveillance Centre
HSE Health Services Executive
HSE E HSE Eastern Region
HSE M HSE Midland Area
HSE MW HSE Mid-Western Area
HSE NE HSE North Eastern Area
HSE NW HSE North Western Area
HSE SE HSE South Eastern Area
HSE S HSE Southern Area
HSE W HSE Western Area
MRSA Meticillin Resistant Staphylococcus aureus
MSM Men who have Sex with Men
NSRL National Salmonella Reference Laboratory
NVRL National Virus Reference Laboratory
STIs Sexually Transmitted Infections
TB Tuberculosis
WHO World Health Organisation
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